

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 705 903 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
10.04.1996 Bulletin 1996/15

(51) Int Cl.<sup>6</sup>: C12N 15/12, C07K 14/82,  
C12Q 1/68, G01N 33/574,  
C12N 5/10

(21) Application number: 95305605.8

(22) Date of filing: 11.08.1995

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE

• CANCER INSTITUTE  
Tokyo 107 (JP)

(30) Priority: 12.08.1994 US 289221  
02.09.1994 US 300266  
16.09.1994 US 308104  
29.11.1994 US 348824  
24.03.1995 US 409305  
07.06.1995 US 480784  
07.06.1995 US 483553

(72) Inventors:

• Shattuck-Eidens, Donna M.  
Salt Lake City, Utah 84108 (US)  
• Simard, Jacques  
Quebec, Canada G3A 1ZG (CA)  
• Emi, Mitsuru  
Tokyo (JP)  
• Nakamura, Yusuke  
Yokohama-shi, 225, Kanagawa-ken (JP)  
• Durocher, Francine  
Ste-foy, Quebec, G1X 1C1 (CA)

(71) Applicants:

• MYRIAD GENETICS, INC.  
Salt Lake City, Utah 84108 (US)  
• CENTRE DE RECHERCHE DU CHUL  
Sainte-Foy, Québec G1V 4G2 (CA)

(74) Representative: Irvine, Jonquil Claire  
J.A. KEMP & CO.  
14 South Square  
Gray's Inn  
London WC1R 5LX (GB)

(54) **In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene**

(57) The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline

mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer.

EP 0 705 903 A1

see page 59

Nonsense mutation in exon 13

" "

FS + MS = Exon 16

## Description

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular, breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated herein by reference, and for convenience, are referenced by author and date in the following text and respectively grouped in the appended List of References.

## BACKGROUND OF THE INVENTION

The genetics of cancer is complicated, involving multiple dominant, positive regulators of the transformed state (oncogenes) as well as multiple recessive, negative regulators (tumor suppressor genes). Over one hundred oncogenes have been characterized. Fewer than a dozen tumor suppressor genes have been identified, but the number is expected to increase beyond fifty (Knudson, 1993).

The involvement of so many genes underscores the complexity of the growth control mechanisms that operate in cells to maintain the integrity of normal tissue. This complexity is manifest in another way. So far, no single gene has been shown to participate in the development of all, or even the majority of human cancers. The most common oncogenic mutations are in the H-ras gene, found in 10-15% of all solid tumors (Anderson *et al.*, 1992). The most frequently mutated tumor suppressor genes are the TP53 gene, homozygously deleted in roughly 50% of all tumors, and CDKN2, which was homozygously deleted in 46% of tumor cell lines examined (Kamb *et al.*, 1994). Without a target that is common to all transformed cells, the dream of a "magic bullet" that can destroy or revert cancer cells while leaving normal tissue unharmed is improbable. The hope for a new generation of specifically targeted antitumor drugs may rest on the ability to identify tumor suppressor genes or oncogenes that play general roles in control of cell division.

The tumor suppressor genes which have been cloned and characterized influence susceptibility to: 1) Retinoblastoma (RB1); 2) Wilms' tumor (WT1); 3) Li-Fraumeni (TP53); 4) Familial adenomatous polyposis (APC); 5) Neurofibromatosis type 1 (NF1); 6) Neurofibromatosis type 2 (NF2); 7) von Hippel-Lindau syndrome (VHL); 8) Multiple endocrine neoplasia type 2A (MEN2A); and 9) Melanoma (CDKN2).

Tumor suppressor loci that have been mapped genetically but not yet isolated include genes for: Multiple endocrine neoplasia type 1 (MEN1); Lynch cancer family syndrome 2 (LCFS2); Neuroblastoma (NB); Basal cell nevus syndrome (BCNS); Beckwith-Wiedemann syndrome (BWS); Renal cell carcinoma (RCC); Tuberous sclerosis 1 (TSC1); and Tuberous sclerosis 2 (TSC2). The tumor suppressor genes that have been characterized to date encode products with similarities to a variety of protein types, including DNA binding proteins (WT1), ancillary transcription regulators (RB1), GTPase activating proteins or GAPs (NF1), cytoskeletal components (NF2), membrane bound receptor kinases (MEN2A), cell cycle regulators (CDKN2) and others with no obvious similarity to known proteins (APC and VHL).

In many cases, the tumor suppressor gene originally identified through genetic studies has been shown to be lost or mutated in some sporadic tumors. This result suggests that regions of chromosomal aberration may signify the position of important tumor suppressor genes involved both in genetic predisposition to cancer and in sporadic cancer.

One of the hallmarks of several tumor suppressor genes characterized to date is that they are deleted at high frequency in certain tumor types. The deletions often involve loss of a single allele, a so-called loss of heterozygosity (LOH), but may also involve homozygous deletion of both alleles. For LOH, the remaining allele is presumed to be nonfunctional, either because of a preexisting inherited mutation, or because of a secondary sporadic mutation.

Breast cancer is one of the most significant diseases that affects women. At the current rate, American women have a 1 in 8 risk of developing breast cancer by age 95 (American Cancer Society, 1992). Treatment of breast cancer at later stages is often futile and disfiguring, making early detection a high priority in medical management of the disease. Ovarian cancer, although less frequent than breast cancer is often rapidly fatal and is the fourth most common cause of cancer mortality in American women. Genetic factors contribute to an ill-defined proportion of breast cancer incidence, estimated to be about 5% of all cases but approximately 25% of cases diagnosed before age 40 (Claus *et al.*, 1991). Breast cancer has been subdivided into two types, early-age onset and late-age onset, based on an inflection in the age-specific incidence curve around age 50. Mutation of one gene, BRCA1, is thought to account for approximately

45% of familial breast cancer, but at least 80% of families with both breast and ovarian cancer (Easton *et al.*, 1993).

Intense efforts to isolate the BRCA1 gene have proceeded since it was first mapped in 1990 (Hall *et al.*, 1990; Narod *et al.*, 1991). A second locus, BRCA2, has recently been mapped to chromosome 13q (Wooster *et al.*, 1994) and appears to account for a proportion of early-onset breast cancer roughly equal to BRCA1, but confers a lower risk of ovarian cancer. The remaining susceptibility to early-onset breast cancer is divided between as yet unmapped genes for familial cancer, and rarer germline mutations in genes such as TP53 (Malkin *et al.*, 1990). It has also been suggested that heterozygote carriers for defective forms of the Ataxia-Telangiectasia gene are at higher risk for breast cancer (Swift *et al.*, 1976; Swift *et al.*, 1991). Late-age onset breast cancer is also often familial although the risks in relatives are not as high as those for early-onset breast cancer (Cannon-Albright *et al.*, 1994; Mettlin *et al.*, 1990). However, the percentage of such cases due to genetic susceptibility is unknown.

Breast cancer has long been recognized to be, in part, a familial disease (Anderson, 1972). Numerous investigators have examined the evidence for genetic inheritance and concluded that the data are most consistent with dominant inheritance for a major susceptibility locus or loci (Bishop and Gardner, 1980; Go *et al.*, 1983; Willms and Anderson, 1984; Bishop *et al.*, 1988; Newman *et al.*, 1988; Claus *et al.*, 1991). Recent results demonstrate that at least three loci exist which convey susceptibility to breast cancer as well as other cancers. These loci are the TP53 locus on chromosome 17p (Malkin *et al.*, 1990), a 17q-linked susceptibility locus known as BRCA1 (Hall *et al.*, 1990), and one or more loci responsible for the unmapped residual. Hall *et al.* (1990) indicated that the inherited breast cancer susceptibility in kindreds with early age onset is linked to chromosome 17q21; although subsequent studies by this group using a more appropriate genetic model partially refuted the limitation to early onset breast cancer (Margaritte *et al.*, 1992).

Most strategies for cloning the 17q-linked breast cancer predisposing gene (BRCA1) require precise genetic localization studies. The simplest model for the functional role of BRCA1 holds that alleles of BRCA1 that predispose to cancer are recessive to wild type alleles; that is, cells that contain at least one wild type BRCA1 allele are not cancerous. However, cells that contain one wild type BRCA1 allele and one predisposing allele may occasionally suffer loss of the wild type allele either by random mutation or by chromosome loss during cell division (nondisjunction). All the progeny of such a mutant cell lack the wild type function of BRCA1 and may develop into tumors. According to this model, predisposing alleles of BRCA1 are recessive, yet susceptibility to cancer is inherited in a dominant fashion: women who possess one predisposing allele (and one wild type allele) risk developing cancer, because their mammary epithelial cells may spontaneously lose the wild type BRCA1 allele. This model applies to a group of cancer susceptibility loci known as tumor suppressors or antioncogenes, a class of genes that includes the retinoblastoma gene and neurofibromatosis gene. By inference this model may also explain the BRCA1 function, as has recently been suggested (Smith *et al.*, 1992).

A second possibility is that BRCA1 predisposing alleles are truly dominant; that is, a wild type allele of BRCA1 cannot overcome the tumor forming role of the predisposing allele. Thus, a cell that carries both wild type and mutant alleles would not necessarily lose the wild type copy of BRCA1 before giving rise to malignant cells. Instead, mammary cells in predisposed individuals would undergo some other stochastic change(s) leading to cancer.

If BRCA1 predisposing alleles are recessive, the BRCA1 gene is expected to be expressed in normal mammary tissue but not functionally expressed in mammary tumors. In contrast, if BRCA1 predisposing alleles are dominant, the wild type BRCA1 gene may or may not be expressed in normal mammary tissue. However, the predisposing allele will likely be expressed in breast tumor cells.

The 17q linkage of BRCA1 was independently confirmed in three of five kindreds with both breast cancer and ovarian cancer (Narod *et al.*, 1991). These studies claimed to localize the gene within a very large region, 15 centimorgans (cM), or approximately 15 million base pairs, to either side of the linked marker pCMM86 (D17S74). However, attempts to define the region further by genetic studies, using markers surrounding pCMM86, proved unsuccessful. Subsequent studies indicated that the gene was considerably more proximal (Easton *et al.*, 1993) and that the original analysis was flawed (Margaritte *et al.*, 1992). Hall *et al.* (1992) recently localized the BRCA1 gene to an approximately 8 cM interval (approximately 8 million base pairs) bounded by Mfd15 (D17S250) on the proximal side and the human GIP gene on the distal side. A slightly narrower interval for the BRCA1 locus, based on publicly available data, was agreed upon at the Chromosome 17 workshop in March of 1992 (Fain, 1992). The size of these regions and the uncertainty associated with them has made it exceedingly difficult to design and implement physical mapping and/or cloning strategies for isolating the BRCA1 gene.

Identification of a breast cancer susceptibility locus would permit the early detection of susceptible individuals and greatly increase our ability to understand the initial steps which lead to cancer. As susceptibility loci are often altered during tumor progression, cloning these genes could also be important in the development of better diagnostic and prognostic products, as well as better cancer therapies.

#### SUMMARY OF THE INVENTION

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to

methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA1), some alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the present invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The invention further relates to somatic mutations in the BRCA1 gene in human breast cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing the order of loci neighboring BRCA1 as determined by the chromosome 17 workshop. Figure 1 is reproduced from Fain, 1992.

Figure 2 is a schematic map of YACs which define part of Mfd15-Mfd188 region.

Figure 3 is a schematic map of STSs, P1s and BACs in the BRCA1 region.

Figure 4 is a schematic map of human chromosome 17. The pertinent region containing BRCA1 is expanded to indicate the relative positions of two previously identified genes, CA125 and RNU2. BRCA1 spans the marker D17S855.

Figure 5 shows alignment of the BRCA1 zinc-finger domain with 3 other zinc-finger domains that scored highest in a Smith-Waterman alignment. RPT1 encodes a protein that appears to be a negative regulator of the IL-2 receptor in mouse. RIN1 encodes a DNA-binding protein that includes a RING-finger motif related to the zinc-finger. RFP1 encodes a putative transcription factor that is the N-terminal domain of the RET oncogene product. The bottom line contains the C3HC4 consensus zinc-finger sequence showing the positions of cysteines and one histidine that form the zinc ion binding pocket.

Figure 6 is a diagram of BRCA1 mRNA showing the locations of introns and the variants of BRCA1 mRNA produced by alternative splicing. Intron locations are shown by dark triangles and the exons are numbered below the line representing the cDNA. The top cDNA is the composite used to generate the peptide sequence of BRCA1. Alternative forms identified as cDNA clones or hybrid selection clones are shown below.

Figure 7 shows the tissue expression pattern of BRCA1. The blot was obtained from Clontech and contains RNA from the indicated tissues. Hybridization conditions were as recommended by the manufacturer using a probe consisting of nucleotide positions 3631 to 3930 of BRCA1. Note that both breast and ovary are heterogeneous tissues and the percentage of relevant epithelial cells can be variable. Molecular weight standards are in kilobases.

Figure 8 is a diagram of the 5' untranslated region plus the beginning of the translated region of BRCA1 showing the locations of introns and the variants of BRCA1 mRNA produced by alternative splicing. Intron locations are shown by broken dashed lines. Six alternate splice forms are shown.

Figure 9A shows a nonsense mutation in Kindred 2082. P indicates the person originally screened, b and c are haplotype carriers, a, d, e, f, and g do not carry the BRCA1 haplotype. The C to T mutation results in a stop codon and creates a site for the restriction enzyme AvrII. PCR amplification products are cut with this enzyme. The carriers are heterozygous for the site and therefore show three bands. Non-carriers remain uncut.

Figure 9B shows a mutation and cosegregation analysis in BRCA1 kindreds. Carrier individuals are represented as filled circles and squares in the pedigree diagrams. Frameshift mutation in Kindred 1910. The first three lanes are control, noncarrier samples. Lanes labeled 1-3 contain sequences from carrier individuals. Lane 4 contains DNA from a kindred member who does not carry the BRCA1 mutation. The diamond is used to prevent identification of the kindred. The frameshift resulting from the additional C is apparent in lanes labeled 1, 2, and 3.

Figure 9C shows a mutation and cosegregation analysis in BRCA1 kindreds. Carrier individuals are represented as filled circles and squares in the pedigree diagrams. Inferred regulatory mutation in Kindred 2035. ASO analysis of carriers and noncarriers of 2 different polymorphisms (PM1 and PM7) which were examined for heterozygosity in the germline and compared to the heterozygosity of lymphocyte mRNA. The top 2 rows of each panel contain PCR products amplified from genomic DNA and the bottom 2 rows contain PCR products amplified from cDNA. "A" and "G" are the two alleles detected by the ASO. The dark spots indicate that a particular allele is present in the sample. The first three lanes of PM7 represent the three genotypes in the general population.

Figures 10A-10H show genomic sequence of BRCA1. The lower case letters denote intron sequence while the upper case letters denote exon sequence. Indefinite intervals within introns are designated with vvvvvvvvvvvv. Known polymorphic sites are shown as underlined and boldface type.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA1), some alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the present invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The invention further relates to somatic mutations in the BRCA1 gene in human breast cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

The present invention provides an isolated polynucleotide comprising all, or a portion of the BRCA1 locus or of a mutated BRCA1 locus, preferably at least eight bases and not more than about 100 kb in length. Such polynucleotides may be antisense polynucleotides. The present invention also provides a recombinant construct comprising such an isolated polynucleotide, for example, a recombinant construct suitable for expression in a transformed host cell.

Also provided by the present invention are methods of detecting a polynucleotide comprising a portion of the BRCA1 locus or its expression product in an analyte. Such methods may further comprise the step of amplifying the portion of the BRCA1 locus, and may further include a step of providing a set of polynucleotides which are primers for amplification of said portion of the BRCA1 locus. The method is useful for either diagnosis of the predisposition to cancer or the diagnosis or prognosis of cancer.

The present invention also provides isolated antibodies, preferably monoclonal antibodies, which specifically bind to an isolated polypeptide comprised of at least five amino acid residues encoded by the BRCA1 locus.

The present invention also provides kits for detecting in an analyte a polynucleotide comprising a portion of the BRCA1 locus, the kits comprising a polynucleotide complementary to the portion of the BRCA1 locus packaged in a suitable container, and instructions for its use.

The present invention further provides methods of preparing a polynucleotide comprising polymerizing nucleotides to yield a sequence comprised of at least eight consecutive nucleotides of the BRCA1 locus; and methods of preparing a polypeptide comprising polymerizing amino acids to yield a sequence comprising at least five amino acids encoded within the BRCA1 locus.

The present invention further provides methods of screening the BRCA1 gene to identify mutations. Such methods may further comprise the step of amplifying a portion of the BRCA1 locus, and may further include a step of providing a set of polynucleotides which are primers for amplification of said portion of the BRCA1 locus. The method is useful for identifying mutations for use in either diagnosis of the predisposition to cancer or the diagnosis or prognosis of cancer.

The present invention further provides methods of screening suspected BRCA1 mutant alleles to identify mutations in the BRCA1 gene.

In addition, the present invention provides methods of screening drugs for cancer therapy to identify suitable drugs for restoring BRCA1 gene product function.

Finally, the present invention provides the means necessary for production of gene-based therapies directed at cancer cells. These therapeutic agents may take the form of polynucleotides comprising all or a portion of the BRCA1 locus placed in appropriate vectors or delivered to target cells in more direct ways such that the function of the BRCA1 protein is reconstituted. Therapeutic agents may also take the form of polypeptides based on either a portion of, or the entire protein sequence of BRCA1. These may functionally replace the activity of BRCA1 *in vivo*.

It is a discovery of the present invention that the BRCA1 locus which predisposes individuals to breast cancer and ovarian cancer, is a gene encoding a BRCA1 protein, which has been found to have no significant homology with known protein or DNA sequences. This gene is termed BRCA1 herein. It is a discovery of the present invention that mutations in the BRCA1 locus in the germline are indicative of a predisposition to breast cancer and ovarian cancer. Finally, it is a discovery of the present invention that somatic mutations in the BRCA1 locus are also associated with breast cancer, ovarian cancer and other cancers, which represents an indicator of these cancers or of the prognosis of these cancers. The mutational events of the BRCA1 locus can involve deletions, insertions and point mutations within the coding sequence and the non-coding sequence.

Starting from a region on the long arm of human chromosome 17 of the human genome, 17q, which has a size estimated at about 8 million base pairs, a region which contains a genetic locus, BRCA1, which causes susceptibility to cancer, including breast and ovarian cancer, has been identified.

The region containing the BRCA1 locus was identified using a variety of genetic techniques. Genetic mapping techniques initially defined the BRCA1 region in terms of recombination with genetic markers. Based upon studies of large extended families ("kindreds") with multiple cases of breast cancer (and ovarian cancer cases in some kindreds),

a chromosomal region has been pinpointed that contains the BRCA1 gene as well as other putative susceptibility alleles in the BRCA1 locus. Two meiotic breakpoints have been discovered on the distal side of the BRCA1 locus which are expressed as recombinants between genetic markers and the disease, and one recombinant on the proximal side of the BRCA1 locus. Thus, a region which contains the BRCA1 locus is physically bounded by these markers.

The use of the genetic markers provided by this invention allowed the identification of clones which cover the region from a human yeast artificial chromosome (YAC) or a human bacterial artificial chromosome (BAC) library. It also allowed for the identification and preparation of more easily manipulated cosmid, P1 and BAC clones from this region and the construction of a contig from a subset of the clones. These cosmids, P1s, YACs and BACs provide the basis for cloning the BRCA1 locus and provide the basis for developing reagents effective, for example, in the diagnosis and treatment of breast and/or ovarian cancer. The BRCA1 gene and other potential susceptibility genes have been isolated from this region. The isolation was done using software trapping (a computational method for identifying sequences likely to contain coding exons, from contiguous or discontinuous genomic DNA sequences), hybrid selection techniques and direct screening, with whole or partial cDNA inserts from cosmids, P1s and BACs, in the region to screen cDNA libraries. These methods were used to obtain sequences of loci expressed in breast and other tissue. These candidate loci were analyzed to identify sequences which confer cancer susceptibility. We have discovered that there are mutations in the coding sequence of the BRCA1 locus in kindreds which are responsible for the 17q-linked cancer susceptibility known as BRCA1. This gene was not known to be in this region. The present invention not only facilitates the early detection of certain cancers, so vital to patient survival, but also permits the detection of susceptible individuals before they develop cancer.

#### Population Resources

Large, well-documented Utah kindreds are especially important in providing good resources for human genetic studies. Each large kindred independently provides the power to detect whether a BRCA1 susceptibility allele is segregating in that family. Recombinants informative for localization and isolation of the BRCA1 locus could be obtained only from kindreds large enough to confirm the presence of a susceptibility allele. Large sibships are especially important for studying breast cancer, since penetrance of the BRCA1 susceptibility allele is reduced both by age and sex, making informative sibships difficult to find. Furthermore, large sibships are essential for constructing haplotypes of deceased individuals by inference from the haplotypes of their close relatives.

While other populations may also provide beneficial information, such studies generally require much greater effort, and the families are usually much smaller and thus less informative. Utah's age-adjusted breast cancer incidence is 20% lower than the average U.S. rate. The lower incidence in Utah is probably due largely to an early age at first pregnancy, increasing the probability that cases found in Utah kindreds carry a genetic predisposition.

#### Genetic Mapping

Given a set of informative families, genetic markers are essential for linking a disease to a region of a chromosome. Such markers include restriction fragment length polymorphisms (RFLPs) (Botstein *et al.*, 1980), markers with a variable number of tandem repeats (VNTRs) (Jeffreys *et al.*, 1985; Nakamura *et al.*, 1987), and an abundant class of DNA polymorphisms based on short tandem repeats (STRs), especially repeats of CpA (Weber and May, 1989; Litt *et al.*, 1989). To generate a genetic map, one selects potential genetic markers and tests them using DNA extracted from members of the kindreds being studied.

Genetic markers useful in searching for a genetic locus associated with a disease can be selected on an *ad hoc* basis, by densely covering a specific chromosome, or by detailed analysis of a specific region of a chromosome. A preferred method for selecting genetic markers linked with a disease involves evaluating the degree of informativeness of kindreds to determine the ideal distance between genetic markers of a given degree of polymorphism, then selecting markers from known genetic maps which are ideally spaced for maximal efficiency. Informativeness of kindreds is measured by the probability that the markers will be heterozygous in unrelated individuals. It is also most efficient to use STR markers which are detected by amplification of the target nucleic acid sequence using PCR; such markers are highly informative, easy to assay (Weber and May, 1989), and can be assayed simultaneously using multiplexing strategies (Skolnick and Wallace, 1988), greatly reducing the number of experiments required.

Once linkage has been established, one needs to find markers that flank the disease locus, i.e., one or more markers proximal to the disease locus, and one or more markers distal to the disease locus. Where possible, candidate markers can be selected from a known genetic map. Where none is known, new markers can be identified by the STR technique, as shown in the Examples.

Genetic mapping is usually an iterative process. In the present invention, it began by defining flanking genetic markers around the BRCA1 locus, then replacing these flanking markers with other markers that were successively closer to the BRCA1 locus. As an initial step, recombination events, defined by large extended kindreds, helped spe-

cifically to localize the BRCA1 locus as either distal or proximal to a specific genetic marker (Goldgar *et al.*, 1994).

The region surrounding BRCA1, until the disclosure of the present invention, was not well mapped and there were few markers. Therefore, short repetitive sequences on cosmids subcloned from YACs, which had been physically mapped, were analyzed in order to develop new genetic markers. Using this approach, one marker of the present invention, 42D6, was discovered which replaced pCMM86 as the distal flanking marker for the BRCA1 region. Since 42D6 is approximately 14 cM from pCMM86, the BRCA1 region was thus reduced by approximately 14 centiMorgans (Easton *et al.*, 1993). The present invention thus began by finding a much more closely linked distal flanking marker of the BRCA1 region. BRCA1 was then discovered to be distal to the genetic marker Mfd15. Therefore, BRCA1 was shown to be in a region of 6 to 10 million bases bounded by Mfd15 and 42D6. Marker Mfd191 was subsequently discovered to be distal to Mfd15 and proximal to BRCA1. Thus, Mfd15 was replaced with Mfd191 as the closest proximal genetic marker. Similarly, it was discovered that genetic marker Mfd188 could replace genetic marker 42D6, narrowing the region containing the BRCA1 locus to approximately 1.5 million bases. Then the marker Mfd191 was replaced with tdj1474 as the proximal marker and Mfd188 was replaced with U5R as the distal marker, further narrowing the BRCA1 region to a small enough region to allow isolation and characterization of the BRCA1 locus (see Figure 3), using techniques known in the art and described herein.

### Physical Mapping

Three distinct methods were employed to physically map the region. The first was the use of yeast artificial chromosomes (YACs) to clone the region which is flanked by tdj1474 and U5R. The second was the creation of a set of P1, BAC and cosmid clones which cover the region containing the BRCA1 locus.

### Yeast Artificial Chromosomes (YACs).

Once a sufficiently small region containing the BRCA1 locus was identified, physical isolation of the DNA in the region proceeded by identifying a set of overlapping YACs which covers the region. Useful YACs can be isolated from known libraries, such as the St. Louis and CEPH YAC libraries, which are widely distributed and contain approximately 50,000 YACs each. The YACs isolated were from these publicly accessible libraries and can be obtained from a number of sources including the Michigan Genome Center. Clearly, others who had access to these YACs, without the disclosure of the present invention, would not have known the value of the specific YACs we selected since they would not have known which YACs were within, and which YACs outside of, the smallest region containing the BRCA1 locus.

### Cosmid, P1 and BAC Clones.

In the present invention, it is advantageous to proceed by obtaining cosmid, P1, and BAC clones to cover this region. The smaller size of these inserts, compared to YAC inserts, makes them more useful as specific hybridization probes. Furthermore, having the cloned DNA in bacterial cells, rather than in yeast cells, greatly increases the ease with which the DNA of interest can be manipulated, and improves the signal-to-noise ratio of hybridization assays. For cosmid subclones of YACs, the DNA is partially digested with the restriction enzyme Sau3A and cloned into the BamHI site of the pWE15 cosmid vector (Stratagene, cat. #1251201). The cosmids containing human sequences are screened by hybridization with human repetitive DNA (e.g., Gibco/BRL, Human C<sub>0</sub>t-1 DNA, cat. 5279SA), and then fingerprinted by a variety of techniques, as detailed in the Examples.

P1 and BAC clones are obtained by screening libraries constructed from the total human genome with specific sequence tagged sites (STSs) derived from the YACs, cosmids or P1s and BACs, isolated as described herein.

These P1, BAC and cosmid clones can be compared by interspersed repetitive sequence (IRS) PCR and/or restriction enzyme digests followed by gel electrophoresis and comparison of the resulting DNA fragments ("fingerprints") (Maniatis *et al.*, 1982). The clones can also be characterized by the presence of STSs. The fingerprints are used to define an overlapping contiguous set of clones which covers the region but is not excessively redundant, referred to herein as a "minimum tiling path". Such a minimum tiling path forms the basis for subsequent experiments to identify cDNAs which may originate from the BRCA1 locus.

### Coverage of the Gap with P1 and BAC Clones.

To cover any gaps in the BRCA1 contig between the identified cosmids with genomic clones, clones in P1 and BAC vectors which contain inserts of genomic DNA roughly twice as large as cosmids for P1s and still greater for BACs (Sternberg, 1990; Sternberg *et al.*, 1990; Pierce *et al.*, 1992; Shizuya *et al.*, 1992) were used. P1 clones were isolated by Genome Sciences using PCR primers provided by us for screening. BACs were provided by hybridization techniques in Dr. Mel Simon's laboratory. The strategy of using P1 clones also permitted the covering of the genomic region with

an independent set of clones not derived from YACs. This guards against the possibility of other deletions in YACs that have not been detected. These new sequences derived from the P1 clones provide the material for further screening for candidate genes, as described below.

## 5 Gene Isolation.

There are many techniques for testing genomic clones for the presence of sequences likely to be candidates for the coding sequence of a locus one is attempting to isolate, including but not limited to:

- 10 a. zoo blots
- b. identifying HTF islands
- c. exon trapping
- 15 d. hybridizing cDNA to cosmid or YACs.
- e. screening cDNA libraries.

## 20 (a) Zoo blots.

The first technique is to hybridize cosmids to Southern blots to identify DNA sequences which are evolutionarily conserved, and which therefore give positive hybridization signals with DNA from species of varying degrees of relationship to humans (such as monkey, cow, chicken, pig, mouse and rat). Southern blots containing such DNA from a variety of species are commercially available (Clontech, Cat. 7753-1).

## (b) Identifying HTF islands.

The second technique involves finding regions rich in the nucleotides C and G, which often occur near or within coding sequences. Such sequences are called HTF (HpaI tiny fragment) or CpG islands, as restriction enzymes specific for sites which contain CpG dimers cut frequently in these regions (Lindsay *et al.*, 1987).

## (c) Exon trapping.

The third technique is exon trapping, a method that identifies sequences in genomic DNA which contain splice junctions and therefore are likely to comprise coding sequences of genes. Exon amplification (Buckler *et al.*, 1991) is used to select and amplify exons from DNA clones described above. Exon amplification is based on the selection of RNA sequences which are flanked by functional 5' and/or 3' splice sites. The products of the exon amplification are used to screen the breast cDNA libraries to identify a manageable number of candidate genes for further study. Exon trapping can also be performed on small segments of sequenced DNA using computer programs or by software trapping.

## (d) Hybridizing cDNA to Cosmids, P1s, BACs or YACs.

The fourth technique is a modification of the selective enrichment technique which utilizes hybridization of cDNA to cosmids, P1s, BACs or YACs and permits transcribed sequences to be identified in, and recovered from cloned genomic DNA (Kandpal *et al.*, 1990). The selective enrichment technique, as modified for the present purpose, involves binding DNA from the region of BRCA1 present in a YAC to a column matrix and selecting cDNAs from the relevant libraries which hybridize with the bound DNA, followed by amplification and purification of the bound DNA, resulting in a great enrichment for cDNAs in the region represented by the cloned genomic DNA.

## (e) Identification of cDNAs.

The fifth technique is to identify cDNAs that correspond to the BRCA1 locus. Hybridization probes containing putative coding sequences, selected using any of the above techniques, are used to screen various libraries, including breast tissue cDNA libraries, ovarian cDNA libraries, and any other necessary libraries.

Another variation on the theme of direct selection of cDNA was also used to find candidate genes for BRCA1 (Lovett *et al.*, 1991; Futreal, 1993). This method uses cosmid, P1 or BAC DNA as the probe. The probe DNA is digested with a blunt cutting restriction enzyme such as HaeIII. Double stranded adapters are then ligated onto the DNA and serve

as binding sites for primers in subsequent PCR amplification reactions using biotinylated primers. Target cDNA is generated from mRNA derived from tissue samples, e.g., breast tissue, by synthesis of either random primed or oligo(dT) primed first strand followed by second strand synthesis. The cDNA ends are rendered blunt and ligated onto double-stranded adapters. These adapters serve as amplification sites for PCR. The target and probe sequences are denatured and mixed with human C<sub>0</sub>t-1 DNA to block repetitive sequences. Solution hybridization is carried out to high C<sub>0</sub>t-1/2 values to ensure hybridization of rare target cDNA molecules. The annealed material is then captured on avidin beads, washed at high stringency and the retained cDNAs are eluted and amplified by PCR. The selected cDNA is subjected to further rounds of enrichment before cloning into a plasmid vector for analysis.

#### Testing the cDNA for Candidacy

Proof that the cDNA is the BRCA1 locus is obtained by finding sequences in DNA extracted from affected kindred members which create abnormal BRCA1 gene products or abnormal levels of BRCA1 gene product. Such BRCA1 susceptibility alleles will co-segregate with the disease in large kindreds. They will also be present at a much higher frequency in non-kindred individuals with breast and ovarian cancer than in individuals in the general population. Finally, since tumors often mutate somatically at loci which are in other instances mutated in the germline, we expect to see normal germline BRCA1 alleles mutated into sequences which are identical or similar to BRCA1 susceptibility alleles in DNA extracted from tumor tissue. Whether one is comparing BRCA1 sequences from tumor tissue to BRCA1 alleles from the germline of the same individuals, or one is comparing germline BRCA1 alleles from cancer cases to those from unaffected individuals, the key is to find mutations which are serious enough to cause obvious disruption to the normal function of the gene product. These mutations can take a number of forms. The most severe forms would be frame shift mutations or large deletions which would cause the gene to code for an abnormal protein or one which would significantly alter protein expression. Less severe disruptive mutations would include small in-frame deletions and nonconservative base pair substitutions which would have a significant effect on the protein produced, such as changes to or from a cysteine residue, from a basic to an acidic amino acid, or vice versa, from a hydrophobic to hydrophilic amino acid or vice versa, or other mutations which would affect secondary, tertiary or quaternary protein structure. Silent mutations or those resulting in conservative amino acid substitutions would not generally be expected to disrupt protein function.

According to the diagnostic and prognostic method of the present invention, alteration of the wild-type BRCA1 locus is detected. In addition, the method can be performed by detecting the wild-type BRCA1 locus and confirming the lack of a predisposition to cancer at the BRCA1 locus. "Alteration of a wild-type gene" encompasses all forms of mutations including deletions, insertions and point mutations in the coding and noncoding regions. Deletions may be of the entire gene or of only a portion of the gene. Point mutations may result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those which occur only in certain tissues, e.g., in the tumor tissue, and are not inherited in the germline. Germline mutations can be found in any of a body's tissues and are inherited. If only a single allele is somatically mutated, an early neoplastic state is indicated. However, if both alleles are somatically mutated, then a late neoplastic state is indicated. The finding of BRCA1 mutations thus provides both diagnostic and prognostic information. A BRCA1 allele which is not deleted (e.g., found on the sister chromosome to a chromosome carrying a BRCA1 deletion) can be screened for other mutations, such as insertions, small deletions, and point mutations. It is believed that many mutations found in tumor tissues will be those leading to decreased expression of the BRCA1 gene product. However, mutations leading to non-functional gene products would also lead to a cancerous state. Point mutational events may occur in regulatory regions, such as in the promoter of the gene, leading to loss or diminution of expression of the mRNA. Point mutations may also abolish proper RNA processing, leading to loss of expression of the BRCA1 gene product, or to a decrease in mRNA stability or translation efficiency.

Useful diagnostic techniques include, but are not limited to fluorescent *in situ* hybridization (FISH), direct DNA sequencing, PFGE analysis, Southern blot analysis, single stranded conformation analysis (SSCA), RNase protection assay, allele-specific oligonucleotide (ASO), dot blot analysis and PCR-SSCP, as discussed in detail further below.

Predisposition to cancers, such as breast and ovarian cancer, and the other cancers identified herein, can be ascertained by testing any tissue of a human for mutations of the BRCA1 gene. For example, a person who has inherited a germline BRCA1 mutation would be prone to develop cancers. This can be determined by testing DNA from any tissue of the person's body. Most simply, blood can be drawn and DNA extracted from the cells of the blood. In addition, prenatal diagnosis can be accomplished by testing fetal cells, placental cells or amniotic cells for mutations of the BRCA1 gene. Alteration of a wild-type BRCA1 allele, whether, for example, by point mutation or deletion, can be detected by any of the means discussed herein.

There are several methods that can be used to detect DNA sequence variation. Direct DNA sequencing, either manual sequencing or automated fluorescent sequencing can detect sequence variation. For a gene as large as BRCA1, manual sequencing is very labor-intensive, but under optimal conditions, mutations in the coding sequence of a gene are rarely missed. Another approach is the single-stranded conformation polymorphism assay (SSCA) (Orita *et al.*, 1989). This method does not detect all sequence changes, especially if the DNA fragment size is greater than 200 bp,

but can be optimized to detect most DNA sequence variation. The reduced detection sensitivity is a disadvantage, but the increased throughput possible with SSCA makes it an attractive, viable alternative to direct sequencing for mutation detection on a research basis. The fragments which have shifted mobility on SSCA gels are then sequenced to determine the exact nature of the DNA sequence variation. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE) (Sheffield *et al.*, 1991), heteroduplex analysis (HA) (White *et al.*, 1992) and chemical mismatch cleavage (CMC) (Grompe *et al.*, 1989). None of the methods described above will detect large deletions, duplications or insertions, nor will they detect a regulatory mutation which affects transcription or translation of the protein. Other methods which might detect these classes of mutations such as a protein truncation assay or the asymmetric assay, detect only specific types of mutations and would not detect missense mutations. A review of currently available methods of detecting DNA sequence variation can be found in a recent review by Grompe (1993). Once a mutation is known, an allele specific detection approach such as allele specific oligonucleotide (ASO) hybridization can be utilized to rapidly screen large numbers of other samples for that same mutation.

In order to detect the alteration of the wild-type BRCA1 gene in a tissue, it is helpful to isolate the tissue free from surrounding normal tissues. Means for enriching tissue preparation for tumor cells are known in the art. For example, the tissue may be isolated from paraffin or cryostat sections. Cancer cells may also be separated from normal cells by flow cytometry. These techniques, as well as other techniques for separating tumor cells from normal cells, are well known in the art. If the tumor tissue is highly contaminated with normal cells, detection of mutations is more difficult.

A rapid preliminary analysis to detect polymorphisms in DNA sequences can be performed by looking at a series of Southern blots of DNA cut with one or more restriction enzymes, preferably with a large number of restriction enzymes. Each blot contains a series of normal individuals and a series of cancer cases, tumors, or both. Southern blots displaying hybridizing fragments (differing in length from control DNA when probed with sequences near or including the BRCA1 locus) indicate a possible mutation. If restriction enzymes which produce very large restriction fragments are used, then pulsed field gel electrophoresis (PFGE) is employed.

Detection of point mutations may be accomplished by molecular cloning of the BRCA1 allele(s) and sequencing the allele(s) using techniques well known in the art. Alternatively, the gene sequences can be amplified directly from a genomic DNA preparation from the tumor tissue, using known techniques. The DNA sequence of the amplified sequences can then be determined.

There are six well known methods for a more complete, yet still indirect, test for confirming the presence of a susceptibility allele: 1) single stranded conformation analysis (SSCA) (Orita *et al.*, 1989); 2) denaturing gradient gel electrophoresis (DGGE) (Wartell *et al.*, 1990; Sheffield *et al.*, 1989); 3) RNase protection assays (Finkelstein *et al.*, 1990; Kinszler *et al.*, 1991); 4) allele-specific oligonucleotides (ASOs) (Conner *et al.*, 1983); 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein (Modrich, 1991); and 6) allele-specific PCR (Rano & Kidd, 1989). For allele-specific PCR, primers are used which hybridize at their 3' ends to a particular BRCA1 mutation. If the particular BRCA1 mutation is not present, an amplification product is not observed. Amplification Refractory Mutation System (ARMS) can also be used, as disclosed in European Patent Application Publication No. 0332435 and in Newton *et al.*, 1989. Insertions and deletions of genes can also be detected by cloning, sequencing and amplification. In addition, restriction fragment length polymorphism (RFLP) probes for the gene or surrounding marker genes can be used to score alteration of an allele or an insertion in a polymorphic fragment. Such a method is particularly useful for screening relatives of an affected individual for the presence of the BRCA1 mutation found in that individual. Other techniques for detecting insertions and deletions as known in the art can be used.

In the first three methods (SSCA, DGGE and RNase protection assay), a new electrophoretic band appears. SSCA detects a band which migrates differentially because the sequence change causes a difference in single-strand, intramolecular base pairing. RNase protection involves cleavage of the mutant polynucleotide into two or more smaller fragments. DGGE detects differences in migration rates of mutant sequences compared to wild-type sequences, using a denaturing gradient gel. In an allele-specific oligonucleotide assay, an oligonucleotide is designed which detects a specific sequence, and the assay is performed by detecting the presence or absence of a hybridization signal. In the mutS assay, the protein binds only to sequences that contain a nucleotide mismatch in a heteroduplex between mutant and wild-type sequences.

Mismatches, according to the present invention, are hybridized nucleic acid duplexes in which the two strands are not 100% complementary. Lack of total homology may be due to deletions, insertions, inversions or substitutions. Mismatch detection can be used to detect point mutations in the gene or in its mRNA product. While these techniques are less sensitive than sequencing, they are simpler to perform on a large number of tumor samples. An example of a mismatch cleavage technique is the RNase protection method. In the practice of the present invention, the method involves the use of a labeled riboprobe which is complementary to the human wild-type BRCA1 gene coding sequence. The riboprobe and either mRNA or DNA isolated from the tumor tissue are annealed (hybridized) together and subsequently digested with the enzyme RNase A which is able to detect some mismatches in a duplex RNA structure. If a mismatch is detected by RNase A, it cleaves at the site of the mismatch. Thus, when the annealed RNA preparation is

separated on an electrophoretic gel matrix, if a mismatch has been detected and cleaved by RNase A, an RNA product will be seen which is smaller than the full length duplex RNA for the riboprobe and the mRNA or DNA. The riboprobe need not be the full length of the BRCA1 mRNA or gene but can be a segment of either. If the riboprobe comprises only a segment of the BRCA1 mRNA or gene, it will be desirable to use a number of these probes to screen the whole mRNA sequence for mismatches.

In similar fashion, DNA probes can be used to detect mismatches, through enzymatic or chemical cleavage. See, e.g., Cotton *et al.*, 1988; Shenk *et al.*, 1975; Novack *et al.*, 1986. Alternatively, mismatches can be detected by shifts in the electrophoretic mobility of mismatched duplexes relative to matched duplexes. See, e.g., Cariello, 1988. With either riboprobes or DNA probes, the cellular mRNA or DNA which might contain a mutation can be amplified using PCR (see below) before hybridization. Changes in DNA of the BRCA1 gene can also be detected using Southern hybridization, especially if the changes are gross rearrangements, such as deletions and insertions.

DNA sequences of the BRCA1 gene which have been amplified by use of PCR may also be screened using allele-specific probes. These probes are nucleic acid oligomers, each of which contains a region of the BRCA1 gene sequence harboring a known mutation. For example, one oligomer may be about 30 nucleotides in length, corresponding to a portion of the BRCA1 gene sequence. By use of a battery of such allele-specific probes, PCR amplification products can be screened to identify the presence of a previously identified mutation in the BRCA1 gene. Hybridization of allele-specific probes with amplified BRCA1 sequences can be performed, for example, on a nylon filter. Hybridization to a particular probe under stringent hybridization conditions indicates the presence of the same mutation in the tumor tissue as in the allele-specific probe.

The most definitive test for mutations in a candidate locus is to directly compare genomic BRCA1 sequences from cancer patients with those from a control population. Alternatively, one could sequence messenger RNA after amplification, e.g., by PCR, thereby eliminating the necessity of determining the exon structure of the candidate gene.

Mutations from cancer patients falling outside the coding region of BRCA1 can be detected by examining the non-coding regions, such as introns and regulatory sequences near or within the BRCA1 gene. An early indication that mutations in noncoding regions are important may come from Northern blot experiments that reveal messenger RNA molecules of abnormal size or abundance in cancer patients as compared to control individuals.

Alteration of BRCA1 mRNA expression can be detected by any techniques known in the art. These include Northern blot analysis, PCR amplification and RNase protection. Diminished mRNA expression indicates an alteration of the wild-type BRCA1 gene. Alteration of wild-type BRCA1 genes can also be detected by screening for alteration of wild-type BRCA1 protein. For example, monoclonal antibodies immunoreactive with BRCA1 can be used to screen a tissue. Lack of cognate antigen would indicate a BRCA1 mutation. Antibodies specific for products of mutant alleles could also be used to detect mutant BRCA1 gene product. Such immunological assays can be done in any convenient formats known in the art. These include Western blots, immunohistochemical assays and ELISA assays. Any means for detecting an altered BRCA1 protein can be used to detect alteration of wild-type BRCA1 genes. Functional assays, such as protein binding determinations, can be used. In addition, assays can be used which detect BRCA1 biochemical function. Finding a mutant BRCA1 gene product indicates alteration of a wild-type BRCA1 gene.

Mutant BRCA1 genes or gene products can also be detected in other human body samples, such as serum, stool, urine and sputum. The same techniques discussed above for detection of mutant BRCA1 genes or gene products in tissues can be applied to other body samples. Cancer cells are sloughed off from tumors and appear in such body samples. In addition, the BRCA1 gene product itself may be secreted into the extracellular space and found in these body samples even in the absence of cancer cells. By screening such body samples, a simple early diagnosis can be achieved for many types of cancers. In addition, the progress of chemotherapy or radiotherapy can be monitored more easily by testing such body samples for mutant BRCA1 genes or gene products.

The methods of diagnosis of the present invention are applicable to any tumor in which BRCA1 has a role in tumorigenesis. The diagnostic method of the present invention is useful for clinicians, so they can decide upon an appropriate course of treatment.

The primer pairs of the present invention are useful for determination of the nucleotide sequence of a particular BRCA1 allele using PCR. The pairs of single-stranded DNA primers can be annealed to sequences within or surrounding the BRCA1 gene on chromosome 17q21 in order to prime amplifying DNA synthesis of the BRCA1 gene itself. A complete set of these primers allows synthesis of all of the nucleotides of the BRCA1 gene coding sequences, i.e., the exons. The set of primers preferably allows synthesis of both intron and exon sequences. Allele-specific primers can also be used. Such primers anneal only to particular BRCA1 mutant alleles, and thus will only amplify a product in the presence of the mutant allele as a template.

In order to facilitate subsequent cloning of amplified sequences, primers may have restriction enzyme site sequences appended to their 5' ends. Thus, all nucleotides of the primers are derived from BRCA1 sequences or sequences adjacent to BRCA1, except for the few nucleotides necessary to form a restriction enzyme site. Such enzymes and sites are well known in the art. The primers themselves can be synthesized using techniques which are well known in the art. Generally, the primers can be made using oligonucleotide synthesizing machines which are commercially available. Given the

sequence of the BRCA1 open reading frame shown in SEQ ID NO:1, design of particular primers is well within the skill of the art.

The nucleic acid probes provided by the present invention are useful for a number of purposes. They can be used in Southern hybridization to genomic DNA and in the RNase protection method for detecting point mutations already discussed above. The probes can be used to detect PCR amplification products. They may also be used to detect mismatches with the BRCA1 gene or mRNA using other techniques.

It has been discovered that individuals with the wild-type BRCA1 gene do not have cancer which results from the BRCA1 allele. However, mutations which interfere with the function of the BRCA1 protein are involved in the pathogenesis of cancer. Thus, the presence of an altered (or a mutant) BRCA1 gene which produces a protein having a loss of function, or altered function, directly correlates to an increased risk of cancer. In order to detect a BRCA1 gene mutation, a biological sample is prepared and analyzed for a difference between the sequence of the BRCA1 allele being analyzed and the sequence of the wild-type BRCA1 allele. Mutant BRCA1 alleles can be initially identified by any of the techniques described above. The mutant alleles are then sequenced to identify the specific mutation of the particular mutant allele. Alternatively, mutant BRCA1 alleles can be initially identified by identifying mutant (altered) BRCA1 proteins, using conventional techniques. The mutant alleles are then sequenced to identify the specific mutation for each allele. The mutations, especially those which lead to an altered function of the BRCA1 protein, are then used for the diagnostic and prognostic methods of the present invention.

### Definitions

The present invention employs the following definitions:

**"Amplification of Polynucleotides"** utilizes methods such as the polymerase chain reaction (PCR), ligation amplification (or ligase chain reaction, LCR) and amplification methods based on the use of Q-beta replicase. These methods are well known and widely practiced in the art. See, e.g., U.S. Patents 4,683,195 and 4,683,202 and Innis *et al.*, 1990 (for PCR); and Wu *et al.*, 1989a (for LCR). Reagents and hardware for conducting PCR are commercially available. Primers useful to amplify sequences from the BRCA1 region are preferably complementary to, and hybridize specifically to sequences in the BRCA1 region or in regions that flank a target region therein. BRCA1 sequences generated by amplification may be sequenced directly. Alternatively, but less desirably, the amplified sequence(s) may be cloned prior to sequence analysis. A method for the direct cloning and sequence analysis of enzymatically amplified genomic segments has been described by Scharf, 1986.

**"Analyte polynucleotide"** and **"analyte strand"** refer to a single- or double-stranded polynucleotide which is suspected of containing a target sequence, and which may be present in a variety of types of samples, including biological samples.

**"Antibodies."** The present invention also provides polyclonal and/or monoclonal antibodies and fragments thereof, and immunologic binding equivalents thereof, which are capable of specifically binding to the BRCA1 polypeptides and fragments thereof or to polynucleotide sequences from the BRCA1 region, particularly from the BRCA1 locus or a portion thereof. The term **"antibody"** is used both to refer to a homogeneous molecular entity, or a mixture such as a serum product made up of a plurality of different molecular entities. Polypeptides may be prepared synthetically in a peptide synthesizer and coupled to a carrier molecule (e.g., keyhole limpet hemocyanin) and injected over several months into rabbits. Rabbit sera is tested for immunoreactivity to the BRCA1 polypeptide or fragment. Monoclonal antibodies may be made by injecting mice with the protein polypeptides, fusion proteins or fragments thereof. Monoclonal antibodies will be screened by ELISA and tested for specific immunoreactivity with BRCA1 polypeptide or fragments thereof. See, Harlow & Lane, 1988. These antibodies will be useful in assays as well as pharmaceuticals.

Once a sufficient quantity of desired polypeptide has been obtained, it may be used for various purposes. A typical use is the production of antibodies specific for binding. These antibodies may be either polyclonal or monoclonal, and may be produced by *in vitro* or *in vivo* techniques well known in the art. For production of polyclonal antibodies, an appropriate target immune system, typically mouse or rabbit, is selected. Substantially purified antigen is presented to the immune system in a fashion determined by methods appropriate for the animal and by other parameters well known to immunologists. Typical sites for injection are in footpads, intramuscularly, intraperitoneally, or intradermally. Of course, other species may be substituted for mouse or rabbit. Polyclonal antibodies are then purified using techniques known in the art, adjusted for the desired specificity.

An immunological response is usually assayed with an immunoassay. Normally, such immunoassays involve some purification of a source of antigen, for example, that produced by the same cells and in the same fashion as the antigen. A variety of immunoassay methods are well known in the art. See, e.g., Harlow & Lane, 1988, or Goding, 1986.

Monoclonal antibodies with affinities of  $10^{-8}$  M<sup>-1</sup> or preferably  $10^{-9}$  to  $10^{-10}$  M<sup>-1</sup> or stronger will typically be made by standard procedures as described, e.g., in Harlow & Lane, 1988 or Goding, 1986. Briefly, appropriate animals will be selected and the desired immunization protocol followed. After the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused, typically, to immortalized myeloma cells under appropriate selec-

tion conditions. Thereafter, the cells are clonally separated and the supernatants of each clone tested for their production of an appropriate antibody specific for the desired region of the antigen.

Other suitable techniques involve *in vitro* exposure of lymphocytes to the antigenic polypeptides, or alternatively, to selection of libraries of antibodies in phage or similar vectors. See Huse *et al.*, 1989. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles and the like. Patents teaching the use of such labels include U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced (see U.S. Patent 4,816,567).

**"Binding partner"** refers to a molecule capable of binding a ligand molecule with high specificity, as for example, an antigen and an antigen-specific antibody or an enzyme and its inhibitor. In general, the specific binding partners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of polynucleotide hybridization) under the isolation conditions. Specific binding partners are known in the art and include, for example, biotin and avidin or streptavidin, IgG and protein A, the numerous, known receptor-ligand couples, and complementary polynucleotide strands. In the case of complementary polynucleotide binding partners, the partners are normally at least about 15 bases in length, and may be at least 40 bases in length. The polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs.

A **"biological sample"** refers to a sample of tissue or fluid suspected of containing an analyte polynucleotide or polypeptide from an individual including, but not limited to, e.g., plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, blood cells, tumors, organs, tissue and samples of *in vitro* cell culture constituents.

As used herein, the terms **"diagnosing"** or **"prognosing,"** as used in the context of neoplasia, are used to indicate 1) the classification of lesions as neoplasia, 2) the determination of the severity of the neoplasia, or 3) the monitoring of the disease progression, prior to, during and after treatment.

**"Encode"**. A polynucleotide is said to "encode" a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for and/or the polypeptide or a fragment thereof. The anti-sense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.

**"Isolated"** or **"substantially pure"**. An "isolated" or "substantially pure" nucleic acid (e.g., an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components which naturally accompany a native human sequence or protein, e.g., ribosomes, polymerases, many other human genome sequences and proteins. The term embraces a nucleic acid sequence or protein which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems.

**"BRCA1 Allele"** refers to normal alleles of the BRCA1 locus as well as alleles carrying variations that predispose individuals to develop cancer of many sites including, for example, breast, ovarian, colorectal and prostate cancer. Such predisposing alleles are also called **"BRCA1 susceptibility alleles"**.

**"BRCA1 Locus," "BRCA1 Gene," "BRCA1 Nucleic Acids" or "BRCA1 Polynucleotide"** each refer to polynucleotides, all of which are in the BRCA1 region, that are likely to be expressed in normal tissue, certain alleles of which predispose an individual to develop breast, ovarian, colorectal and prostate cancers. Mutations at the BRCA1 locus may be involved in the initiation and/or progression of other types of tumors. The locus is indicated in part by mutations that predispose individuals to develop cancer. These mutations fall within the BRCA1 region described *infra*. The BRCA1 locus is intended to include coding sequences, intervening sequences and regulatory elements controlling transcription and/or translation. The BRCA1 locus is intended to include all allelic variations of the DNA sequence.

These terms, when applied to a nucleic acid, refer to a nucleic acid which encodes a BRCA1 polypeptide, fragment, homolog or variant, including, e.g., protein fusions or deletions. The nucleic acids of the present invention will possess a sequence which is either derived from, or substantially similar to a natural BRCA1-encoding gene or one having substantial homology with a natural BRCA1-encoding gene or a portion thereof. The coding sequence for a BRCA1 polypeptide is shown in SEQ ID NO:1, with the amino acid sequence shown in SEQ ID NO:2.

The polynucleotide compositions of this invention include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha ano-

meric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

The present invention provides recombinant nucleic acids comprising all or part of the BRCA1 region. The recombinant construct may be capable of replicating autonomously in a host cell. Alternatively, the recombinant construct may become integrated into the chromosomal DNA of the host cell. Such a recombinant polynucleotide comprises a polynucleotide of genomic, cDNA, semi-synthetic, or synthetic origin which, by virtue of its origin or manipulation, 1) is not associated with all or a portion of a polynucleotide with which it is associated in nature; 2) is linked to a polynucleotide other than that to which it is linked in nature; or 3) does not occur in nature.

Therefore, recombinant nucleic acids comprising sequences otherwise not naturally occurring are provided by this invention. Although the wild-type sequence may be employed, it will often be altered, e.g., by deletion, substitution or insertion.

cDNA or genomic libraries of various types may be screened as natural sources of the nucleic acids of the present invention, or such nucleic acids may be provided by amplification of sequences resident in genomic DNA or other natural sources, e.g., by PCR. The choice of cDNA libraries normally corresponds to a tissue source which is abundant in mRNA for the desired proteins. Phage libraries are normally preferred, but other types of libraries may be used. Clones of a library are spread onto plates, transferred to a substrate for screening, denatured and probed for the presence of desired sequences.

The DNA sequences used in this invention will usually comprise at least about five codons (15 nucleotides), more usually at least about 7-15 codons, and most preferably, at least about 35 codons. One or more introns may also be present. This number of nucleotides is usually about the minimal length required for a successful probe that would hybridize specifically with a BRCA1-encoding sequence.

Techniques for nucleic acid manipulation are described generally, for example, in Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992. Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from such vendors as New England BioLabs, Boehringer Mannheim, Amersham, Promega Biotec, U. S. Biochemicals, New England Nuclear, and a number of other sources. The recombinant nucleic acid sequences used to produce fusion proteins of the present invention may be derived from natural or synthetic sequences. Many natural gene sequences are obtainable from various cDNA or from genomic libraries using appropriate probes. See, GenBank, National Institutes of Health.

"**BRCA1 Region**" refers to a portion of human chromosome 17q21 bounded by the markers tdj1474 and U5R. This region contains the BRCA1 locus, including the BRCA1 gene.

As used herein, the terms "**BRCA1 locus**," "**BRCA1 allele**" and "**BRCA1 region**" all refer to the double-stranded DNA comprising the locus, allele, or region, as well as either of the single-stranded DNAs comprising the locus, allele or region.

As used herein, a "**portion**" of the BRCA1 locus or region or allele is defined as having a minimal size of at least about eight nucleotides, or preferably about 15 nucleotides, or more preferably at least about 25 nucleotides, and may have a minimal size of at least about 40 nucleotides.

"**BRCA1 protein**" or "**BRCA1 polypeptide**" refer to a protein or polypeptide encoded by the BRCA1 locus, variants or fragments thereof. The term "polypeptide" refers to a polymer of amino acids and its equivalent and does not refer to a specific length of the product: thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. This term also does not refer to, or exclude modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages as well as other modifications known in the art, both naturally and non-naturally occurring. Ordinarily, such polypeptides will be at least about 50% homologous to the native BRCA1 sequence, preferably in excess of about 90%, and more preferably at least about 95% homologous. Also included are proteins encoded by DNA which hybridize under high or low stringency conditions, to BRCA1-encoding nucleic acids and closely related polypeptides or proteins retrieved by antisera to the BRCA1 protein(s).

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues.

"**Operably linked**" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression.

"**Probes**". Polynucleotide polymorphisms associated with BRCA1 alleles which predispose to certain cancers or are associated with most cancers are detected by hybridization with a polynucleotide probe which forms a stable hybrid with that of the target sequence, under stringent to moderately stringent hybridization and wash conditions. If it is expected that the probes will be perfectly complementary to the target sequence, stringent conditions will be used. Hy-

bridization stringency may be lessened if some mismatching is expected, for example, if variants are expected with the result that the probe will not be completely complementary. Conditions are chosen which rule out nonspecific/adventitious bindings, that is, which minimize noise. Since such indications identify neutral DNA polymorphisms as well as mutations, these indications need further analysis to demonstrate detection of a BRCA1 susceptibility allele.

Probes for BRCA1 alleles may be derived from the sequences of the BRCA1 region or its cDNAs. The probes may be of any suitable length, which span all or a portion of the BRCA1 region, and which allow specific hybridization to the BRCA1 region. If the target sequence contains a sequence identical to that of the probe, the probes may be short, e.g., in the range of about 8-30 base pairs, since the hybrid will be relatively stable under even stringent conditions. If some degree of mismatch is expected with the probe, i.e., if it is suspected that the probe will hybridize to a variant region, a longer probe may be employed which hybridizes to the target sequence with the requisite specificity.

The probes will include an isolated polynucleotide attached to a label or reporter molecule and may be used to isolate other polynucleotide sequences, having sequence similarity by standard methods. For techniques for preparing and labeling probes see, e.g., Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992. Other similar polynucleotides may be selected by using homologous polynucleotides. Alternatively, polynucleotides encoding these or similar polypeptides may be synthesized or selected by use of the redundancy in the genetic code. Various codon substitutions may be introduced, e.g., by silent changes (thereby producing various restriction sites) or to optimize expression for a particular system. Mutations may be introduced to modify the properties of the polypeptide, perhaps to change ligand-binding affinities, interchain affinities, or the polypeptide degradation or turnover rate.

Probes comprising synthetic oligonucleotides or other polynucleotides of the present invention may be derived from naturally occurring or recombinant single- or double-stranded polynucleotides, or be chemically synthesized. Probes may also be labeled by nick translation, Klenow fill-in reaction, or other methods known in the art.

Portions of the polynucleotide sequence having at least about eight nucleotides, usually at least about 15 nucleotides, and fewer than about 6 kb, usually fewer than about 1.0 kb, from a polynucleotide sequence encoding BRCA1 are preferred as probes. The probes may also be used to determine whether mRNA encoding BRCA1 is present in a cell or tissue.

**"Protein modifications or fragments"** are provided by the present invention for BRCA1 polypeptides or fragments thereof which are substantially homologous to primary structural sequence but which include, e.g., *in vivo* or *in vitro* chemical and biochemical modifications or which incorporate unusual amino acids. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labeling, e.g., with radionuclides, and various enzymatic modifications, as will be readily appreciated by those well skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as <sup>32</sup>P, ligands which bind to labeled antiligands (e.g., antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods of labeling polypeptides are well known in the art. See, e.g., Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992.

Besides substantially full-length polypeptides, the present invention provides for biologically active fragments of the polypeptides. Significant biological activities include ligand-binding, immunological activity and other biological activities characteristic of BRCA1 polypeptides. Immunological activities include both immunogenic function in a target immune system, as well as sharing of immunological epitopes for binding, serving as either a competitor or substitute antigen for an epitope of the BRCA1 protein. As used herein, "epitope" refers to an antigenic determinant of a polypeptide. An epitope could comprise three amino acids in a spatial conformation which is unique to the epitope. Generally, an epitope consists of at least five such amino acids, and more usually consists of at least 8-10 such amino acids. Methods of determining the spatial conformation of such amino acids are known in the art.

For immunological purposes, tandem-repeat polypeptide segments may be used as immunogens, thereby producing highly antigenic proteins. Alternatively, such polypeptides will serve as highly efficient competitors for specific binding. Production of antibodies specific for BRCA1 polypeptides or fragments thereof is described below.

The present invention also provides for fusion polypeptides, comprising BRCA1 polypeptides and fragments. Homologous polypeptides may be fusions between two or more BRCA1 polypeptide sequences or between the sequences of BRCA1 and a related protein. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative proteins. For example, ligand-binding or other domains may be "swapped" between different new fusion polypeptides or fragments. Such homologous or heterologous fusion polypeptides may display, for example, altered strength or specificity of binding. Fusion partners include immunoglobulins, bacterial  $\beta$ -galactosidase, trpE, protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase and yeast alpha mating factor. See, e.g., Godowski *et al.*, 1988.

Fusion proteins will typically be made by either recombinant nucleic acid methods, as described below, or may be chemically synthesized. Techniques for the synthesis of polypeptides are described, for example, in Merrifield, 1963.

**"Protein purification"** refers to various methods for the isolation of the BRCA1 polypeptides from other biological

material, such as from cells transformed with recombinant nucleic acids encoding BRCA1, and are well known in the art. For example, such polypeptides may be purified by immuno-affinity chromatography employing, e.g., the antibodies provided by the present invention. Various methods of protein purification are well known in the art, and include those described in Deutscher, 1990 and Scopes, 1982.

5 The terms **"isolated"**, **"substantially pure"**, and **"substantially homogeneous"** are used interchangeably to describe a protein or polypeptide which has been separated from components which accompany it in its natural state. A monomeric protein is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure protein will typically comprise about 60 to 90% W/W of a protein sample, more usually about 95%, and preferably will be over about 99% pure. Protein purity or homogeneity may be indicated by a number  
10 of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art which are utilized for purification.

A BRCA1 protein is substantially free of naturally associated components when it is separated from the native contaminants which accompany it in its natural state. Thus, a polypeptide which is chemically synthesized or synthesized  
15 in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. A protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A polypeptide produced as an expression product of an isolated and manipulated genetic sequence is an "isolated polypeptide," as used herein, even if expressed in a homologous cell type. Synthetically made forms or molecules  
20 expressed by heterologous cells are inherently isolated molecules.

**"Recombinant nucleic acid"** is a nucleic acid which is not naturally occurring, or which is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a  
25 conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.

**"Regulatory sequences"** refers to those sequences normally within 100 kb of the coding region of a locus, but they may also be more distant from the coding region, which affect the expression of the gene (including transcription of the gene, and translation, splicing, stability or the like of the messenger RNA).

**"Substantial homology or similarity"**. A nucleic acid or fragment thereof is "substantially homologous" ("or substantially similar") to another if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases.  
30

Alternatively, substantial homology or (similarity) exists when a nucleic acid or fragment thereof will hybridize to another nucleic acid (or a complementary strand thereof) under selective hybridization conditions, to a strand, or to its complement. Selectivity of hybridization exists when hybridization which is substantially more selective than total lack of specificity occurs. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably  
35 at least about 90%. See, Kanehisa, 1984. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, or organic solvents,  
45 in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, typically in excess of 37°C, and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur & Davidson, 1968.  
50

Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

The terms **"substantial homology"** or **"substantial identity"**, when referring to polypeptides, indicate that the polypeptide or protein in question exhibits at least about 30% identity with an entire naturally-occurring protein or a portion thereof, usually at least about 70% identity, and preferably at least about 95% identity.  
55

**"Substantially similar function"** refers to the function of a modified nucleic acid or a modified protein, with reference to the wild-type BRCA1 nucleic acid or wild-type BRCA1 polypeptide. The modified polypeptide will be substan-

tially homologous to the wild-type BRCA1 polypeptide and will have substantially the same function. The modified polypeptide may have an altered amino acid sequence and/or may contain modified amino acids. In addition to the similarity of function, the modified polypeptide may have other useful properties, such as a longer half-life. The similarity of function (activity) of the modified polypeptide may be substantially the same as the activity of the wild-type BRCA1 polypeptide. Alternatively, the similarity of function (activity) of the modified polypeptide may be higher than the activity of the wild-type BRCA1 polypeptide. The modified polypeptide is synthesized using conventional techniques, or is encoded by a modified nucleic acid and produced using conventional techniques. The modified nucleic acid is prepared by conventional techniques. A nucleic acid with a function substantially similar to the wild-type BRCA1 gene function produces the modified protein described above.

Homology, for polypeptides, is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wisconsin 53705. Protein analysis software matches similar sequences using measure of homology assigned to various substitutions, deletions and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

A polypeptide "**fragment**," "**portion**" or "**segment**" is a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino acids and, most preferably, at least about 20 to 30 or more contiguous amino acids.

The polypeptides of the present invention, if soluble, may be coupled to a solid-phase support, e.g., nitrocellulose, nylon, column packing materials (e.g., Sepharose beads), magnetic beads, glass wool, plastic, metal, polymer gels, cells, or other substrates. Such supports may take the form, for example, of beads, wells, dipsticks, or membranes.

"**Target region**" refers to a region of the nucleic acid which is amplified and/or detected. The term "**target sequence**" refers to a sequence with which a probe or primer will form a stable hybrid under desired conditions.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, and immunology. See, e.g., Maniatis *et al.*, 1982; Sambrook *et al.*, 1989; Ausubel *et al.*, 1992; Glover, 1985; Anand, 1992; Guthrie & Fink, 1991. A general discussion of techniques and materials for human gene mapping, including mapping of human chromosome 17q, is provided, e.g., in White and Lalouel, 1988.

#### Preparation of recombinant or chemically synthesized nucleic acids: vectors, transformation, host cells

Large amounts of the polynucleotides of the present invention may be produced by replication in a suitable host cell. Natural or synthetic polynucleotide fragments coding for a desired fragment will be incorporated into recombinant polynucleotide constructs, usually DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the polynucleotide constructs will be suitable for replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to (with and without integration within the genome) cultured mammalian or plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention is described, e.g., in Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992.

The polynucleotides of the present invention may also be produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage & Carruthers, 1981 or the triester method according to Matteucci and Caruthers, 1981, and may be performed on commercial, automated oligonucleotide synthesizers. A double-stranded fragment may be obtained from the single-stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Polynucleotide constructs prepared for introduction into a prokaryotic or eukaryotic host may comprise a replication system recognized by the host, including the intended polynucleotide fragment encoding the desired polypeptide, and will preferably also include transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences. Secretion signals may also be included where appropriate, whether from a native BRCA1 protein or from other receptors or from secreted polypeptides of the same or related species, which allow the protein to cross and/or lodge in cell membranes, and thus attain its functional topology, or be secreted from the cell. Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992.

An appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host, and may include, when appropriate, those naturally associated with BRCA1 genes. Examples of workable combinations of cell lines and expression vectors are described in Sambrook *et al.*, 1989 or Ausubel *et al.*, 1992; see also, e.g.,

Metzger *et al.*, 1988. Many useful vectors are known in the art and may be obtained from such vendors as Stratagene, New England Biolabs, Promega Biotech, and others. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others. Vectors and promoters suitable for use in yeast expression are further described in Hitzeman *et al.*, EP 73,675A. Appropriate non-native mammalian promoters might include the early and late promoters from SV40 (Fiers *et al.*, 1978) or promoters derived from murine Moloney leukemia virus, mouse tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made. For appropriate enhancer and other expression control sequences, see also *Enhancers and Eukaryotic Gene Expression*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1983).

While such expression vectors may replicate autonomously, they may also replicate by being inserted into the genome of the host cell, by methods well known in the art.

Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene ensures growth of only those host cells which express the inserts. Typical selection genes encode proteins that a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; b) complement auxotrophic deficiencies, or c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.

The vectors containing the nucleic acids of interest can be transcribed *in vitro*, and the resulting RNA introduced into the host cell by well-known methods, e.g., by injection (see, Kubo *et al.*, 1988), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. See generally, Sambrook *et al.*, 1989 and Ausubel *et al.*, 1992. The introduction of the polynucleotides into the host cell by any method known in the art, including, *inter alia*, those described above, will be referred to herein as "transformation." The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.

Large quantities of the nucleic acids and polypeptides of the present invention may be prepared by expressing the BRCA1 nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of *Escherichia coli*, although other prokaryotes, such as *Bacillus subtilis* or *Pseudomonas* may also be used.

Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, or amphibian or avian species, may also be useful for production of the proteins of the present invention. Propagation of mammalian cells in culture is *per se* well known. See, Jakoby and Pastan, 1979. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38, BHK, and COS cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g., to provide higher expression, desirable glycosylation patterns, or other features.

Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, preferably the same DNA molecule. In prokaryotic hosts, the transformant may be selected, e.g., by resistance to ampicillin, tetracycline or other antibiotics. Production of a particular product based on temperature sensitivity may also serve as an appropriate marker.

Prokaryotic or eukaryotic cells transformed with the polynucleotides of the present invention will be useful not only for the production of the nucleic acids and polypeptides of the present invention, but also, for example, in studying the characteristics of BRCA1 polypeptides.

Antisense polynucleotide sequences are useful in preventing or diminishing the expression of the BRCA1 locus, as will be appreciated by those skilled in the art. For example, polynucleotide vectors containing all or a portion of the BRCA1 locus or other sequences from the BRCA1 region (particularly those flanking the BRCA1 locus) may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell will interfere with BRCA1 transcription and/or translation and/or replication.

The probes and primers based on the BRCA1 gene sequences disclosed herein are used to identify homologous BRCA1 gene sequences and proteins in other species. These BRCA1 gene sequences and proteins are used in the diagnostic/prognostic, therapeutic and drug screening methods described herein for the species from which they have been isolated.

Methods of Use: Nucleic Acid Diagnosis and Diagnostic Kits

In order to detect the presence of a BRCA1 allele predisposing an individual to cancer, a biological sample such as blood is prepared and analyzed for the presence or absence of susceptibility alleles of BRCA1. In order to detect the presence of neoplasia, the progression toward malignancy of a precursor lesion, or as a prognostic indicator, a biological sample of the lesion is prepared and analyzed for the presence or absence of mutant alleles of BRCA1. Results of these tests and interpretive information are returned to the health care provider for communication to the tested individual. Such diagnoses may be performed by diagnostic laboratories, or, alternatively, diagnostic kits are manufactured and sold to health care providers or to private individuals for self-diagnosis.

Initially, the screening method involves amplification of the relevant BRCA1 sequences. In another preferred embodiment of the invention, the screening method involves a non-PCR based strategy. Such screening methods include two-step label amplification methodologies that are well known in the art. Both PCR and non-PCR based screening strategies can detect target sequences with a high level of sensitivity.

The most popular method used today is target amplification. Here, the target nucleic acid sequence is amplified with polymerases. One particularly preferred method using polymerase-driven amplification is the polymerase chain reaction (PCR). The polymerase chain reaction and other polymerase-driven amplification assays can achieve over a million-fold increase in copy number through the use of polymerase-driven amplification cycles. Once amplified, the resulting nucleic acid can be sequenced or used as a substrate for DNA probes.

When the probes are used to detect the presence of the target sequences (for example, in screening for cancer susceptibility), the biological sample to be analyzed, such as blood or serum, may be treated, if desired, to extract the nucleic acids. The sample nucleic acid may be prepared in various ways to facilitate detection of the target sequence; e.g. denaturation, restriction digestion, electrophoresis or dot blotting. The targeted region of the analyte nucleic acid usually must be at least partially single-stranded to form hybrids with the targeting sequence of the probe. If the sequence is naturally single-stranded, denaturation will not be required. However, if the sequence is double-stranded, the sequence will probably need to be denatured. Denaturation can be carried out by various techniques known in the art.

Analyte nucleic acid and probe are incubated under conditions which promote stable hybrid formation of the target sequence in the probe with the putative targeted sequence in the analyte. The region of the probes which is used to bind to the analyte can be made completely complementary to the targeted region of human chromosome 17q. Therefore, high stringency conditions are desirable in order to prevent false positives. However, conditions of high stringency are used only if the probes are complementary to regions of the chromosome which are unique in the genome. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, base composition, probe length, and concentration of formamide. These factors are outlined in, for example, Maniatis *et al.*, 1982 and Sambrook *et al.*, 1989. Under certain circumstances, the formation of higher order hybrids, such as triplexes, quadruplexes, etc., may be desired to provide the means of detecting target sequences.

Detection, if any, of the resulting hybrid is usually accomplished by the use of labeled probes. Alternatively, the probe may be unlabeled, but may be detectable by specific binding with a ligand which is labeled, either directly or indirectly. Suitable labels, and methods for labeling probes and ligands are known in the art, and include, for example, radioactive labels which may be incorporated by known methods (e.g., nick translation, random priming or kinasing), biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), enzymes, antibodies and the like. Variations of this basic scheme are known in the art, and include those variations that facilitate separation of the hybrids to be detected from extraneous materials and/or that amplify the signal from the labeled moiety. A number of these variations are reviewed in, e.g., Matthews & Kricka, 1988; Landegren *et al.*, 1988; Mittlin, 1989; U.S. Patent 4,868,105, and in EPO Publication No. 225,807.

As noted above, non-PCR based screening assays are also contemplated in this invention. An exemplary non-PCR based procedure is provided in Example 11. This procedure hybridizes a nucleic acid probe (or an analog such as a methyl phosphonate backbone replacing the normal phosphodiester), to the low level DNA target. This probe may have an enzyme covalently linked to the probe, such that the covalent linkage does not interfere with the specificity of the hybridization. This enzyme-probe-conjugate-target nucleic acid complex can then be isolated away from the free probe enzyme conjugate and a substrate is added for enzyme detection. Enzymatic activity is observed as a change in color development or luminescent output resulting in a  $10^3$ - $10^6$  increase in sensitivity. For an example relating to the preparation of oligodeoxynucleotide-alkaline phosphatase conjugates and their use as hybridization probes see Jablonski *et al.*, 1986.

Two-step label amplification methodologies are known in the art. These assays work on the principle that a small ligand (such as digoxigenin, biotin, or the like) is attached to a nucleic acid probe capable of specifically binding BRCA1. Exemplary probes are provided in Table 9 of this patent application and additionally include the nucleic acid probe corresponding to nucleotide positions 3631 to 3930 of SEQ ID NO:1. Allele specific probes are also contemplated within the scope of this example and exemplary allele specific probes include probes encompassing the predisposing mutations summarized in Tables 11 and 12 of this patent application.

In one example, the small ligand attached to the nucleic acid probe is specifically recognized by an antibody-enzyme conjugate. In one embodiment of this example, digoxigenin is attached to the nucleic acid probe. Hybridization is detected by an antibody-alkaline phosphatase conjugate which turns over a chemiluminescent substrate. For methods for labeling nucleic acid probes according to this embodiment see Martin *et al.*, 1990. In a second example, the small ligand is recognized by a second ligand-enzyme conjugate that is capable of specifically complexing to the first ligand. A well known embodiment of this example is the biotin-avidin type of interactions. For methods for labeling nucleic acid probes and their use in biotin-avidin based assays see Rigby *et al.*, 1977 and Nguyen *et al.*, 1992.

It is also contemplated within the scope of this invention that the nucleic acid probe assays of this invention will employ a cocktail of nucleic acid probes capable of detecting BRCA1. Thus, in one example to detect the presence of BRCA1 in a cell sample, more than one probe complementary to BRCA1 is employed and in particular the number of different probes is alternatively 2, 3, or 5 different nucleic acid probe sequences. In another example, to detect the presence of mutations in the BRCA1 gene sequence in a patient, more than one probe complementary to BRCA1 is employed where the cocktail includes probes capable of binding to the allele-specific mutations identified in populations of patients with alterations in BRCA1. In this embodiment, any number of probes can be used, and will preferably include probes corresponding to the major gene mutations identified as predisposing an individual to breast cancer. Some candidate probes contemplated within the scope of the invention include probes that include the allele-specific mutations identified in Tables 11 and 12 and those that have the BRCA1 regions corresponding to SEQ ID NO:1 both 5' and 3' to the mutation site.

#### Methods of Use: Peptide Diagnosis and Diagnostic Kits

The neoplastic condition of lesions can also be detected on the basis of the alteration of wild-type BRCA1 polypeptide. Such alterations can be determined by sequence analysis in accordance with conventional techniques. More preferably, antibodies (polyclonal or monoclonal) are used to detect differences in, or the absence of BRCA1 peptides. The antibodies may be prepared as discussed above under the heading "Antibodies" and as further shown in Examples 12 and 13. Other techniques for raising and purifying antibodies are well known in the art and any such techniques may be chosen to achieve the preparations claimed in this invention. In a preferred embodiment of the invention, antibodies will immunoprecipitate BRCA1 proteins from solution as well as react with BRCA1 protein on Western or immunoblots of polyacrylamide gels. In another preferred embodiment, antibodies will detect BRCA1 proteins in paraffin or frozen tissue sections, using immunocytochemical techniques.

Preferred embodiments relating to methods for detecting BRCA1 or its mutations include enzyme linked immunosorbent assays (ELISA), radioimmunoassays (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal and/or polyclonal antibodies. Exemplary sandwich assays are described by David *et al.* in U.S. Patent Nos. 4,376,110 and 4,486,530, hereby incorporated by reference, and exemplified in Example 14.

#### Methods of Use: Drug Screening

This invention is particularly useful for screening compounds by using the BRCA1 polypeptide or binding fragment thereof in any of a variety of drug screening techniques.

The BRCA1 polypeptide or fragment employed in such a test may either free in solution, affixed to a solid support, or borne on a cell surface. One method of drug screening utilizes eucaryotic or procaryotic host cells which are stably transformed with recombinant polynucleotides expressing the polypeptide or fragment, preferably in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, for the formation of complexes between a BRCA1 polypeptide or fragment and the agent being tested, or examine the degree to which the formation of a complex between a BRCA1 polypeptide or fragment and a known ligand is interfered with by the agent being tested.

Thus, the present invention provides methods of screening for drugs comprising contacting such an agent with a BRCA1 polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the BRCA1 polypeptide or fragment, or (ii) for the presence of a complex between the BRCA1 polypeptide or fragment and a ligand, by methods well known in the art. In such competitive binding assays the BRCA1 polypeptide or fragment is typically labeled. Free BRCA1 polypeptide or fragment is separated from that present in a protein:protein complex, and the amount of free (i.e., uncomplexed) label is a measure of the binding of the agent being tested to BRCA1 or its interference with BRCA1:ligand binding, respectively.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the BRCA1 polypeptides and is described in detail in Geysen, PCT published application WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with BRCA1

polypeptide and washed. Bound BRCA1 polypeptide is then detected by methods well known in the art.

Purified BRCA1 can be coated directly onto plates for use in the aforementioned drug screening techniques. However, non-neutralizing antibodies to the polypeptide can be used to capture antibodies to immobilize the BRCA1 polypeptide on the solid phase.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of specifically binding the BRCA1 polypeptide compete with a test compound for binding to the BRCA1 polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants of the BRCA1 polypeptide.

A further technique for drug screening involves the use of host eukaryotic cell lines or cells (such as described above) which have a nonfunctional BRCA1 gene. These host cell lines or cells are defective at the BRCA1 polypeptide level. The host cell lines or cells are grown in the presence of drug compound. The rate of growth of the host cells is measured to determine if the compound is capable of regulating the growth of BRCA1 defective cells.

#### Methods of Use: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact (e.g., agonists, antagonists, inhibitors) in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g., enhance or interfere with the function of a polypeptide *in vivo*. See, e.g., Hodgson, 1991. In one approach, one first determines the three-dimensional structure of a protein of interest (e.g., BRCA1 polypeptide) or, for example, of the BRCA1-receptor or ligand complex, by x-ray crystallography, by computer modeling or most typically, by a combination of approaches. Less often, useful information regarding the structure of a polypeptide may be gained by modeling based on the structure of homologous proteins. An example of rational drug design is the development of HIV protease inhibitors (Erickson *et al.*, 1990). In addition, peptides (e.g., BRCA1 polypeptide) are analyzed by an alanine scan (Wells, 1991). In this technique, an amino acid residue is replaced by Ala, and its effect on the peptide's activity is determined. Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.

It is also possible to isolate a target-specific antibody, selected by a functional assay, and then to solve its crystal structure. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idio-typic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of peptides. Selected peptides would then act as the pharmacore.

Thus, one may design drugs which have, e.g., improved BRCA1 polypeptide activity or stability or which act as inhibitors, agonists, antagonists, etc. of BRCA1 polypeptide activity. By virtue of the availability of cloned BRCA1 sequences, sufficient amounts of the BRCA1 polypeptide may be made available to perform such analytical studies as x-ray crystallography. In addition, the knowledge of the BRCA1 protein sequence provided herein will guide those employing computer modeling techniques in place of, or in addition to x-ray crystallography.

#### Methods of Use: Gene Therapy

According to the present invention, a method is also provided of supplying wild-type BRCA1 function to a cell which carries mutant BRCA1 alleles. Supplying such a function should suppress neoplastic growth of the recipient cells. The wild-type BRCA1 gene or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location. If a gene fragment is introduced and expressed in a cell carrying a mutant BRCA1 allele, the gene fragment should encode a part of the BRCA1 protein which is required for non-neoplastic growth of the cell. More preferred is the situation where the wild-type BRCA1 gene or a part thereof is introduced into the mutant cell in such a way that it recombines with the endogenous mutant BRCA1 gene present in the cell. Such recombination requires a double recombination event which results in the correction of the BRCA1 gene mutation. Vectors for introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector may be used. Methods for introducing DNA into cells such as electroporation, calcium phosphate co-precipitation and viral transduction are known in the art, and the choice of method is within the competence of the routineer. Cells transformed with the wild-type BRCA1 gene can be used as model systems to study cancer remission and drug treatments which promote such remission.

As generally discussed above, the BRCA1 gene or fragment, where applicable, may be employed in gene therapy methods in order to increase the amount of the expression products of such genes in cancer cells. Such gene therapy is particularly appropriate for use in both cancerous and pre-cancerous cells, in which the level of BRCA1 polypeptide is absent or diminished compared to normal cells. It may also be useful to increase the level of expression of a given BRCA1 gene even in those tumor cells in which the mutant gene is expressed at a "normal" level, but the gene product

is not fully functional.

Gene therapy would be carried out according to generally accepted methods, for example, as described by Friedman, 1991. Cells from a patient's tumor would be first analyzed by the diagnostic methods described above, to ascertain the production of BRCA1 polypeptide in the tumor cells. A virus or plasmid vector (see further details below), containing a copy of the BRCA1 gene linked to expression control elements and capable of replicating inside the tumor cells, is prepared. Suitable vectors are known, such as disclosed in U.S. Patent 5,252,479 and PCT published application WO 93/07282. The vector is then injected into the patient, either locally at the site of the tumor or systemically (in order to reach any tumor cells that may have metastasized to other sites). If the transfected gene is not permanently incorporated into the genome of each of the targeted tumor cells, the treatment may have to be repeated periodically.

Gene transfer systems known in the art may be useful in the practice of the gene therapy methods of the present invention. These include viral and nonviral transfer methods. A number of viruses have been used as gene transfer vectors, including papovaviruses, e.g., SV40 (Madzak *et al.*, 1992), adenovirus (Berkner, 1992; Berkner *et al.*, 1988; Gorziglia and Kapikian, 1992; Quantin *et al.*, 1992; Rosenfeld *et al.*, 1992; Wilkinson *et al.*, 1992; Stratford-Perricaudet *et al.*, 1990), vaccinia virus (Moss, 1992), adeno-associated virus (Muzyczka, 1992; Ohi *et al.*, 1990), herpesviruses including HSV and EBV (Margolskee, 1992; Johnson *et al.*, 1992; Fink *et al.*, 1992; Breakfield and Geller, 1987; Freese *et al.*, 1990), and retroviruses of avian (Brandyopadhyay and Temin, 1984; Petropoulos *et al.*, 1992), murine (Miller, 1992; Miller *et al.*, 1985; Sorge *et al.*, 1984; Mann and Baltimore, 1985; Miller *et al.*, 1988), and human origin (Shimada *et al.*, 1991; Helseth *et al.*, 1990; Page *et al.*, 1990; Buchschacher and Panganiban, 1992). Most human gene therapy protocols have been based on disabled murine retroviruses.

Nonviral gene transfer methods known in the art include chemical techniques such as calcium phosphate coprecipitation (Graham and van der Eb, 1973; Pellicer *et al.*, 1980); mechanical techniques, for example microinjection (Anderson *et al.*, 1980; Gordon *et al.*, 1980; Brinster *et al.*, 1981; Constantini and Lacy, 1981); membrane fusion-mediated transfer via liposomes (Felgner *et al.*, 1987; Wang and Huang, 1989; Kaneda *et al.*, 1989; Stewart *et al.*, 1992; Nabel *et al.*, 1990; Lim *et al.*, 1992); and direct DNA uptake and receptor-mediated DNA transfer (Wolff *et al.*, 1990; Wu *et al.*, 1991; Zenke *et al.*, 1990; Wu *et al.*, 1989b; Wolff *et al.*, 1991; Wagner *et al.*, 1990; Wagner *et al.*, 1991; Cotten *et al.*, 1990; Curiel *et al.*, 1991a; Curiel *et al.*, 1991b). Viral-mediated gene transfer can be combined with direct *in vivo* gene transfer using liposome delivery, allowing one to direct the viral vectors to the tumor cells and not into the surrounding nondividing cells. Alternatively, the retroviral vector producer cell line can be injected into tumors (Culver *et al.*, 1992). Injection of producer cells would then provide a continuous source of vector particles. This technique has been approved for use in humans with inoperable brain tumors.

In an approach which combines biological and physical gene transfer methods plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein, and the resulting complex is bound to an adenovirus vector. The trimolecular complex is then used to infect cells. The adenovirus vector permits efficient binding, internalization, and degradation of the endosome before the coupled DNA is damaged.

Liposome/DNA complexes have been shown to be capable of mediating direct *in vivo* gene transfer. While in standard liposome preparations the gene transfer process is nonspecific, localized *in vivo* uptake and expression have been reported in tumor deposits, for example, following direct *in situ* administration (Nabel, 1992).

Gene transfer techniques which target DNA directly to breast and ovarian tissues, e.g., epithelial cells of the breast or ovaries, is preferred. Receptor-mediated gene transfer, for example, is accomplished by the conjugation of DNA (usually in the form of covalently closed supercoiled plasmid) to a protein ligand via polylysine. Ligands are chosen on the basis of the presence of the corresponding ligand receptors on the cell surface of the target cell/tissue type. One appropriate receptor/ligand pair may include the estrogen receptor and its ligand, estrogen (and estrogen analogues). These ligand-DNA conjugates can be injected directly into the blood if desired and are directed to the target tissue where receptor binding and internalization of the DNA-protein complex occurs. To overcome the problem of intracellular destruction of DNA, coinfection with adenovirus can be included to disrupt endosome function.

The therapy involves two steps which can be performed singly or jointly. In the first step, prepubescent females who carry a BRCA1 susceptibility allele are treated with a gene delivery vehicle such that some or all of their mammary ductal epithelial precursor cells receive at least one additional copy of a functional normal BRCA1 allele. In this step, the treated individuals have reduced risk of breast cancer to the extent that the effect of the susceptible allele has been countered by the presence of the normal allele. In the second step of a preventive therapy, predisposed young females, in particular women who have received the proposed gene therapeutic treatment, undergo hormonal therapy to mimic the effects on the breast of a full term pregnancy.

#### Methods of Use: Peptide Therapy

Peptides which have BRCA1 activity can be supplied to cells which carry mutant or missing BRCA1 alleles. The sequence of the BRCA1 protein is disclosed (SEQ ID NO:2). Protein can be produced by expression of the cDNA sequence in bacteria, for example, using known expression vectors. Alternatively, BRCA1 polypeptide can be extracted

from BRCA1-producing mammalian cells. In addition, the techniques of synthetic chemistry can be employed to synthesize BRCA1 protein. Any of such techniques can provide the preparation of the present invention which comprises the BRCA1 protein. The preparation is substantially free of other human proteins. This is most readily accomplished by synthesis in a microorganism or *in vitro*.

Active BRCA1 molecules can be introduced into cells by microinjection or by use of liposomes, for example. Alternatively, some active molecules may be taken up by cells, actively or by diffusion. Extracellular application of the BRCA1 gene product may be sufficient to affect tumor growth. Supply of molecules with BRCA1 activity should lead to partial reversal of the neoplastic state. Other molecules with BRCA1 activity (for example, peptides, drugs or organic compounds) may also be used to effect such a reversal. Modified polypeptides having substantially similar function are also used for peptide therapy.

#### Methods of Use: Transformed Hosts

Similarly, cells and animals which carry a mutant BRCA1 allele can be used as model systems to study and test for substances which have potential as therapeutic agents. The cells are typically cultured epithelial cells. These may be isolated from individuals with BRCA1 mutations, either somatic or germline. Alternatively, the cell line can be engineered to carry the mutation in the BRCA1 allele, as described above. After a test substance is applied to the cells, the neoplastically transformed phenotype of the cell is determined. Any trait of neoplastically transformed cells can be assessed, including anchorage-independent growth, tumorigenicity in nude mice, invasiveness of cells, and growth factor dependence. Assays for each of these traits are known in the art.

Animals for testing therapeutic agents can be selected after mutagenesis of whole animals or after treatment of germline cells or zygotes. Such treatments include insertion of mutant BRCA1 alleles, usually from a second animal species, as well as insertion of disrupted homologous genes. Alternatively, the endogenous BRCA1 gene(s) of the animals may be disrupted by insertion or deletion mutation or other genetic alterations using conventional techniques (Capecci, 1989; Valancius and Smithies, 1991; Hasty *et al.*, 1991; Shinkai *et al.*, 1992; Mombaerts *et al.*, 1992; Philpott *et al.*, 1992; Snouwaert *et al.*, 1992; Donehower *et al.*, 1992). After test substances have been administered to the animals, the growth of tumors must be assessed. If the test substance prevents or suppresses the growth of tumors, then the test substance is a candidate therapeutic agent for the treatment of the cancers identified herein. These animal models provide an extremely important testing vehicle for potential therapeutic products.

The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.

#### EXAMPLE 1

##### Ascertain and Study Kindreds Likely to Have a 17q-Linked Breast Cancer Susceptibility Locus

Extensive cancer prone kindreds were ascertained from a defined population providing a large set of extended kindreds with multiple cases of breast cancer and many relatives available to study. The large number of meioses present in these large kindreds provided the power to detect whether the BRCA1 locus was segregating, and increased the opportunity for informative recombinants to occur within the small region being investigated. This vastly improved the chances of establishing linkage to the BRCA1 region, and greatly facilitated the reduction of the BRCA1 region to a manageable size, which permits identification of the BRCA1 locus itself.

Each kindred was extended through all available connecting relatives, and to all informative first degree relatives of each proband or cancer case. For these kindreds, additional breast cancer cases and individuals with cancer at other sites of interest (e.g. ovarian) who also appeared in the kindreds were identified through the tumor registry linked files. All breast cancers reported in the kindred which were not confirmed in the Utah Cancer Registry were researched. Medical records or death certificates were obtained for confirmation of all cancers. Each key connecting individual and all informative individuals were invited to participate by providing a blood sample from which DNA was extracted. We also sampled spouses and relatives of deceased cases so that the genotype of the deceased cases could be inferred from the genotypes of their relatives.

Ten kindreds which had three or more cancer cases with inferable genotypes were selected for linkage studies to 17q markers from a set of 29 kindreds originally ascertained from the linked databases for a study of proliferative breast disease and breast cancer (Skolnick *et al.*, 1990). The criterion for selection of these kindreds was the presence of two sisters or a mother and her daughter with breast cancer. Additionally, two kindreds which have been studied since 1980 as part of our breast cancer linkage studies (K1001, K9018), six kindreds ascertained from the linked databases for the presence of clusters of breast and/or ovarian cancer (K2019, K2073, K2079, K2080, K2039, K2082) and a self-referred kindred with early onset breast cancer (K2035) were included. These kindreds were investigated and expanded in our

clinic in the manner described above. Table 1 displays the characteristics of these 19 kindreds which are the subject of subsequent examples. In Table 1, for each kindred the total number of individuals in our database, the number of typed individuals, and the minimum, median, and maximum age at diagnosis of breast/ovarian cancer are reported. Kindreds are sorted in ascending order of median age at diagnosis of breast cancer. Four women diagnosed with both ovarian and breast cancer are counted in both categories.

5

10

15

20

25

30

35

40

45

50

55

TABLE 1  
Description of the 19 Kindreds

KINDRED	No. of Individuals	Total	Sample	Breast				Ovarian			
				# Aff.	Age at Dx			# Aff.	Age at Dx		
					Min.	Med.	Max.		Min.	Med.	Max.
1910	15	10	4	27	34	49	-	-	-	-	-
11001	133	98	13	28	37	64	-	-	-	-	-
2035	42	25	8	28	37	45	1	-	60	-	-
2027	21	11	4	34	38	41	-	-	-	-	-
9018	54	17	9	30	40	72	2	46	48	50	50
1925	50	27	4	39	42	53	-	-	-	-	-
1927	49	29	5	32	42	51	-	-	-	-	-
1911	28	21	7	28	42	76	-	-	-	-	-
1929	16	11	4	34	43	73	-	-	-	-	-
1901	35	19	10	31	44	76	-	-	-	-	-
2082	180	105	20	27	47	67	10	45	52	66	66
2019	42	19	10	42	53	79	-	-	-	-	-
1900	70	23	8	45	55	70	1	-	78	-	-
2080	264	74	22+	27	55	92	4	45	53	71	71
2073	57	29	9	35	57	80	-	-	-	-	-
1917	16	6	4	43	58	61	-	-	-	-	-
1920	22	14	3	62	63	68	-	-	-	-	-
2079	136	18	14	38	66	84	4	52	59	65	65
2039	87	40	14	44	68	88	4	41	51	75	75

+ Includes one case of male breast cancer.

EXAMPLE 2Selection of Kindreds Which are Linked to Chromosome 17q and Localization of BRCA1 to the Interval Mfd15 - Mfd188

For each sample collected in these 19 kindreds, DNA was extracted from blood (or in two cases from paraffin-embedded tissue blocks) using standard laboratory protocols. Genotyping in this study was restricted to short tandem repeat (STR) markers since, in general, they have high heterozygosity and PCR methods offer rapid turnaround while using very small amounts of DNA. To aid in this effort, four such STR markers on chromosome 17 were developed by screening a chromosome specific cosmid library for CA positive clones. Three of these markers localized to the long arm: (46E6, Easton *et al.*, 1993); (42D6, Easton *et al.*, 1993); 26C2 (D17S514, Oliphant *et al.*, 1991), while the other, 12G6 (D17S513, Oliphant *et al.*, 1991), localized to the short arm near the p53 tumor suppressor locus. Two of these, 42D6 and 46E6, were submitted to the Breast Cancer Linkage Consortium for typing of breast cancer families by investigators worldwide. Oligonucleotide sequences for markers not developed in our laboratory were obtained from published reports, or as part of the Breast Cancer Linkage Consortium, or from other investigators. All genotyping films were scored blindly with a standard lane marker used to maintain consistent coding of alleles. Key samples in the four kindreds presented here underwent duplicate typing for all relevant markers. All 19 kindreds have been typed for two polymorphic CA repeat markers: 42D6 (D17S588), a CA repeat isolated in our laboratory, and Mfd15 (D17S250), a CA repeat provided by J. Weber (Weber *et al.*, 1990). Several sources of probes were used to create genetic markers on chromosome 17, specifically chromosome 17 cosmid and lambda phage libraries created from sorted chromosomes by the Los Alamos National Laboratories (van Dilla *et al.*, 1986).

LOD scores for each kindred with these two markers (42D6, Mfd15) and a third marker, Mfd188 (D17S579, Hall *et al.*, 1992), located roughly midway between these two markers, were calculated for two values of the recombination fraction, 0.001 and 0.1. (For calculation of LOD scores, see Oh, 1985). Likelihoods were computed under the model derived by Claus *et al.*, 1991, which assumes an estimated gene frequency of 0.003, a lifetime risk in gene carriers of about 0.80, and population based age-specific risks for breast cancer in non-gene carriers. Allele frequencies for the three markers used for the LOD score calculations were calculated from our own laboratory typings of unrelated individuals in the CEPH panel (White and Lalouel, 1988). Table 2 shows the results of the pairwise linkage analysis of each kindred with the three markers 42D6, Mfd188, and Mfd15.

**TABLE 2**  
**Pairwise Linkage Analysis of Kindreds**

	Mfd15 (D17S250) Recombination		Mfd188 (D17S579) Recombination		42D6 (D17S588) Recombination	
	0.001	0.1	0.001	0.1	0.001	0.1
<b>KINDRED</b>						
1910	0.06	0.30	0.06	0.30	0.06	0.30
1001	-0.30	-0.09	NT	NT	-0.52	-0.19
2035	2.34	1.85	0.94	0.90	2.34	1.82
2027	-1.22	-0.33	-1.20	-0.42	-1.16	-0.33
9018	-0.54	-0.22	-0.17	-0.10	0.11	0.07
1925	1.08	0.79	0.55	0.38	-0.11	-0.07
1927	-0.41	0.01	-0.35	0.07	-0.44	-0.02
1911	-0.27	-0.13	-0.43	-0.23	0.49	0.38
1929	-0.49	-0.25	NT	NT	-0.49	-0.25
1901	1.50	1.17	0.78	0.57	0.65	0.37
2082	4.25	3.36	6.07	5.11	2.00	3.56
2019	-0.10	-0.01	-0.11	-0.05	-0.18	-0.10
1900	-0.14	-0.11	NT	NT	-0.12	-0.05
2080	-0.16	-0.04	0.76	0.74	-1.25	-0.58
2073	-0.41	-0.29	0.63	0.49	-0.23	-0.13
1917	-0.02	-0.02	NT	NT	-0.01	0.00
1920	-0.03	-0.02	NT	NT	0.00	0.00
2079	0.02	0.01	-0.01	-0.01	0.01	0.01
2039	-1.67	-0.83	0.12	0.59	-1.15	0.02

NT - Kindred not typed for Mfd188.

Using a criterion for linkage to 17q of a LOD score  $> 1.0$  for at least one locus under the CASH model (Claus *et al.*, 1991), four of the 19 kindreds appeared to be linked to 17q (K1901, K1925, K2035, K2082). A number of additional kindreds showed some evidence of linkage but at this time could not be definitively assigned to the linked category. These included kindreds K1911, K2073, K2039, and K2080. Three of the 17q-linked kindreds had informative recom-

binants in this region and these are detailed below.

Kindred 2082 is the largest 17q-linked breast cancer family reported to date by any group. The kindred contains 20 cases of breast cancer, and ten cases of ovarian cancer. Two cases have both ovarian and breast cancer. The evidence of linkage to 17q for this family is overwhelming; the LOD score with the linked haplotype is over 6.0, despite the existence of three cases of breast cancer which appear to be sporadic, i.e., these cases share no part of the linked haplotype between Mfd15 and 42D6. These three sporadic cases were diagnosed with breast cancer at ages 46, 47, and 54. In smaller kindreds, sporadic cancers of this type greatly confound the analysis of linkage and the correct identification of key recombinants. The key recombinant in the 2082 kindred is a woman who developed ovarian cancer at age 45 whose mother and aunt had ovarian cancer at ages 58 and 66, respectively. She inherited the linked portion of the haplotype for both Mfd188 and 42D6 while inheriting unlinked alleles at Mfd15; this recombinant event placed BRCA1 distal to Mfd15.

K1901 is typical of early-onset breast cancer kindreds. The kindred contains 10 cases of breast cancer with a median age at diagnosis of 43.5 years of age; four cases were diagnosed under age 40. The LOD score for this kindred with the marker 42D6 is 1.5, resulting in a posterior probability of 17q-linkage of 0.96. Examination of haplotypes in this kindred identified a recombinant haplotype in an obligate male carrier and his affected daughter who was diagnosed with breast cancer at age 45. Their linked allele for marker Mfd15 differs from that found in all other cases in the kindred (except one case which could not be completely inferred from her children). The two haplotypes are identical for Mfd188 and 42D6. Accordingly, data from Kindred 1901 would also place the BRCA1 locus distal to Mfd15.

Kindred 2035 is similar to K1901 in disease phenotype. The median age of diagnosis for the eight cases of breast cancer in this kindred is 37. One case also had ovarian cancer at age 60. The breast cancer cases in this family descend from two sisters who were both unaffected with breast cancer until their death in the eighth decade. Each branch contains four cases of breast cancer with at least one case in each branch having markedly early onset. This kindred has a LOD score of 2.34 with Mfd15. The haplotypes segregating with breast cancer in the two branches share an identical allele at Mfd15 but differ for the distal loci Mfd188 and NM23 (a marker typed as part of the consortium which is located just distal to 42D6 (Hall *et al.*, 1992)). Although the two haplotypes are concordant for marker 42D6, it is likely that the alleles are shared identical by state (the same allele but derived from different ancestors), rather than identical by descent (derived from a common ancestor) since the shared allele is the second most common allele observed at this locus. By contrast the linked allele shared at Mfd15 has a frequency of 0.04. This is a key recombinant in our dataset as it is the sole recombinant in which BRCA1 segregated with the proximal portion of the haplotype, thus setting the distal boundary to the BRCA1 region. For this event not to be a key recombinant requires that a second mutant BRCA1 gene be present in a spouse marrying into the kindred who also shares the rare Mfd15 allele segregating with breast cancer in both branches of the kindred. This event has a probability of less than one in a thousand. The evidence from this kindred therefore placed the BRCA1 locus proximal to Mfd188.

### EXAMPLE 3

#### Creation of a Fine Structure Map and Refinement of the BRCA1 Region to Mfd191-Mfd188 using Additional STR Polymorphisms

In order to improve the characterization of our recombinants and define closer flanking markers, a dense map of this relatively small region on chromosome 17q was required. The chromosome 17 workshop has produced a consensus map of this region (Figure 1) based on a combination of genetic and physical mapping studies (Fain, 1992). This map contains both highly polymorphic STR polymorphisms, and a number of nonpolymorphic expressed genes. Because this map did not give details on the evidence for this order nor give any measure of local support for inversions in the order of adjacent loci, we viewed it as a rough guide for obtaining resources to be used for the development of new markers and construction of our own detailed genetic and physical map of a small region containing BRCA1. Our approach was to analyze existing STR markers provided by other investigators and any newly developed markers from our laboratory with respect to both a panel of meiotic (genetic) breakpoints identified using DNA from the CEPH reference families and a panel of somatic cell hybrids (physical breakpoints) constructed for this region. These markers included 26C2 developed in our laboratory which maps proximal to Mfd15, Mfd191 (provided by James Weber), THRA1 (Futreal *et al.*, 1992a), and three polymorphisms kindly provided to us by Dr. Donald Black, NM23 (Hall *et al.*, 1992), SCG40 (D17S181), and 6C1 (D17S293).

#### Genetic localization of markers.

In order to localize new markers genetically within the region of interest, we have identified a number of key meiotic breakpoints within the region, both in the CEPH reference panel and in our large breast cancer kindred (K2082). Given the small genetic distance in this region, they are likely to be only a relatively small set of recombinants which can be

used for this purpose, and they are likely to group markers into sets. The orders of the markers within each set can only be determined by physical mapping. However the number of genotypings necessary to position a new marker is minimized. These breakpoints are illustrated in Tables 3 and 4. Using this approach we were able to genetically order the markers THRA1, 6C1, SCG40, and Mfd191. As can be seen from Tables 3 and 4, THRA1 and MFD191 both map inside the Mfd15-Mfd188 region we had previously identified as containing the BRCA1 locus. In Tables 3 and 4, M/P indicates a maternal or paternal recombinant. A "1" indicates inherited allele is of grandpaternal origin, while a "0" indicates grandmaternal origin, and "-" indicates that the locus was untyped or uninformative.

10

15

20

25

30

35

40

45

50

55

TABLE 3  
CEPH Recombinants

Family	ID	M/P	Mfd15	THR1	Mfd191	Mfd188	SCG40	6C1	42D6
13292	4	M	1	1	1	0	0	0	0
13294	4	M	1	1	1	0	0	0	0
13294	6	M	0	0	1	1	-	-	-
1334	3	M	1	1	1	1	1	0	0
1333	4	M	1	1	1	0	-	-	0
1333	6	M	0	0	1	1	-	-	1
1333	8	P	1	0	0	0	-	-	0
1377	8	M	0	-	0	0	0	0	1

TABLE 4

Kindred 2082 Recombinants

Family	ID	M/R	Mfd15	Mfd191	Mfd188	SCG40	6C1	42D6
75		M	0	1	1	1	-	-
63		M	0	0	1	1	-	1
125		M	1	1	1	0	-	0
40		M	1	1	0	0	-	0

Analysis of markers Mfd15, Mfd188, Mfd191, and THRA1 in our recombinant families.

Mfd15, Mfd188, Mfd191 and THRA1 were typed in our recombinant families and examined for additional information

to localize the BRCA1 locus. In kindred 1901, the Mfd15 recombinant was recombinant for THRA1 but uninformative for Mfd191, thus placing BRCA1 distal to THRA1. In K2082, the recombinant with Mfd15 also was recombinant with Mfd191, thus placing the BRCA1 locus distal to Mfd191 (Goldgar *et al.*, 1994). Examination of THRA1 and Mfd191 in kindred K2035 yielded no further localization information as the two branches were concordant for both markers. However, SCG40 and 6C1 both displayed the same pattern as Mfd188, thus increasing our confidence in the localization information provided by the Mfd188 recombinant in this family. The BRCA1 locus, or at least a portion of it, therefore lies within an interval bounded by Mfd191 on the proximal side and Mfd188 on the distal side.

#### EXAMPLE 4

##### Development of Genetic and Physical Resources in the Region of Interest

To increase the number of highly polymorphic loci in the Mfd191-Mfd188 region, we developed a number of STR markers in our laboratory from cosmids and YACs which physically map to the region. These markers allowed us to further refine the region.

STSs were identified from genes known to be in the desired region to identify YACs which contained these loci, which were then used to identify subclones in cosmids, P1s or BACs. These subclones were then screened for the presence of a CA tandem repeat using a  $(CA)_n$  oligonucleotide (Pharmacia). Clones with a strong signal were selected preferentially, since they were more likely to represent CA-repeats which have a large number of repeats and/or are of near-perfect fidelity to the  $(CA)_n$  pattern. Both of these characteristics are known to increase the probability of polymorphism (Weber, 1990). These clones were sequenced directly from the vector to locate the repeat. We obtained a unique sequence on one side of the CA-repeat by using one of a set of possible primers complementary to the end of a CA-repeat, such as  $(GT)_{10}T$ . Based on this unique sequence, a primer was made to sequence back across the repeat in the other direction, yielding a unique sequence for design of a second primer flanking the CA-repeat. STRs were then screened for polymorphism on a small group of unrelated individuals and tested against the hybrid panel to confirm their physical localization. New markers which satisfied these criteria were then typed in a set of 40 unrelated individuals from the Utah and CEPH families to obtain allele frequencies appropriate for the study population. Many of the other markers reported in this study were tested in a smaller group of CEPH unrelated individuals to obtain similarly appropriate allele frequencies.

Using the procedure described above, a total of eight polymorphic STRs was found from these YACS. Of the loci identified in this manner, four were both polymorphic and localized to the BRCA1 region. Four markers did not localize to chromosome 17, reflecting the chimeric nature of the YACs used. The four markers which were in the region were denoted AA1, ED2, 4-7, and YM29. AA1 and ED2 were developed from YACs positive for the RNU2 gene, 4-7 from an EPB3 YAC and YM29 from a cosmid which localized to the region by the hybrid panel. A description of the number of alleles, heterozygosity and source of these four and all other STR polymorphisms analyzed in the breast cancer kindreds is given below in Table 5.

TABLE 5

Polymorphic Short Tandem Repeat Markers Used  
for Fine Structure Mapping of the BRCA1 Locus

Clone	Gene	Na**	Hetero- zygosity	Allele Frequency (%)					
				1	2	3	4	5	6
Mfd15	D17S250	10	0.82	26	22	15	7	7	23
THRA1	THRA1	5							
Mfd191	D17S776	7	0.55	48	20	11	7	7	7
ED2	D17S1327	12	0.55	62	9	8	5	5	11
AA1	D17S1326	7	0.83	28	28	25	8	6	5
CA375	D17S184	10	0.75	26	15	11	9	9	20
4-7	D17S1183	9	0.50	63	15	8	6	4	4
YM29	--	9	0.62	42	24	12	7	7	8
Mfd188	D17S579	12	0.92	33	18	8	8	8	25
SCG40	D17S181	14	0.90	20	18	18	10	8	35
42D6	D17S588	11	0.86	21	17	11	10	9	32
6C1	D17S293	7	0.75	30	30	11	11	9	9
Z109	D17S750	9	0.70	33	27	7	7	7	19
tdj1475	D17S1321	13	0.84	21	16	11	11	8	33
CF4	D17S1320	6	0.63	50	27	9	7	4	3
tdj1239	D17S1328	10	0.80	86	10	9	7	4	14
U5	D17S1325	13	0.83	19	16	12	10	9	34

\* Allele codes 1-5 are listed in decreasing frequency; allele numbers do not correspond to fragment sizes. Allele 6 frequency is the joint frequency of all other alleles for each locus.

\*\* Number of alleles seen in the genetically independent DNA samples used for calculating allele frequencies.

The four STR polymorphisms which mapped physically to the region (4-7, ED2, AA1, YM29) were analyzed in the meiotic breakpoint panel shown initially in Tables 3 and 4. Tables 6 and 7 contain the relevant CEPH data and Kindred 2082 data for localization of these four markers. In the tables, M/P indicates a maternal or paternal recombinant. A "1" indicates inherited allele is of grandpaternal origin, while a "0" indicates grandmaternal origin, and "-" indicates that the locus was untyped or uninformative.

TABLE 6

Key Recombinants Used for Genetic  
Ordering of New STR Loci Developed in  
Our Laboratory Within the BRCA1 Region of 17q

CEPH Family	ID	M/P	Mfd15	THRA1	Mfd191	ED2	AA1	Z109	4-7	YM29	Mfd188	SCG40	42D6
13292	4	M	1	1	1	1	1	0	0	0	0	0	0
13294	4	M	1	0	0	-	0	-	-	-	0	-	-
13294	6	M	0	0	1	-	1	-	-	-	1	-	-
1333	4	M	1	1	1	-	0	-	-	0	0	-	0
1333	6	M	0	0	1	-	1	-	-	1	1	-	1
1333	3	M	0	0	1	-	-	-	1	1	1	-	1

TABLE 7  
Kindred 2082 Recombinants

ID	M/P	Mfd15	Mfd191	ED2	AA1	4-7	YM29	Mfd188	SCG40	42D6
63	M	0	0	1	-	1	1	1	1	1
125	M	1	1	1	-	1	1	1	0	0
40	M	1	1	0	-	0	-	0	0	0
22	P	0	0	1	1	1	1	1	1	1

From CEPH 1333-04, we see that AA1 and YM29 must lie distal to Mfd191. From 13292, it can be inferred that both AA1 and ED2 are proximal to 4-7, YM29, and Mfd188. The recombinants found in K2082 provide some additional ordering information. Three independent observations (individual numbers 22, 40, & 63) place AA1, ED2, 4-7, and YM29, and Mfd188 distal to Mfd191, while ID 125 places 4-7, YM29, and Mfd188 proximal to SCG40. No genetic information on the relative ordering within the two clusters of markers AA1/ED2 and 4-7/YM29/Mfd188 was obtained from the genetic recombinant analysis. Although ordering loci with respect to hybrids which are known to contain "holes" in which small pieces of interstitial human DNA may be missing is problematic, the hybrid patterns indicate that 4-7 lies above both

YM29 and Mfd188.

#### EXAMPLE 5

##### 5 Genetic Analyses of Breast Cancer Kindreds with Markers AA1, 4-7, ED2, and YM29

In addition to the three kindreds containing key recombinants which have been discussed previously, kindred K2039 was shown through analysis of the newly developed STR markers to be linked to the region and to contain a useful recombinant.

10 Table 8 defines the haplotypes (shown in coded form) of the kindreds in terms of specific marker alleles at each locus and their respective frequencies. In Table 8, alleles are listed in descending order of frequency; frequencies of alleles 1-5 for each locus are given in Table 5. Haplotypes coded H are BRCA1 associated haplotypes, P designates a partial H haplotype, and an R indicates an observable recombinant haplotype. As evident in Table 8, not all kindreds were typed for all markers; moreover, not all individuals within a kindred were typed for an identical set of markers, 15 especially in K2082. With one exception, only haplotypes inherited from affected or at-risk kindred members are shown; haplotypes from spouses marrying into the kindred are not described. Thus in a given sibship, the appearance of haplotypes X and Y indicates that both haplotypes from the affected/at-risk individual were seen and neither was a breast cancer associated haplotype.

**TABLE 8**  
Breast Cancer Linked Haplotypes  
Found in the Three Kindreds

Kin.	HAP	Mfd 15	THRA1	Mfd 191	tdj 1475	ED2	AA1	Z109	CA375	4-7	YM29	Mfd 188	SCG40	6C1	42D6
1901	H1	1	5	5	3	1	4	NI	NI	1	1	3	NI	NI	1
	R2	9	2	5	6	1	4	NI	NI	1	1	3	NI	NI	1
2082	H1	3	NI	4	6	6	1	NI	NI	2	1	4	2	NI	1
	P1	3	NI	4	NI	NI	NI	NI	NI	NI	NI	4	2	NI	1
	P2	3	NI	NI	NI	NI	NI	NI	NI	NI	NI	4	NI	NI	NI
	R1	6	NI	1	5	6	1	NI	NI	2	1	4	2	NI	1
	R2	6	NI	4	6	6	1	NI	NI	2	1	4	2	NI	1
	R3	3	NI	4	NI	6	1	NI	NI	2	1	4	1	NI	7
	R4	7	NI	1	NI	1	5	NI	NI	4	6	1	2	NI	1
2035	R5	3	NI	4	NI	NI	NI	NI	NI	NI	2	1	NI	NI	NI
	R6	3	NI	4	3	1	2	NI	NI	1	2	2	6	NI	6
	R7	3	NI	4	3	7	1	NI	NI	1	1	3	7	NI	4
	H1	8	2	1	NI	5	1	1	4	3	1	6	8	2	4
	H2	8	2	1	NI	5	1	1	2	1	1	2	3	1	4
	R2	8	2	1	NI	5	1	1	2	1	1	2	3	6	1

In kindred K1901, the new markers showed no observable recombination with breast cancer susceptibility, indicating that the recombination event in this kindred most likely took place between THRA1 and ED2. Thus, no new BRCA1 localization information was obtained based upon studying the four new markers in this kindred. In kindred 2082 the key recombinant individual has inherited the linked alleles for ED2, 4-7, AA1, and YM29, and was recombinant for tdj1474 indicating that the recombination event occurred in this individual between tdj 1474 and ED2/AA1.

There are three haplotypes of interest in kindred K2035, H1, H2, and R2 shown in Table 8. H1 is present in the four cases and one obligate male carrier descendant from individual 17 while H2 is present or inferred in two cases and two obligate male carriers in descendants of individual 10. R2 is identical to H2 for loci between and including Mfd15 and SCG40, but has recombined between SCG40 and 42D6. Since we have established that BRCA1 is proximal to 42D6, this H2/R2 difference adds no further localization information. H1 and R2 share an identical allele at Mfd15, THRA1,

AA1, and ED2 but differ for loci presumed distal to ED2, i.e., 4-7, Mfd188, SCG40, and 6C1. Although the two haplotypes are concordant for the 5th allele for marker YM29, a marker which maps physically between 4-7 and Mfd188, it is likely that the alleles are shared identical by state rather than identical by descent since this allele is the most common allele at this locus with a frequency estimated in CEPH parents of 0.42. By contrast, the linked alleles shared at the Mfd15 and ED2 loci have frequencies of 0.04 and 0.09, respectively. They also share more common alleles at Mfd191 (frequency = 0.52), THRA1, and AA1 (frequency = 0.28). This is the key recombinant in the set as it is the sole recombinant in which breast cancer segregated with the proximal portion of the haplotype, thus setting the distal boundary. The evidence from this kindred therefore places the BRCA1 locus proximal to 4-7.

The recombination event in kindred 2082 which places BRCA1 distal to tdj 1474 is the only one of the four events described which can be directly inferred; that is, the affected mother's genotype can be inferred from her spouse and offspring, and the recombinant haplotype can be seen in her affected daughter. In this family the odds in favor of affected individuals carrying BRCA1 susceptibility alleles are extremely high: the only possible interpretations of the data are that BRCA1 is distal to Mfd191 or alternatively that the purported recombinant is a sporadic case of ovarian cancer at age 44. Rather than a directly observable or inferred recombinant, interpretation of kindred 2035 depends on the observation of distinct 17q-haplotypes segregating in different and sometimes distantly related branches of the kindred. The observation that portions of these haplotypes have alleles in common for some markers while they differ at other markers places the BRCA1 locus in the shared region. The confidence in this placement depends on several factors: the relationship between the individuals carrying the respective haplotypes, the frequency of the shared allele, the certainty with which the haplotypes can be shown to segregate with the BRCA1 locus, and the density of the markers in the region which define the haplotype. In the case of kindred 2035, the two branches are closely related, and each branch has a number of early onset cases which carry the respective haplotype. While two of the shared alleles are common, (Mfd191, THRA1), the estimated frequencies of the shared alleles at Mfd15, AA1, and ED2 are 0.04, 0.28, and 0.09, respectively. It is therefore highly likely that these alleles are identical by descent (derived from a common ancestor) rather than identical by state (the same allele but derived from the general population).

## EXAMPLE 6

### Refined Physical Mapping Studies Place the BRCA1 Gene in a Region Flanked by tdj1474 and U5R

Since its initial localization to chromosome 17q in 1990 (Hall *et al.*, 1990) a great deal of effort has gone into localizing the BRCA1 gene to a region small enough to allow implementation of effective positional cloning strategies to isolate the gene. The BRCA1 locus was first localized to the interval Mfd15 (D17S250)-42D6 (D17S588) by multipoint linkage analysis (Easton *et al.*, 1993) in the collaborative Breast Cancer Linkage Consortium dataset consisting of 214 families collected worldwide. Subsequent refinements of the localization have been based upon individual recombinant events in specific families. The region THRA1 - D17S183 was defined by Bowcock *et al.*, 1993; and the region THRA1 - D17S78 was defined by Simard *et al.*, 1993.

We further showed that the BRCA1 locus must lie distal to the marker Mfd191 (D17S776) (Goldgar *et al.*, 1994). This marker is known to lie distal to THRA1 and RARA. The smallest published region for the BRCA1 locus is thus between D17S776 and D17S78. This region still contains approximately 1.5 million bases of DNA, making the isolation and testing of all genes in the region a very difficult task. We have therefore undertaken the tasks of constructing a physical map of the region, isolating a set of polymorphic STR markers located in the region, and analyzing these new markers in a set of informative families to refine the location of the BRCA1 gene to a manageable interval.

Four families provide important genetic evidence for localization of BRCA1 to a sufficiently small region for the application of positional cloning strategies. Two families (K2082, K1901) provide data relating to the proximal boundary for BRCA1 and the other two (K2035, K1813) fix the distal boundary. These families are discussed in detail below. A total of 15 Short Tandem Repeat markers assayable by PCR were used to refine this localization in the families studied. These markers include DS17S7654, DS17S975, tdj1474, and tdj1239. Primer sequences for these markers are provided in SEQ ID NO:3 and SEQ ID NO:4 for DS17S754; in SEQ ID NO:5 and SEQ ID NO:6 for DS17S975; in SEQ ID NO:7 and SEQ ID NO:8 for tdj 1474; and, in SEQ ID NO:9 and SEQ ID NO:10 for tdj1239.

### Kindred 2082

Kindred 2082 is the largest BRCA1-linked breast/ovarian cancer family studied to date. It has a LOD score of 8.6, providing unequivocal evidence for 17q linkage. This family has been previously described and shown to contain a critical recombinant placing BRCA1 distal to MFD191 (D17S776). This recombinant occurred in a woman diagnosed with ovarian cancer at age 45 whose mother had ovarian cancer at age 63. The affected mother was deceased; however, from her children, she could be inferred to have the linked haplotype present in the 30 other linked cases in the family in the region between Mfd15 and Mfd188. Her affected daughter received the linked allele at the loci ED2, 4-7, and

Mfd188, but received the allele on the non-BRCA1 chromosome at Mfd15 and Mfd191. In order to further localize this recombination breakpoint, we tested the key members of this family for the following markers derived from physical mapping resources: tdj1474, tdj1239, CF4, D17S855. For the markers tdj1474 and CF4, the affected daughter did not receive the linked allele. For the STR locus tdj1239, however, the mother could be inferred to be informative and her daughter did receive the BRCA1-associated allele. D17S855 was not informative in this family. Based on this analysis, the order is 17q centromere - Mfd191 - 17HSD - CF4 - tdj1474 - tdj1239 - D17S855 - ED2 - 4-7 - Mfd188 - 17q telomere. The recombinant described above therefore places BRCA1 distal to tdj1474, and the breakpoint is localized to the interval between tdj1474 and tdj 1239. The only alternative explanation for the data in this family other than that of BRCA1 being located distal to tdj1474, is that the ovarian cancer present in the recombinant individual is caused by reasons independent of the BRCA1 gene. Given that ovarian cancer diagnosed before age 50 is rare, this alternate explanation is exceedingly unlikely.

#### Kindred 1901

Kindred 1901 is an early-onset breast cancer family with 7 cases of breast cancer diagnosed before 50, 4 of which were diagnosed before age 40. In addition, there were three cases of breast cancer diagnosed between the ages of 50 and 70. One case of breast cancer also had ovarian cancer at age 61. This family currently has a LOD score of 1.5 with D17S855. Given this linkage evidence and the presence of at least one ovarian cancer case, this family has a posterior probability of being due to BRCA1 of over 0.99. In this family, the recombination comes from the fact that an individual who is the brother of the ovarian cancer case from which the majority of the other cases descend, only shares a portion of the haplotype which is cosegregating with the other cases in the family. However, he passed this partial haplotype to his daughter who developed breast cancer at age 44. If this case is due to the BRCA1 gene, then only the part of the haplotype shared between this brother and his sister can contain the BRCA1 gene. The difficulty in interpretation of this kind of information is that while one can be sure of the markers which are not shared and therefore recombinant, markers which are concordant can either be shared because they are non-recombinant, or because their parent was homozygous. Without the parental genotypic data it is impossible to discriminate between these alternatives. Inspection of the haplotype in K1901, shows that he does not share the linked allele at Mfd15 (D17S250), THRA1, CF4 (D17S1320), and tdj1474 (D17S1321). He does share the linked allele at Mfd191 (D17S776), ED2 (D17S1327), tdj1239 (D17S1328), and Mfd188 (D17S579). Although the allele shared at Mfd191 is relatively rare (0.07), we would presume that the parent was homozygous since they are recombinant with markers located nearby on either side, and a double recombination event in this region would be extremely unlikely. Thus the evidence in this family would also place the BRCA1 locus distal to tdj1474. However, the lower limit of this breakpoint is impossible to determine without parental genotype information. It is intriguing that the key recombinant breakpoint in this family confirms the result in Kindred 2082. As before, the localization information in this family is only meaningful if the breast cancer was due to the BRCA1 gene. However, her relatively early age at diagnosis (44) makes this seem very likely since the risk of breast cancer before age 45 in the general population is low (approximately 1%).

#### Kindred 2035

This family is similar to K1901 in that the information on the critical recombinant events is not directly observed but is inferred from the observation that the two haplotypes which are cosegregating with the early onset breast cancer in the two branches of the family appear identical for markers located in the proximal portion of the 17q BRCA1 region but differ at more distal loci. Each of these two haplotypes occurs in at least four cases of early-onset or bilateral breast cancer. The overall LOD score with ED2 in this family is 2.2, and considering that there is a case of ovarian cancer in the family (indicating a prior probability of BRCA1 linkage of 80%), the resulting posterior probability that this family is linked to BRCA1 is 0.998. The haplotypes are identical for the markers Mfd15, THRA1, Mfd191, ED2, AA1, D17S858 and D17S902. The common allele at Mfd15 and ED2 are both quite rare, indicating that this haplotype is shared identical by descent. The haplotypes are discordant, however, for CA375, 4-7, and Mfd188, and several more distal markers. This indicates that the BRCA1 locus must lie above the marker CA-375. This marker is located approximately 50 kb below D17S78, so it serves primarily as additional confirmation of this previous lower boundary as reported in Simard *et al.* (1993).

#### Kindred 1813

Kindred 1813 is a small family with four cases of breast cancer diagnosed under the age of 40 whose mother had breast cancer diagnosed at age 45 and ovarian cancer at age 61. This situation is somewhat complicated by the fact the four cases appear to have three different fathers, only one of whom has been genotyped. However, by typing a number of different markers in the BRCA1 region as well as highly polymorphic markers elsewhere in the genome, the

paternity of all children in the family has been determined with a high degree of certainty. This family yields a maximum multipoint LOD score of 0.60 with 17q markers and, given that there is at least one case of ovarian cancer, results in a posterior probability of being a BRCA1 linked family of 0.93. This family contains a directly observable recombination event in individual 18 (see Figure 5 in Simard *et al.*, *Human Mol. Genet.* 2:1193-1199 (1993)), who developed breast cancer at age 34. The genotype of her affected mother at the relevant 17q loci can be inferred from her genotypes, her affected sister's genotypes, and the genotypes of three other unaffected siblings. Individual 18 inherits the BRCA1-linked alleles for the following loci: Mfd15, THRA1, D17S800, D17S855, AA1, and D17S931. However, for markers below D17S931, i.e., U5R, vrs31, D17S858, and D17S579, she has inherited the alleles located on the non-disease bearing chromosome. The evidence from this family therefore would place the BRCA1 locus proximal to the marker U5R. Because of her early age at diagnosis (34) it is extremely unlikely that the recombinant individual's cancer is not due to the gene responsible for the other cases of breast/ovarian cancer in this family; the uncertainty in this family comes from our somewhat smaller amount of evidence that breast cancer in this family is due to BRCA1 rather than a second, as yet unmapped, breast cancer susceptibility locus.

#### Size of the region containing BRCA1

Based on the genetic data described in detail above, the BRCA1 locus must lie in the interval between the markers tdj 1474 and U5R, both of which were isolated in our laboratory. Based upon the physical maps shown in Figures 2 and 3, we can try to estimate the physical distance between these two loci. It takes approximately 14 P1 clones with an average insert size of approximately 80 kb to span the region. However, because all of these P1s overlap to some unknown degree, the physical region is most likely much smaller than 14 times 80 kb. Based on restriction maps of the clones covering the region, we estimate the size of the region containing BRCA1 to be approximately 650 kb.

#### EXAMPLE 7

##### Identification of Candidate cDNA Clones for the BRCA1 Locus by Genomic Analysis of the Contig Region

##### Complete screen of the plausible region.

The first method to identify candidate cDNAs, although labor intensive, used known techniques. The method comprised the screening of cosmids and P1 and BAC clones in the contig to identify putative coding sequences. The clones containing putative coding sequences were then used as probes on filters of cDNA libraries to identify candidate cDNA clones for future analysis. The clones were screened for putative coding sequences by either of two methods.

##### Zoo blots.

The first method for identifying putative coding sequences was by screening the cosmid and P1 clones for sequences conserved through evolution across several species. This technique is referred to as "zoo blot analysis" and is described by Monaco, 1986. Specifically, DNAs from cow, chicken, pig, mouse and rat were digested with the restriction enzymes EcoRI and HindIII (8 µg of DNA per enzyme). The digested DNAs were separated overnight on an 0.7% gel at 20 volts for 16 hours (14 cm gel), and the DNA transferred to Nylon membranes using standard Southern blot techniques. For example, the zoo blot filter was treated at 65°C in 0.1 x SSC, 0.5% SDS, and 0.2M Tris, pH 8.0, for 30 minutes and then blocked overnight at 42°C in 5x SSC, 10% PEG 8000, 20 mM NaPO<sub>4</sub> pH 6.8, 100 µg/ml Salmon Sperm DNA, 1x Denhardt's, 50% formamide, 0.1% SDS, and 2 µg/ml C<sub>6</sub>t-1 DNA.

The cosmid and P1 clones to be analyzed were digested with a restriction enzyme to release the human DNA from the vector DNA. The DNA was separated on a 14 cm, 0.5% agarose gel run overnight at 20 volts for 16 hours. The human DNA bands were cut out of the gel and electroeluted from the gel wedge at 100 volts for at least two hours in 0.5x Tris Acetate buffer (Maniatis *et al.*, 1982). The eluted Not I digested DNA (~15 kb to 25 kb) was then digested with EcoRI restriction enzyme to give smaller fragments (~0.5 kb to 5.0 kb) which melt apart more easily for the next step of labeling the DNA with radionucleotides. The DNA fragments were labeled by means of the hexamer random prime labeling method (Boehringer-Mannheim, Cat. #1004760). The labeled DNA was spermine precipitated (add 100 µl TE, 5 µl 0.1 M spermine, and 5 µl of 10 mg/ml salmon sperm DNA) to remove unincorporated radionucleotides. The labeled DNA was then resuspended in 100 µl TE, 0.5 M NaCl at 65°C for 5 minutes and then blocked with Human C<sub>6</sub>t-1 DNA for 2-4 hrs. as per the manufacturer's instructions (Gibco/BRL, Cat. #5279SA). The C<sub>6</sub>t-1 blocked probe was incubated on the zoo blot filters in the blocking solution overnight at 42°C. The filters were washed for 30 minutes at room temperature in 2 x SSC, 0.1% SDS, and then in the same buffer for 30 minutes at 55°C. The filters were then exposed 1 to 3 days at -70°C to Kodak XAR-5 film with an intensifying screen. Thus, the zoo blots were hybridized with either the pool of Eco-R1 fragments from the insert, or each of the fragments individually.

HTF island analysis.

The second method for identifying cosmids to use as probes on the cDNA libraries was HTF island analysis. Since the pulsed-field map can reveal HTF islands, cosmids that map to these HTF island regions were analyzed with priority. HTF islands are segments of DNA which contain a very high frequency of unmethylated CpG dinucleotides (Tonolio *et al.*, 1990) and are revealed by the clustering of restriction sites of enzymes whose recognition sequences include CpG dinucleotides. Enzymes known to be useful in HTF-island analysis are *Ascl*, *NotI*, *BssHII*, *EagI*, *SacII*, *NaeI*, *NarI*, *SmaI*, and *MluI* (Anand, 1992). A pulsed-field map was created using the enzymes *NotI*, *NruI*, *EagI*, *SacII*, and *Sall*, and two HTF islands were found. These islands are located in the distal end of the region, one being distal to the GP2B locus, and the other being proximal to the same locus, both outside the BRCA1 region. The cosmids derived from the YACs that cover these two locations were analyzed to identify those that contain these restriction sites, and thus the HTF islands.

cDNA screening.

Those clones that contain HTF islands or show hybridization to other species DNA besides human are likely to contain coding sequences. The human DNA from these clones was isolated as whole insert or as *EcoRI* fragments and labeled as described above. The labeled DNA was used to screen filters of various cDNA libraries under the same conditions as the zoo blots except that the cDNA filters undergo a more stringent wash of 0.1 x SSC, 0.1% SDS at 65°C for 30 minutes twice.

Most of the cDNA libraries used to date in our studies (libraries from normal breast tissue, breast tissue from a woman in her eighth month of pregnancy and a breast malignancy) were prepared at Clontech, Inc. The cDNA library generated from breast tissue of an 8 month pregnant woman is available from Clontech (Cat. #HL1037a) in the Lambda gt-10 vector, and is grown in C600Hf1 bacterial host cells. Normal breast tissue and malignant breast tissue samples were isolated from a 37 year old Caucasian female and one-gram of each tissue was sent to Clontech for mRNA processing and cDNA library construction. The latter two libraries were generated using both random and oligo-dT priming, with size selection of the final products which were then cloned into the Lambda Zap II vector, and grown in XL1-blue strain of bacteria as described by the manufacturer. Additional tissue-specific cDNA libraries include human fetal brain (Stratagene, Cat. 936206), human testis (Clontech Cat. HL3024), human thymus (Clontech Cat. HL1127n), human brain (Clontech Cat. HL11810), human placenta (Clontech Cat. 1075b), and human skeletal muscle (Clontech Cat. HL1124b).

The cDNA libraries were plated with their host cells on NZCYM plates, and filter lifts are made in duplicate from each plate as per Maniatis *et al.* (1982). Insert (human) DNA from the candidate genomic clones was purified and radioactively labeled to high specific activity. The radioactive DNA was then hybridized to the cDNA filters to identify those cDNAs which correspond to genes located within the candidate cosmid clone. cDNAs identified by this method were picked, replated, and screened again with the labeled clone insert or its derived *EcoRI* fragment DNA to verify their positive status. Clones that were positive after this second round of screening were then grown up and their DNA purified for Southern blot analysis and sequencing. Clones were either purified as plasmid through *in vivo* excision of the plasmid from the Lambda vector as described in the protocols from the manufacturers, or isolated from the Lambda vector as a restriction fragment and subcloned into plasmid vector.

The Southern blot analysis was performed in duplicate, one using the original genomic insert DNA as a probe to verify that cDNA insert contains hybridizing sequences. The second blot was hybridized with cDNA insert DNA from the largest cDNA clone to identify which clones represent the same gene. All cDNAs which hybridize with the genomic clone and are unique were sequenced and the DNA analyzed to determine if the sequences represent known or unique genes. All cDNA clones which appear to be unique were further analyzed as candidate BRCA1 loci. Specifically, the clones are hybridized to Northern blots to look for breast specific expression and differential expression in normal versus breast tumor RNAs. They are also analyzed by PCR on clones in the BRCA1 region to verify their location. To map the extent of the locus, full length cDNAs are isolated and their sequences used as PCR probes on the YACs and the clones surrounding and including the original identifying clones. Intron-exon boundaries are then further defined through sequence analysis.

We have screened the normal breast, 8 month pregnant breast and fetal brain cDNA libraries with zoo blot-positive *EcoRI* fragments from cosmid BAC and P1 clones in the region. Potential BRCA1 cDNA clones were identified among the three libraries. Clones were picked, replated, and screened again with the original probe to verify that they were positive.

Analysis of hybrid-selected cDNA.

cDNA fragments obtained from direct selection were checked by Southern blot hybridization against the probe DNA

to verify that they originated from the contig. Those that passed this test were sequenced in their entirety. The set of DNA sequences obtained in this way were then checked against each other to find independent clones that overlapped. For example, the clones 69465, 1240-1 and 1240-33 were obtained independently and subsequently shown to derive from the same contiguous cDNA sequence which has been named EST:489:1.

#### Analysis of candidate clones.

One or more of the candidate genes generated from above were sequenced and the information used for identification and classification of each expressed gene. The DNA sequences were compared to known genes by nucleotide sequence comparisons and by translation in all frames followed by a comparison with known amino acid sequences. This was accomplished using Genetic Data Environment (GDE) version 2.2 software and the Basic Local Alignment Search Tool (Blast) series of client/server software packages (e.g., BLASTN 1.3.13MP), for sequence comparison against both local and remote sequence databases (e.g., GenBank), running on Sun SPARC workstations. Sequences reconstructed from collections of cDNA clones identified with the cosmids and P1s have been generated. All candidate genes that represented new sequences were analyzed further to test their candidacy for the putative BRCA1 locus.

#### Mutation screening.

To screen for mutations in the affected pedigrees, two different approaches were followed. First, genomic DNA isolated from family members known to carry the susceptibility allele of BRCA1 was used as a template for amplification of candidate gene sequences by PCR. If the PCR primers flank or overlap an intron/exon boundary, the amplified fragment will be larger than predicted from the cDNA sequence or will not be present in the amplified mixture. By a combination of such amplification experiments and sequencing of P1, BAC or cosmid clones using the set of designed primers it is possible to establish the intron/exon structure and ultimately obtain the DNA sequences of genomic DNA from the pedigrees.

A second approach that is much more rapid if the intron/exon structure of the candidate gene is complex involves sequencing fragments amplified from pedigree lymphocyte cDNA. cDNA synthesized from lymphocyte mRNA extracted from pedigree blood was used as a substrate for PCR amplification using the set of designed primers. If the candidate gene is expressed to a significant extent in lymphocytes, such experiments usually produce amplified fragments that can be sequenced directly without knowledge of intron/exon junctions.

The products of such sequencing reactions were analyzed by gel electrophoresis to determine positions in the sequence that contain either mutations such as deletions or insertions, or base pair substitutions that cause amino acid changes or other detrimental effects.

Any sequence within the BRCA1 region that is expressed in breast is considered to be a candidate gene for BRCA1. Compelling evidence that a given candidate gene corresponds to BRCA1 comes from a demonstration that pedigree families contain defective alleles of the candidate.

### EXAMPLE 8

#### Identification of BRCA1

#### Identification of BRCA1.

Using several strategies, a detailed map of transcripts was developed for the 600 kb region of 17q21 between D17S1321 and D17S1324. Candidate expressed sequences were defined as DNA sequences obtained from: 1) direct screening of breast, fetal brain, or lymphocyte cDNA libraries, 2) hybrid selection of breast, lymphocyte or ovary cDNAs, or 3) random sequencing of genomic DNA and prediction of coding exons by XPOUND (Thomas and Skolnick, 1994). These expressed sequences in many cases were assembled into contigs composed of several independently identified sequences. Candidate genes may comprise more than one of these candidate expressed sequences. Sixty-five candidate expressed sequences within this region were identified by hybrid selection, by direct screening of cDNA libraries, and by random sequencing of P1 subclones. Expressed sequences were characterized by transcript size, DNA sequence, database comparison, expression pattern, genomic structure, and, most importantly, DNA sequence analysis in individuals from kindreds segregating 17q-linked breast and ovarian cancer susceptibility.

Three independent contigs of expressed sequence, 1141:1 (649 bp), 694:5 (213 bp) and 754:2 (1079 bp) were isolated and eventually shown to represent portions of BRCA1. When ESTs for these contigs were used as hybridization probes for Northern analysis, a single transcript of approximately 7.8 kb was observed in normal breast mRNA, suggesting that they encode different portions of a single gene. Screens of breast, fetal brain, thymus, testes, lymphocyte and placental cDNA libraries and PCR experiments with breast mRNA linked the 1141:1, 694:5 and 754:2 contigs. 5'

RACE experiments with thymus, testes, and breast mRNA extended the contig to the putative 5' end, yielding a composite full length sequence. PCR and direct sequencing of P1s and BACs in the region were used to identify the location of introns and allowed the determination of splice donor and acceptor sites. These three expressed sequences were merged into a single transcription unit that proved in the final analysis to be BRCA1. This transcription unit is located adjacent to D17S855 in the center of the 600 kb region (Fig. 4).

Combination of sequences obtained from cDNA clones, hybrid selection sequences, and amplified PCR products allowed construction of a composite full length BRCA1 cDNA (SEQ ID NO:1). The sequence of the BRCA1 cDNA (up through the stop codon) has also been deposited with GenBank and assigned accession number U-14680. This deposited sequence is incorporated herein by reference. The cDNA clone extending farthest in the 3' direction contains a poly (A) tract preceded by a polyadenylation signal. Conceptual translation of the cDNA revealed a single long open reading frame of 208 kilodaltons (amino acid sequence: SEQ ID NO:2) with a potential initiation codon flanked by sequences resembling the Kozak consensus sequence (Kozak, 1987). Smith-Waterman (Smith and Waterman, 1981) and BLAST (Altschul *et al.*, 1990) searches identified a sequence near the amino terminus with considerable homology to zinc-finger domains (Fig. 5). This sequence contains cysteine and histidine residues present in the consensus C3HC4 zinc-finger motif and shares multiple other residues with zinc-finger proteins in the databases. The BRCA1 gene is composed of 23 coding exons arrayed over more than 100 kb of genomic DNA (Fig. 6). Northern blots using fragments of the BRCA1 cDNA as probes identified a single transcript of about 7.8 kb, present most abundantly in breast, thymus and testis, and also present in ovary (Fig. 7). Four alternatively spliced products were observed as independent cDNA clones: 3 of these were detected in breast and 2 in ovary mRNA (Fig. 6). A PCR survey from tissue cDNAs further supports the idea that there is considerable heterogeneity near the 5' end of transcripts from this gene: the molecular basis for the heterogeneity involves differential choice of the first splice donor site, and the changes detected all alter the transcript in the region 5' of the identified start codon. We have detected six potential alternate splice donors in this 5' untranslated region, with the longest deletion being 1,155 bp. The predominant form of the BRCA1 protein in breast and ovary lacks exon 4. The nucleotide sequence for BRCA1 exon 4 is shown in SEQ ID NO:11, with the predicted amino acid sequence shown in SEQ ID NO:12.

Additional 5' sequence of BRCA1 genomic DNA is set forth in SEQ ID NO:13. The G at position 1 represents the potential start site in testis. The A in position 140 represents the potential start site in somatic tissue. There are six alternative splice forms of this 5' sequence as shown in Figure 8. The G at position 356 represents the canonical first splice donor site. The G at position 444 represents the first splice donor site in two clones (testis 1 and testis 2). The G at position 889 represents the first splice donor site in thymus 3. A fourth splice donor site is the G at position 1230. The T at position 1513 represents the splice acceptor site for all of the above splice donors. A fifth alternate splice form has a first splice donor site at position 349 with a first acceptor site at position 591 and a second splice donor site at position 889 and a second acceptor site at position 1513. A sixth alternate form is unspliced in this 5' region. The A at position 1532 is the canonical start site, which appears at position 120 of SEQ ID NO:1. Partial genomic DNA sequences determined for BRCA1 are set forth in Figures 10A-10H and SEQ ID Numbers:14-34. The lower case letters (in figures 10A-10H) denote intron sequence while the upper case letters denote exon sequence. Indefinite intervals within introns are designated with vvvvvvvvvvvv in Figure's 10A-10H. The intron/exon junctions are shown in Table 9. The CAG found at the 5' end of exons 8 and 14 is found in some cDNAs but not in others. Known polymorphic sites are shown in Figures 10A-10H in boldface type and are underlined. The known polymorphisms are listed in Tables 18 and 19.

TABLE 2

Exon No.	Base Position		Length	Intron Borders	
	5'	3'		5'	3'
e1	1	100	100	GATAAATTAAACTGCGACTGCGGCGTG <sup>15</sup>	GTAGTAGAGTCCCGGAAGGGACAGGGGG <sup>36</sup>
e2	101	199	99	ATATATATATATGTTTTTCTAANGTGTAAAG <sup>17</sup>	GTAAGTCAGCACAAAGAGTGTATTAAATTTGG <sup>38</sup>
e3	200	253	54	TTTCTTTTCTCCCCCCCCCTACCCCTGCTAG <sup>39</sup>	GTAAGTTTGAATGTGTTATGTGGCTCCATT <sup>40</sup>
e4	***	***	111	AGCTACTTTTTTTTTTTTTTTTTTTTGAGACAG <sup>41</sup>	GTAAGTGCACACCACCATATCCAGCTAAAT <sup>42</sup>
e5	254	331	78	AATTGTTCTTTCTTTCTTTTATAATTATAG <sup>43</sup>	GTATATAAATTTGGTAATGATGCTAGTTGG <sup>44</sup>
e6	332	420	89	GAGTGTGTTTCTCAACAATTTAATTTTCAG <sup>45</sup>	GTAAGTGTGAATATATCCCAAGAATGACACT <sup>46</sup>
e7	421	560	140	AAACATAATGTTTTTCCCTTGATTTTACAG <sup>47</sup>	GTAAAACCAATTTGTTTCTTCTTCTCTTC <sup>48</sup>
e8	561	666	106	TGCTTGACTGTCTCTTTACCATACTGTTTAG <sup>49</sup>	GTAAGGTCTCAGGTTTTTTTAAAGTATTTAA <sup>50</sup>
e9	667	712	46	TGATTATTTTTTTGGGGGAAATTTTGTAG <sup>51</sup>	GTGAGTCAAAGAGAACCTTTGTCTATGAAG <sup>52</sup>
e10	713	789	77	TCATTATAGGACTCTGTCTTTTCCCTATAG <sup>53</sup>	GTAATGGCAAAGTTTGCCAACTTAACAGGC <sup>54</sup>
e11	790	4215	3426	GAGTACCTTGTTATTTTTTTGATATATTTTCAG <sup>55</sup>	GTATTGGAACCAAGGTTTTTTGTGTTGCCCC <sup>56</sup>
e12	4216	4302	87	ACATCTGAACCTCTGTTTTTTTGTATTAAAG <sup>57</sup>	AGGTAAAAAGCGTGTGTGTGTGCACATG <sup>58</sup>
e13	4303	4476	174	CATTTTCTTGGTACCATTATCGTTTTTTTGA <sup>59</sup>	GTGTGTATTGTTGGCCAAACACTGATATCT <sup>60</sup>
e14	4477	4603	127	AGTAGATTGTTTTTCTCATTTCCATTAAAG <sup>61</sup>	GTAAGAAACATCAATGTAAAGATGCTGTGG <sup>62</sup>

\* Base numbers in SEQ ID NO:1.

\*\* Numbers in superscript refer to SEQ ID NOS.

\*\*\* e4 from SEQ ID NO:11.

TABLE 2 (cont'd)

Exon No.	Base Position 5' 3'	Length	5'	Intron Borders	3'
e15	4604 4794	191	ATGGTTTCTCCTTCCATTTATCTTTCTAG <sup>63**</sup>	GTATATTTTCATCTGCTGTATTGGAAACAAA <sup>64</sup>	
e16	4795 5105	311	TGTAAATTAAACTTCTCCCATTCCTTTTCAG <sup>65</sup>	GTGAGTGTATCCATATGTATCTCCCTAATG <sup>66</sup>	
e17	5106 5193	88	ATGATAATGGAATATTTGATTTTAAATTCAG <sup>67</sup>	GTATACCAAGAACCTTTTACAGAAATACCTTG <sup>68</sup>	
e18	5194 5271	78	CTAATCCTTTGAGTGTTTTTCATTTCTGCAG <sup>69</sup>	GTAAGTATAAATACTAATTTCTCCCTCCTCC <sup>70</sup>	
e19	5272 5312	41	TGTAACCTGTCTTTTCTATGATCTCTTTAG <sup>71</sup>	GTAAGTACTTGATGTTTACAAACTAACCCAGA <sup>72</sup>	
e20	5313 5396	84	TCCTGATGGGTGTGTGTTGGTTTCTTTTCAG <sup>73</sup>	GTAAAGCTCCCTCCCTCAAGTTGACAAAAA <sup>74</sup>	
e21	5397 5451	55	CTGTCCCTCTCTCTTCTCTCTCTTCTCCAG <sup>75</sup>	GTAAGAGCCTGGGAGAACCCAGAGTTCCA <sup>76</sup>	
e22	5452 5525	74	AGTGATTTTACATGTAAATGTCCATTTTAG <sup>77</sup>	GTAAGTATTGGGTGCCCTGTCTCAGTGTGGGA <sup>78</sup>	
e23	5526 5586	61	TTGAATGCTCTTTTCTCTCTCTGGGATCCAG <sup>79</sup>	GTAAGGTGCCCTCGCATGTACCTGTGCTATT <sup>80</sup>	
e24	5587 5914	328	CTAATCTCTGCTTGTGTTCTCTCTCTCTCCAG <sup>81</sup>		

\* Base numbers in SEQ ID NO:1.

\*\* Numbers in superscript refer to SEQ ID NOS.

Low stringency blots in which genomic DNA from organisms of diverse phylogenetic background were probed with BRCA1 sequences that lack the zinc-finger region revealed strongly hybridizing fragments in human, monkey, sheep and pig, and very weak hybridization signals in rodents. This result indicates that, apart from the zinc-finger domain, BRCA1 is conserved only at a moderate level through evolution.

#### Germline BRCA1 mutations in 17q-linked kindreds.

The most rigorous test for BRCA1 candidate genes is to search for potentially disruptive mutations in carrier individuals from kindreds that segregate 17q-linked susceptibility to breast and ovarian cancer. Such individuals must contain

BRCA1 alleles that differ from the wildtype sequence. The set of DNA samples used in this analysis consisted of DNA from individuals representing 8 different BRCA1 kindreds (Table 10).

TABLE 10

## KINDRED DESCRIPTIONS AND ASSOCIATED LOD SCORES

Kindred	Cases (n)			Sporadic Cases <sup>1</sup> (n)	LOD Score	Marker(s)
	Br	Br<50	Ov			
2082	31	20	22	7	9.49	D17S1327
2099	22	14	2*	0	2.36	D17S800/D17S855 <sup>2</sup>
2035	10	8	1*	0	2.25	D17S1327
1901	10	7	1*	0	1.50	D17S855
1925	4	3	0	0	0.55	D17S579
1910	5	4	0	0	0.36	D17S579/D17S250 <sup>2</sup>
1927	5	4	0	1	-0.44	D17S250
1911	8	5	0	2	-0.20	D17S250

<sup>1</sup> Number of women with breast cancer (diagnosed under age 50) or ovarian cancer (diagnosed at any age) who do not share the BRCA1-linked haplotype segregating in the remainder of the cases in the kindred.

<sup>2</sup> Multipoint LOD score calculated using both markers

\* kindred contains one individual who had both breast and ovarian cancer; this individual is counted as a breast cancer case and as an ovarian cancer case.

The logarithm of the odds (LOD) scores in these kindreds range from 9.49 to -0.44 for a set of markers in 17q21. Four of the families have convincing LOD scores for linkage, and 4 have low positive or negative LOD scores. The latter kindreds were included because they demonstrate haplotype sharing at chromosome 17q21 for at least 3 affected members. Furthermore, all kindreds in the set display early age of breast cancer onset and 4 of the kindreds include at least one case of ovarian cancer, both hallmarks of BRCA1 kindreds. One kindred, 2082, has nearly equal incidence of breast and ovarian cancer, an unusual occurrence given the relative rarity of ovarian cancer in the population. All of the kindreds except two were ascertained in Utah. K2035 is from the midwest. K2099 is an African-American kindred from the southern USA.

In the initial screen for predisposing mutations in BRCA1, DNA from one individual who carries the predisposing haplotype in each kindred was tested. The 23 coding exons and associated splice junctions were amplified either from genomic DNA samples or from cDNA prepared from lymphocyte mRNA. When the amplified DNA sequences were compared to the wildtype sequence, 4 of the 8 kindred samples were found to contain sequence variants (Table 11).

TABLE 11

## PREDISPOSING MUTATIONS

	Kindred Number	Mutation	Coding Effect	Location*
10	2082	C→T	Gln→Stop	4056
	1910	extra C	frameshift	5385
	2099	T→G	Met→Arg	5443
	2035	?	loss of transcript	
15	1901	11 bp deletion	frameshift	189

\* In Sequence ID NO:1

All four sequence variants are heterozygous and each appears in only one of the kindreds. Kindred 2082 contains a nonsense mutation in coding exon 10 (Fig. 9A), Kindred 1910 contains a single nucleotide insertion in coding exon 19 (Fig. 9B), and Kindred 2099 contains a missense mutation in coding exon 20, resulting in a Met→Arg substitution (Fig. 9C). The frameshift and nonsense mutations are likely disruptive to the function of the BRCA1 product. The peptide encoded by the frameshift allele in Kindred 1910 would contain an altered amino acid sequence beginning 107 residues from the wildtype C-terminus. The peptide encoded by the frameshift allele in Kindred 1901 would contain an altered amino acid sequence beginning with the 24th residue from the wildtype N-terminus. The mutant allele in Kindred 2082 would encode a protein missing 548 residues from the C-terminus. The missense substitution observed in Kindred 2099 is potentially disruptive as it causes the replacement of a small hydrophobic amino acid (Met), by a large charged residue (Arg). Eleven common polymorphisms were also identified, 8 in coding sequence and 3 in introns.

The individual studied in Kindred 2035 evidently contains a regulatory mutation in BRCA1. In her cDNA, a polymorphic site (A→G at base 3667) appeared homozygous, whereas her genomic DNA revealed heterozygosity at this position (Fig. 9C). A possible explanation for this observation is that mRNA from her mutated BRCA1 allele is absent due to a mutation that affects its production or stability. This possibility was explored further by examining 5 polymorphic sites in the BRCA1 coding region, which are separated by as much as 3.5 kb in the BRCA1 transcript. In all cases where her genomic DNA appeared heterozygous for a polymorphism, cDNA appeared homozygous. In individuals from other kindreds and in non-haplotype carriers in Kindred 2035, these polymorphic sites could be observed as heterozygous in cDNA, implying that amplification from cDNA was not biased in favor of one allele. This analysis indicates that a BRCA1 mutation in Kindred 2035 either prevents transcription or causes instability or aberrant splicing of the BRCA1 transcript.

#### Cosegregation of BRCA1 mutations with BRCA1 haplotypes and population frequency analysis.

In addition to potentially disrupting protein function, two criteria must be met for a sequence variant to qualify as a candidate predisposing mutation. The variant must: 1) be present in individuals from the kindred who carry the predisposing BRCA1 haplotype and absent in other members of the kindred, and 2) be rare in the general population.

Each mutation was tested for cosegregation with BRCA1. For the frameshift mutation in Kindred 1910, two other haplotype carriers and one non-carrier were sequenced (Fig. 9B). Only the carriers exhibited the frameshift mutation. The C to T change in Kindred 2082 created a new AvrII restriction site. Other carriers and non-carriers in the kindred were tested for the presence of the restriction site (Fig. 9A). An allele-specific oligonucleotide (ASO) was designed to detect the presence of the sequence variant in Kindred 2099. Several individuals from the kindred, some known to carry the haplotype associated with the predisposing allele, and others known not to carry the associated haplotype, were screened by ASO for the mutation previously detected in the kindred. In each kindred, the corresponding mutant allele was detected in individuals carrying the BRCA1-associated haplotype, and was not detected in noncarriers. In the case of the potential regulatory mutation observed in the individual from Kindred 2035, cDNA and genomic DNA from carriers in the kindred were compared for heterozygosity at polymorphic sites. In every instance, the extinguished allele in the cDNA sample was shown to lie on the chromosome that carries the BRCA1 predisposing allele (Fig. 9C).

To exclude the possibility that the mutations were simply common polymorphisms in the population, ASOs for each mutation were used to screen a set of normal DNA samples. Gene frequency estimates in Caucasians were based on random samples from the Utah population. Gene frequency estimates in African-Americans were based on 39 samples provided by M. Peracek-Vance which originate from African-Americans used in her linkage studies and 20 newborn

Utah African-Americans. None of the 4 potential predisposing mutations was found in the appropriate control population, indicating that they are rare in the general population. Thus, two important requirements for BRCA1 susceptibility alleles were fulfilled by the candidate predisposing mutations: 1) cosegregation of the mutant allele with disease, and 2) absence of the mutant allele in controls, indicating a low gene frequency in the general population.

#### Phenotypic Expression of BRCA1 Mutations.

The effect of the mutations on the BRCA1 protein correlated with differences in the observed phenotypic expression in the BRCA1 kindreds. Most BRCA1 kindreds have a moderately increased ovarian cancer risk, and a smaller subset have high risks of ovarian cancer, comparable to those for breast cancer (Easton *et al.*, 1993). Three of the four kindreds in which BRCA1 mutations were detected fall into the former category, while the fourth (K2082) falls into the high ovarian cancer risk group. Since the BRCA1 nonsense mutation found in K2082 lies closer to the amino terminus than the other mutations detected, it might be expected to have a different phenotype. In fact, Kindred K2082 mutation has a high incidence of ovarian cancer, and a later mean age at diagnosis of breast cancer cases than the other kindreds (Goldgar *et al.*, 1994). This difference in age of onset could be due to an ascertainment bias in the smaller, more highly penetrant families, or it could reflect tissue-specific differences in the behavior of BRCA1 mutations. The other 3 kindreds that segregate known BRCA1 mutations have, on average, one ovarian cancer for every 10 cases of breast cancer, but have a high proportion of breast cancer cases diagnosed in their late 20's or early 30's. Kindred 1910, which has a frameshift mutation, is noteworthy because three of the four affected individuals had bilateral breast cancer, and in each case the second tumor was diagnosed within a year of the first occurrence. Kindred 2035, which segregates a potential regulatory BRCA1 mutation, might also be expected to have a dramatic phenotype. Eighty percent of breast cancer cases in this kindred occur under age 50. This figure is as high as any in the set, suggesting a BRCA1 mutant allele of high penetrance (Table 10).

Although the mutations described above clearly are deleterious, causing breast cancer in women at very young ages, each of the four kindreds with mutations includes at least one woman who carries the mutation who lived until age 80 without developing a malignancy. It will be of utmost importance in the studies that follow to identify other genetic or environmental factors that may ameliorate the effects of BRCA1 mutations.

In four of the eight putative BRCA1-linked kindreds, potential predisposing mutations were not found. Three of these four have LOD scores for BRCA1-linked markers of less than 0.55. Thus, these kindreds may not in reality segregate BRCA1 predisposing alleles. Alternatively, the mutations in these four kindreds may lie in regions of BRCA1 that, for example, affect the level of transcript and therefore have thus far escaped detection.

#### Role of BRCA1 in Cancer.

Most tumor suppressor genes identified to date give rise to protein products that are absent, nonfunctional, or reduced in function. The majority of TP53 mutations are missense: some of these have been shown to produce abnormal p53 molecules that interfere with the function of the wildtype product (Shaulian *et al.* 1992; Srivastava *et al.*, 1993). A similar dominant negative mechanism of action has been proposed for some adenomatous polyposis coli (APC) alleles that produce truncated molecules (Su *et al.*, 1993), and for point mutations in the Wilms' tumor gene (WT1) that alter DNA binding of the protein (Little *et al.*, 1993). The nature of the mutations observed in the BRCA1 coding sequence is consistent with production of either dominant negative proteins or nonfunctional proteins. The regulatory mutation inferred in Kindred 2035 cannot be a dominant negative; rather, this mutation likely causes reduction or complete loss of BRCA1 expression from the affected allele.

The BRCA1 protein contains a C<sub>3</sub>HC<sub>4</sub> zinc-finger domain, similar to those found in numerous DNA binding proteins and implicated in zinc-dependent binding to nucleic acids. The first 180 amino acids of BRCA1 contain five more basic residues than acidic residues. In contrast, the remainder of the molecule is very acidic, with a net excess of 70 acidic residues. The excess negative charge is particularly concentrated near the C-terminus. Thus, one possibility is that BRCA1 encodes a transcription factor with an N-terminal DNA binding domain and a C-terminal transactivational "acidic blob" domain. Interestingly, another familial tumor suppressor gene, WT1, also contains a zinc-finger motif (Haber *et al.*, 1990). Many cancer predisposing mutations in WT1 alter zinc-finger domains (Little *et al.*, 1993; Haber *et al.*, 1990; Little *et al.*, 1992). WT1 encodes a transcription factor, and alternative splicing of exons that encode parts of the zinc-finger domain alter the DNA binding properties of WT1 (Bickmore *et al.*, 1992). Some alternatively spliced forms of WT1 mRNA generate molecules that act as transcriptional repressors (Drummond *et al.*, 1994). Some BRCA1 splicing variants may alter the zinc-finger motif, raising the possibility that a regulatory mechanism similar to that which occurs in WT1 may apply to BRCA1.

**EXAMPLE 9****Analysis of Tumors for BRCA1 Mutations**

To focus the analysis on tumors most likely to contain BRCA1 mutations, primary breast and ovarian carcinomas were typed for LOH in the BRCA1 region. Three highly polymorphic, simple tandem repeat markers were used to assess LOH: D17S1323 and D17S855, which are intragenic to BRCA1, and D17S1327, which lies approximately 100 kb distal to BRCA1. The combined LOH frequency in informative cases (i.e., where the germline was heterozygous) was 32/72 (44%) for the breast carcinomas and 12/21 (57%) for the ovarian carcinomas, consistent with previous measurements of LOH in the region (Futreal *et al.*, 1992b; Jacobs *et al.*, 1993; Sato *et al.*, 1990; Eccles *et al.*, 1990; Cropp *et al.*, 1994). The analysis thus defined a panel of 32 breast tumors and 12 ovarian tumors of mixed race and age of onset to be examined for BRCA mutations. The complete 5,589 bp coding region and intron/exon boundary sequences of the gene were screened in this tumor set by direct sequencing alone or by a combination of single-strand conformation analysis (SSCA) and direct sequencing.

A total of six mutations was found, one in an ovarian tumor, four in breast tumors and one in a male unaffected haplotype carrier (Table 12). One mutation, Glu1541Ter, introduced a stop codon that would create a truncated protein missing 273 amino acids at the carboxy terminus. In addition, two missense mutations were identified. These are Ala1708Glu and Met1775Arg and involve substitutions of small, hydrophobic residues by charged residues. Patients 17764 and 19964 are from the same family. In patient OV24 nucleotide 2575 is deleted and in patients 17764 and 19964 nucleotides 2993-2996 are deleted.

**TABLE 12****Predisposing Mutations**

<u>Patient</u>	<u>Codon</u>	<u>Nucleotide Change</u>	<u>Amino Acid Change</u>	<u>Age of Onset</u>	<u>Family History</u>
BT098	1541	GAG → TAG	Glu → Stop	39	-
OV24	819	1 bp deletion	frameshift	44	-
BT106	1708	GCG → GAG	Ala → Glu	24	+
MC44	1775	ATG → AGG	Met → Arg	42	+
17764	958	4 bp deletion	frameshift	31	+
19964	958	4 bp deletion	frameshift		++

Unaffected haplotype carrier, male

Several lines of evidence suggest that all five mutations represent BRCA1 susceptibility alleles:

(i) all mutations are present in the germline;

(ii) all are absent in appropriate control populations, suggesting they are not common polymorphisms;

(iii) each mutant allele is retained in the tumor, as is the case in tumors from patients belonging to kindreds that segregate BRCA1 susceptibility alleles (Smith *et al.*, 1992; Kelsell *et al.*, 1993) (if the mutations represented neutral polymorphisms, they should be retained in only 50% of the cases);

(iv) the age of onset in the four breast cancer cases with mutations varied between 24 and 42 years of age, consistent with the early age of onset of breast cancer in individuals with BRCA1 susceptibility; similarly, the ovarian cancer case was diagnosed at 44, an age that falls in the youngest 13% of all ovarian cancer cases; and finally,

(v) three of the five cases have positive family histories of breast or ovarian cancer found retrospectively in their medical records, although the tumor set was not selected with regard to this criterion.

BT106 was diagnosed at age 24 with breast cancer. Her mother had ovarian cancer, her father had melanoma, and her paternal grandmother also had breast cancer. Patient MC44, an African-American, had bilateral breast cancer at age 42. This patient had a sister who died of breast cancer at age 34, another sister who died of lymphoma, and a brother who died of lung cancer. Her mutation (Met1775Arg) had been detected previously in Kindred 2099, an African-American family that segregates a BRCA1 susceptibility allele, and was absent in African-American and Caucasian controls. Patient MC44, to our knowledge, is unrelated to Kindred 2099. The detection of a rare mutant allele, once in a BRCA1 kindred and once in the germline of an apparently unrelated early-onset breast cancer case, suggests that the Met1775Arg change may be a common predisposing mutation in African-Americans. Collectively, these observations indicate that all four BRCA1 mutations in tumors represent susceptibility alleles; no somatic mutations were detected in the samples analyzed.

The paucity of somatic BRCA1 mutations is unexpected, given the frequency of LOH on 17q, and the usual role of susceptibility genes as tumor suppressors in cancer progression. There are three possible explanations for this result: (i) some BRCA1 mutations in coding sequences were missed by our screening procedure; (ii) BRCA1 somatic mutations fall primarily outside the coding exons; and (iii) LOH events in 17q do not reflect BRCA1 somatic mutations.

If somatic BRCA1 mutations truly are rare in breast and ovary carcinomas, this would have strong implications for the biology of BRCA1. The apparent lack of somatic BRCA1 mutations implies that there may be some fundamental difference in the genesis of tumors in genetically predisposed BRCA1 carriers, compared with tumors in the general population. For example, mutations in BRCA1 may have an effect only on tumor formation at a specific stage early in breast and ovarian development. This possibility is consistent with a primary function for BRCA1 in premenopausal breast cancer. Such a model for the role of BRCA1 in breast and ovarian cancer predicts an interaction between reproductive hormones and BRCA1 function. However, no clinical or pathological differences in familial versus sporadic breast and ovary tumors, other than age of onset, have been described (Lynch *et al.*, 1990). On the other hand, the recent finding of increased TP53 mutation and microsatellite instability in breast tumors from patients with a family history of breast cancer (Glebov *et al.*, 1994) may reflect some difference in tumors that arise in genetically predisposed persons. The involvement of BRCA1 in this phenomenon can now be addressed directly. Alternatively, the lack of somatic BRCA1 mutations may result from the existence of multiple genes that function in the same pathway of tumor suppression as BRCA1, but which collectively represent a more favored target for mutation in sporadic tumors. Since mutation of a single element in a genetic pathway is generally sufficient to disrupt the pathway, BRCA1 might mutate at a rate that is far lower than the sum of the mutational rates of the other elements.

A separate study to analyze tumors for BRCA1 mutations was performed in Japan. A panel of 103 patients representing early-onset cases (<35 years of age) (46 patients), members of multiply-affected families (12 patients), and/or had developed bilateral breast cancers (59 patients) were screened for mutations in BRCA1. Primary breast tumors from these patients were screened for mutations in coding exons of BRCA1 using single-strand conformation polymorphism (SSCP) analysis. For exon 11, which is 3425 bp long, PCR primers were designed to amplify eleven overlapping segments of this exon separately. Each of the other 22 exons was amplified individually in a single PCR. Thus 33 PCR-SSCP analyses were carried out for each case. Mutations were detected in tumors from four patients, all of whom had developed breast cancers bilaterally (Table 12A). One mutation resulted in a frame shift due to a 2 bp deletion (deletion of AA) at codon 797. This gives rise to a truncated protein missing 1065 amino acids at the COOH terminus. A second mutation was a nonsense mutation at codon 1214 due to a G → T transversion of the first nucleotide of the codon. This results in a premature stop codon in place of glutamic acid at this site and results in a truncated protein missing 649 amino acids at the COOH terminus. There were also two missense mutations. One was a G → A transition at the first nucleotide of codon 271 resulting in a Val → Met substitution. The second was at codon 1150 (a C → T transition in the first nucleotide of the codon) causing a Pro → Ser substitution, a replacement of a hydrophobic nonpolar amino acid with a polar uncharged amino acid. These mutations were all found to be germline mutations. The mean age of onset in these four patients was 49. These studies also found a common neutral polymorphism of either C or T at the first nucleotide of codon 771.

TABLE 12A

Predisposing Mutations				
Patient	Codon	Nucleotide Change	Amino Acid Change	Age of Onset
23	1150	CCT→TCT	Pro→Ser	49 & 64
44	1214	GAG→TAG	Glu→Stop	51 & 51
98	271	GTG→ATG	Val→Met	45 & 45
100	797	2bp deletion	frameshift	50 & 71

Continuation of the Table on the next page

TABLE 12A (continued)

<u>Predisposing Mutations</u>				
Patient	Codon	Nucleotide Change	Amino Acid Change	Age of Onset
5	482-483	4bp deletion	frameshift	45
6	856	TAT→CAT	Tyr→His	54
7	271	GTG→ATG	Val→Met	49 & 49
8	852	1bp deletion	frameshift	62

Although patients 98 and 7 show the same mutation, they are not related to each other.

#### EXAMPLE 10

##### Analysis of the BRCA1 Gene

The structure and function of BRCA1 gene are determined according to the following methods.

##### Biological Studies.

Mammalian expression vectors containing BRCA1 cDNA are constructed and transfected into appropriate breast carcinoma cells with lesions in the gene. Wild-type BRCA1 cDNA as well as altered BRCA1 cDNA are utilized. The altered BRCA1 cDNA can be obtained from altered BRCA1 alleles or produced as described below. Phenotypic reversion in cultures (e.g., cell morphology, doubling time, anchorage-independent growth) and in animals (e.g., tumorigenicity) is examined. The studies will employ both wild-type and mutant forms (Section B) of the gene.

##### Molecular Genetics Studies.

*In vitro* mutagenesis is performed to construct deletion mutants and missense mutants (by single base-pair substitutions in individual codons and cluster charged → alanine scanning mutagenesis). The mutants are used in biological, biochemical and biophysical studies.

##### Mechanism Studies.

The ability of BRCA1 protein to bind to known and unknown DNA sequences is examined. Its ability to transactivate promoters is analyzed by transient reporter expression systems in mammalian cells. Conventional procedures such as particle-capture and yeast two-hybrid system are used to discover and identify any functional partners. The nature and functions of the partners are characterized. These partners in turn are targets for drug discovery.

##### Structural Studies.

Recombinant proteins are produced in *E. coli*, yeast, insect and/or mammalian cells and are used in crystallographical and NMR studies. Molecular modeling of the proteins is also employed. These studies facilitate structure-driven drug design.

#### EXAMPLE 11

##### Two Step Assay to Detect the Presence of BRCA1 in a Sample

Patient sample is processed according to the method disclosed by Antonarakis, *et al.* (1985), separated through a 1% agarose gel and transferred to nylon membrane for Southern blot analysis. Membranes are UV cross linked at 150 mJ using a GS Gene Linker (Bio-Rad). BRCA1 probe corresponding to nucleotide positions 3631-3930 of SEQ ID NO:1 is subcloned into pTZ18U. The phagemids are transformed into *E. coli* MV1190 infected with M13K07 helper phage (Bio-Rad, Richmond, CA). Single stranded DNA is isolated according to standard procedures (see Sambrook, *et al.*, 1989).

Blots are prehybridized for 15-30 min at 65°C in 7% sodium dodecyl sulfate (SDS) in 0.5 M NaPO<sub>4</sub>. The methods follow those described by Nguyen, *et al.*, 1992. The blots are hybridized overnight at 65°C in 7% SDS, 0.5 M NaPO<sub>4</sub> with 25-50 ng/ml single stranded probe DNA. Post-hybridization washes consist of two 30 min washes in 5% SDS, 40

mM NaPO<sub>4</sub> at 65°C, followed by two 30-min washes in 1% SDS, 40 mM NaPO<sub>4</sub> at 65°C.

Next the blots are rinsed with phosphate buffered saline (pH 6.8) for 5 min at room temperature and incubated with 0.2% casein in PBS for 30-60 min at room temperature and rinsed in PBS for 5 min. The blots are then preincubated for 5-10 minutes in a shaking water bath at 45°C with hybridization buffer consisting of 6 M urea, 0.3 M NaCl, and 5X Denhardt's solution (see Sambrook, *et al.*, 1989). The buffer is removed and replaced with 50-75 µl/cm<sup>2</sup> fresh hybridization buffer plus 2.5 nM of the covalently cross-linked oligonucleotide-alkaline phosphatase conjugate with the nucleotide sequence complementary to the universal primer site (UP-AP, Bio-Rad). The blots are hybridized for 20-30 min at 45°C and post hybridization washes are incubated at 45°C as two 10 min washes in 6 M urea, 1x standard saline citrate (SSC), 0.1% SDS and one 10 min wash in 1x SSC, 0.1% Triton®X-100. The blots are rinsed for 10 min at room temperature with 1x SSC.

Blots are incubated for 10 min at room temperature with shaking in the substrate buffer consisting of 0.1 M diethanolamine, 1 mM MgCl<sub>2</sub>, 0.02% sodium azide, pH 10.0. Individual blots are placed in heat sealable bags with substrate buffer and 0.2 mM AMPPD (3-(2'-spiroadamantane)-4-methoxy-4-(3'-phosphoryloxy)phenyl-1,2-dioxetane, disodium salt, Bio-Rad). After a 20 min incubation at room temperature with shaking, the excess AMPPD solution is removed. The blot is exposed to X-ray film overnight. Positive bands indicate the presence of BRCA1.

## EXAMPLE 12

### Generation of Polyclonal Antibody against BRCA1

Segments of BRCA1 coding sequence were expressed as fusion protein in *E. coli*. The overexpressed protein was purified by gel elution and used to immunize rabbits and mice using a procedure similar to the one described by Harlow and Lane, 1988. This procedure has been shown to generate Abs against various other proteins (for example, see Kraemer, *et al.*, 1993).

Briefly, a stretch of BRCA1 coding sequence was cloned as a fusion protein in plasmid PET5A (Novagen, Inc., Madison, WI). The BRCA1 incorporated sequence includes the amino acids corresponding to #1361-1554 of SEQ ID NO:2. After induction with IPTG, the overexpression of a fusion protein with the expected molecular weight was verified by SDS/PAGE. Fusion protein was purified from the gel by electroelution. The identification of the protein as the BRCA1 fusion product was verified by protein sequencing at the N-terminus. Next, the purified protein was used as immunogen in rabbits. Rabbits were immunized with 100 µg of the protein in complete Freund's adjuvant and boosted twice in 3 week intervals, first with 100 µg of immunogen in incomplete Freund's adjuvant followed by 100 µg of immunogen in PBS. Antibody containing serum is collected two weeks thereafter.

This procedure is repeated to generate antibodies against the mutant forms of the BRCA1 gene. These antibodies, in conjunction with antibodies to wild type BRCA1, are used to detect the presence and the relative level of the mutant forms in various tissues and biological fluids.

## EXAMPLE 13

### Generation of Monoclonal Antibodies Specific for BRCA1

Monoclonal antibodies are generated according to the following protocol. Mice are immunized with immunogen comprising intact BRCA1 or BRCA1 peptides (wild type or mutant) conjugated to keyhole limpet hemocyanin using glutaraldehyde or EDC as is well known.

The immunogen is mixed with an adjuvant. Each mouse receives four injections of 10 to 100 µg of immunogen and after the fourth injection blood samples are taken from the mice to determine if the serum contains antibody to the immunogen. Serum titer is determined by ELISA or RIA. Mice with sera indicating the presence of antibody to the immunogen are selected for hybridoma production.

Spleens are removed from immune mice and a single cell suspension is prepared (see Harlow and Lane, 1988). Cell fusions are performed essentially as described by Kohler and Milstein, 1975. Briefly, P3.65.3 myeloma cells (American Type Culture Collection, Rockville, MD) are fused with immune spleen cells using polyethylene glycol as described by Harlow and Lane, 1988. Cells are plated at a density of 2x10<sup>5</sup> cells/well in 96 well tissue culture plates. Individual wells are examined for growth and the supernatants of wells with growth are tested for the presence of BRCA1 specific antibodies by ELISA or RIA using wild type or mutant BRCA1 target protein. Cells in positive wells are expanded and subcloned to establish and confirm monoclonality.

Clones with the desired specificities are expanded and grown as ascites in mice or in a hollow fiber system to produce sufficient quantities of antibody for characterization and assay development.

**EXAMPLE 14****Sandwich Assay for BRCA1**

5 Monoclonal antibody is attached to a solid surface such as a plate, tube, bead, or particle. Preferably, the antibody is attached to the well surface of a 96-well ELISA plate. 100  $\mu$ l sample (e.g., serum, urine, tissue cytosol) containing the BRCA1 peptide/protein (wild-type or mutant) is added to the solid phase antibody. The sample is incubated for 2 hrs at room temperature. Next the sample fluid is decanted, and the solid phase is washed with buffer to remove unbound material. 100  $\mu$ l of a second monoclonal antibody (to a different determinant on the BRCA1 peptide/protein) is added to the solid phase. This antibody is labeled with a detector molecule (e.g., 125-I, enzyme, fluorophore, or a chromophore) and the solid phase with the second antibody is incubated for two hrs at room temperature. The second antibody is decanted and the solid phase is washed with buffer to remove unbound material.

10 The amount of bound label, which is proportional to the amount of BRCA1 peptide/protein present in the sample, is quantitated. Separate assays are performed using monoclonal antibodies which are specific for the wild-type BRCA1 as well as monoclonal antibodies specific for each of the mutations identified in BRCA1.

**EXAMPLE 15****Analysis of BRCA1 Mutations**

20 The DNA samples which were screened for BRCA1 mutations were extracted from blood or tumor samples from patients with breast or ovarian cancer (or known carriers by haplotype analysis) who were participating in research studies on the genetics of breast cancer. All subjects signed appropriate informed consent. Table 13 details the number of samples, ascertainment criteria, and screening method for each set of samples screened.

**TABLE 13**  
**Sets of DNA Samples Screened for Mutations in BRCA1**

Source of Samples	Description of Samples <sup>1</sup>	Screening Method <sup>2</sup>	No. Samples Screened	No. Mutations Found to Date
UTAH-2	Br/Ov Families	SEQ	10	2
MONTREAL	Br/Ov Families	SEQ	30	13
MSKCC-1	Br and Br/Ov Families	SEQ	14	2
MSK/UT-1	Early Onset Br Cases	SEQ	24	1
STRANG	Br and Br/Ov Families	SEQ	12	4
STOCKHOLM	Br and Br/Ov Families	SEQ	15	4
USC-1	Bilat Br Proband, High-Risk	SEQ	7	3
TUMOR-3	Early Onset Br Tumors	SEQ	14	1
USC-2	Bilat Br<50 + 1° rel Br	ASO	59	5
MSK/UT-2	Early Onset Br Cases	ASO	109	3
YN	Bilateral; Early Onset	SSCA	103	4
Texas	Br/Ov Families	SEQ	15	2
Utah	Br/Ov Families	SEQ	10	1
Pisa	Br/Ov Families	SEQ	21	4

TABLE 13 (cont'd)

Tumor/mod	SEQ	1
MSKCC-2 Early Onset Br Cases	SEQ	3
<hr/>		
<p>1 Most sample groups contained a heterogeneous mixture of samples. The most representative description of each set is given.</p> <p>2 SEQ - Direct sequencing of PCR products; SSCA - Single Strand Conformation Assay; ASO - Allele-Specific Oligo</p>		

Although the original mutations described in Miki *et al.*, 1994 were detected through screening of cDNA, 25 pairs of

intronic PCR primers were used to amplify the complete coding sequence and splice junctions from genomic DNA for the majority of the remaining samples. Updated primer information is publicly available via anonymous ftp from mor-gan.med.utah.edu in the directory pub/BRCA1. Where possible, DNA sequence variations were tested for cosegregation with breast or ovarian cancer in the family. Further evidence of a causal role of a sequence variant in cancer was provided by proving the absence of the putative mutation in a set of control individuals. Screening for specific, previously-identified mutations in large sets of selected samples was performed using ASO hybridization.

Table 14 describes many of the mutations found screening the entire BRCA1 coding sequence as well as the intron/exon boundaries and by finding polymorphic sites in genomic DNA reduced to monomorphic sites in cDNA. Two common mutations were found and their frequencies in other samples were examined by ASO analysis (Table 15). Tables 16 and 17 describe the distribution of mutations by type and by location within the BRCA1 coding sequence, respectively. By far, the majority of mutations identified were frameshifts. Globally, no statistically significant departure from a random distribution across the coding sequence of BRCA1 was found ( $\chi^2 = 2.00$ , 2 df,  $p = 0.37$ ) among the distinct mutations found in the coding sequence of BRCA1 to date.

TABLE 14  
Mutations Identified by Complete Screening of the BRCA1 Gene

Sample Set	Family	# Cases		Type <sup>1</sup>	Mutation Description	
		BR	OV		Exon	Codon Mutation <sup>2</sup>
TEXAS	132-000					
MONTREAL	180	2	2	FS	2	23 185 ins A -> ter 40
MONTREAL	235	4	2	FS	2	23 185 del AG -> ter 39
MONTREAL	253	1	3	FS	2	23 185 del AG -> ter 39
MONTREAL	255	0	7	FS	2	23 185 del AG -> ter 39
				FS	2	23 185 del AG -> ter 39
MSKCC	210311	3	0	FS	2	23 185 del AG -> ter 39
USC-1	008	2	1	FS	2	23 185 del AG -> ter 39
PISA	27	8	5	MS	5	64 Cys 64 Arg
UTAH				SP	I-5	I-5 T->G ins 59 -> ter 75
MSKCC	19921			SP	I-6	I-6 del A at -2 of 3' splice
TUMOR-3 <sup>4</sup>	-	1	0	FS	11	270 926 ins 10 -> ter 289
MSK/UT-1	-	1	0	FS	11	270 926 ins 10 -> ter 289
YN98	-	1	0	MS	11	271 Val 271 Met
YN7	-	1	0	MS	11	271 Val 271 Met
MONTREAL	270	4	3	FS	11	339 1128 ins A -> ter 345
STRANG	2903	1	2	FS	11	339 1128 ins A -> ter 345
MONTREAL	185	1	3	FS	11	392 1294 del 40 -> ter 396
PISA	6			FS	11	461 1499 ins A -> ter 479
PISA	17			FS	11	461 1499 ins A -> ter 479
PISA	31			FS	11	461 1499 ins A -> ter 479
YN5	-	1	0	FS	11	482 del 4 -> ter

TABLE 14 (Cont'd)  
Mutations Identified by Complete Screening of the BRCA1 Gene

Sample Set	Family	# Cases		Type <sup>1</sup>	Mutation Description	
		BR	QV		Exon	Codon Mutation <sup>2</sup>
USC-1	052	5	1	FS	11	655 2080 ins A -> ter 672
USC-1	068	2	1	FS	11	655 2080 ins A -> ter 672
PISA				MS	11	667 Gln 667 His
STRANG	2802	2	2	FS	11	725 2293 del G -> ter 735
YN100	-	1	0	FS	11	797 2509 del AA -> ter 799
TUMOR1mod	OV24	0	1	FS	11	819 2575 del C -> ter 845
MONTREAL	179	2	3	MS	11	826 Thr 826 Lys
STOCKHOLM	AL48	3	1	FS	11	826 2596 del C -> ter 845
STOCKHOLM	BR33	5	1	FS	11	826 2596 del C -> ter 845
YN8		1	0	FS	11	852 del 1 -> ter 891
YN6		1	0	MS	11	856 Tyr 856 His
UTAH-2	2305	2	7	FS	11	958 2993 del 4 -> ter 998
MONTREAL	218	5	1	FS	11	1002 3121 del A -> ter 1023
MSK17572				MS	11	1008 Met 1008 Ile
STOCKHOLM	BR24	2	1	FS	11	1016 3166 ins 5 -> ter 1025
MONTREAL				FS	11	1110 3447 del 4 -> ter 1115
MONTREAL	448			FS	11	1110 3449 del 4 -> ter 1115
TEXAS	BC110-001			FS	11	1111 3450 del 4 -> ter 1115
YN23	-	1	0	MS	11	1150 Pro 1150 Ser
STOCKHOLM	PAL33	1	0	FS	11	1209 3745 del T -> ter 1209
YN44	-	1	0	NS	11	1214 Glu 1214 ter

TABLE 14 (Cont'd)  
Mutations Identified by Complete Screening of the BRCA1 Gene

Sample Set	Family	# Cases BR OV	Mutation Description	
			Type <sup>1</sup> Exon Codon	Mutation <sup>2</sup>
MSK12871			MS 11 1219	Glu 1219 Asp
TEXAS	BC215-000		FS 11 1252	3873 del 4 -> ter 1262
UTAH-2	2039	3 2	MS 11 1347	Arg 1347 Gly
MONTREAL	183	4 1	FS 11 1355	4184 del 4 -> ter 1364
STRANG	1900 <sup>3</sup>	3 1	NS 13 1443	Arg 1443 ter
TUMOR-2		1 0	NS 15 1541	Glu 1541 ter
PISA	#8		FS 16 1585	4873 del CA -> ter 1620
MSK9646			MS 16 1628	Met 1628 Val
STRANG	8622 <sup>3</sup>	4 1	FS 16 1656	5085 del 19 -> ter 1670
MONTREAL	101	2 2	FS 20 1756	5382 ins C -> ter 1829
MONTREAL	162	3 1	FS 20 1756	5382 ins C -> ter 1829
MONTREAL	166	5 2	FS 20 1756	5382 ins C -> ter 1829
MONTREAL	279	4 0	FS 20 1756	5382 ins C -> ter 1829
MSKCC	193549	0 3	FS 20 1756	5382 ins C -> ter 1829
MSK7542			MS 24 1852	Thr 1852 Ser

<sup>1</sup> FS-Frameshift; NS-Nonsense; MS-Missense; SP-Splice Site.

<sup>2</sup> For Missense and Nonsense mutations, the mutation description contains: wild type amino acid, affected codon, altered amino acid (or ter). For frameshift mutations, the format is: nucleotide, insertion or deletion, specific nucleotides changed (if <3) or number inserted or deleted (if >2) and the amino acid [accounting for the insertion or deletion] in which the frameshift results in a termination signal. Nucleotides refer to the BRCA1 cDNA sequence in GENBANK under Accession No. U-14680.

<sup>3</sup> The mutation in this family was independently identified in both the Myriad and University of Pennsylvania Labs.

<sup>4</sup> The mutation identified in this tumor was also found in the germline of the individual.

TABLE 15

<u>Frequency of Two Common BRCA1 Mutations</u>			
Set	Number Studied	Number of Mutations Found	
		<i>185 del AG</i>	<i>5382 ins C</i>
USC-1	59	4	1
MSK/UT-2	109	3	0
GLASGOW-2	100	Not tested	3
GLASGOW-3	100	Not tested	2
CRC-OV	250	Not tested	1

TABLE 16

Observed Frequency of Different Types of Mutations

<u>Mutation Type</u>	Number (Percent)	
	<u>Distinct Mutations<sup>1</sup></u>	<u>All Mutations<sup>2</sup></u>
Frameshift	42 (65)	81 (72)
Nonsense	10 (16)	13 (12)
Missense	9 (14)	14 (12)
Other	3 (5)	5 (4)

<sup>1</sup> Identical mutations are counted only once in this column.

<sup>2</sup> Each sample in which a mutation has been identified is counted in this column.

TABLE 17

<u>Distribution of Identified Mutations in BRCA1 Coding Sequence</u>			
Mutations	1-621	Amino Acids 622-1242	1243-1863
Distinct	18	23	21
All	44	28	39

Mutations have been found in many different regions of the gene - phenotypically severe mutations have been found both in the extreme 5' end of BRCA1 as well as in the extreme 3' portion of the gene. One such mutation found in a family with seven early-onset breast cancer cases produces a protein that is only missing the terminal 10 amino acids, indicating that this region of BRCA1 plays a role in normal gene function. It is noteworthy the overwhelming majority of alterations in BRCA1 have been either frameshift or nonsense mutations resulting in an unstable or truncated protein product.

In BRCA1, to date, two mutations appear to be relatively common. The *5382 ins C* BRCA1 mutation in codon 1756 and the *185 del AG* mutation in codon 23 were identified by direct sequencing in seven (10%) and eight (12%) of the 68 probands studied in the initial studies in which mutations were identified, respectively. In addition to these common mutations, additional mutations have been found in more than one family by a complete screen of the cDNA. Many of the probands screened to date for BRCA1 mutations were selected for having a high prior probability of having such mutations. Thus the mutations found in this set may not be representative of those which would be identified in other sets of patients. However, the two most frequent BRCA1 mutations (*5382 ins C* and *185 del AG*) have been found

multiple times in targeted screening in sets of probands who were either unselected for family history or ascertained with minimal family history.

Besides the mutations shown above, many polymorphisms were also detected during the screening of samples. These polymorphisms are listed in Tables 18 and 19.

#### Industrial Utility

As previously described above, the present invention provides materials and methods for use in testing BRCA1 alleles of an individual and an interpretation of the normal or predisposing nature of the alleles. Individuals at higher than normal risk might modify their lifestyles appropriately. In the case of BRCA1, the most significant non-genetic risk factor is the protective effect of an early, full term pregnancy. Therefore, women at risk could consider early childbearing or a therapy designed to simulate the hormonal effects of an early full-term pregnancy. Women at high risk would also strive for early detection and would be more highly motivated to learn and practice breast self examination. Such women would also be highly motivated to have regular mammograms, perhaps starting at an earlier age than the general population. Ovarian screening could also be undertaken at greater frequency. Diagnostic methods based on sequence analysis of the BRCA1 locus could also be applied to tumor detection and classification. Sequence analysis could be used to diagnose precursor lesions.

TABLE 18  
Polymorphisms in BRCA1 Genomic DNA Exons

Name	Exon #	Codon	Base Position <sup>1</sup>	Base Change	Effect
PM01	11	356	1186	A ↔ G	gln ↔ arg
PM02	13	1436	4427	T ↔ C	ser ↔ ser
PM03	16	1613	4956	A ↔ G	ser ↔ gly
PM06	11	871	2731	C ↔ T	pro ↔ leu
PM07	11	1183	3667	A ↔ G	lys ↔ arg
PM09	11	694	2201	C ↔ T	ser ↔ ser
PM10	11	771	2430	T ↔ C	leu ↔ leu
PM12	16	1561	4801	C ↔ T	thr ↔ ile
PM14	11	1038	3233	A ↔ G	glu ↔ glu
PM17	9	197	710	C ↔ T	cys ↔ cys
PM18	11	693	2196	G ↔ A	asp ↔ asn
PM19	11	841	2640	C ↔ T	arg ↔ trp
PM20	11	1040	3238	G ↔ A	ser ↔ asn
PM21	4	61 <sup>2</sup>	48 <sup>3</sup>	C ↔ T	ala ↔ val
PM22	11	327	1100	A ↔ G	thr ↔ thr
PM23	11	1316	4067	C ↔ A	phe ↔ leu
PM24	11	1008	3143	G ↔ A	met ↔ ile
PM25	11	1316	4067	C ↔ G	phe ↔ leu
PM26	11	1322	4083	A ↔ G	lys ↔ glu
PM27	11	1347	4158	A ↔ G	arg ↔ gly
PM28	11	707	2240	T ↔ C	gly ↔ gly
PM29	11	675	2144	A ↔ C	ala ↔ ala

<sup>1</sup> Base position as shown in SEQ ID NO:1

<sup>2</sup> Codon number with exon 4 included in the coding region

<sup>3</sup> Base position as shown in SEQ ID NO:11 (exon 4 alone)

TABLE 19  
Polymorphisms in BRCA1 Genomic DNA Introns

Name	Intron #	Base Position <sup>1</sup>	Base Change	Effect
PM04	11	15284	C ↔ A	unknown
PM05	18	20334	A ↔ G	unknown
PM11	16	19231	G ↔ A	unknown
PM15	8	9106	del T	unknown
PM16	22	22914	T ↔ C	unknown
PMA02.1	1	1295	G ↔ A	unknown
PMA03.1	2	2141	G ↔ C	unknown
PMA06.1	5	3653	A ↔ G	unknown
PMA07.1	7	insert between 4391-4392	TTC	unknown
PMA08.1	7	6538	C ↔ T	unknown
PMA08.2	8	6823	A ↔ T	unknown
PMA09.2	9	9376	T ↔ C	unknown
PMA13.1	13	16243	G ↔ A	unknown
PMA15.1	14	insert between 17335-17336	CCAAC	unknown
PMA15.2	14	17399	A ↔ T	unknown
PMA15.3	14	17473	C ↔ G	unknown
PMA18.1	17	20138	C ↔ T	unknown
PMA22.1	21	22680	A ↔ G	unknown

<sup>1</sup> Base position as shown in Figures 10A-H

With the evolution of the method and the accumulation of information about BRCA1 and other causative loci, it could become possible to separate cancers into benign and malignant.

Women with breast cancers may follow different surgical procedures if they are predisposed, and therefore likely to have additional cancers, than if they are not predisposed. Other therapies may be developed, using either peptides or small molecules (rational drug design). Peptides could be the missing gene product itself or a portion of the missing gene product. Alternatively, the therapeutic agent could be another molecule that mimics the deleterious gene's function, either a peptide or a nonpeptidic molecule that seeks to counteract the deleterious effect of the inherited locus. The therapy could also be gene based, through introduction of a normal BRCA1 allele into individuals to make a protein which will counteract the effect of the deleterious allele. These gene therapies may take many forms and may be directed

either toward preventing the tumor from forming, curing a cancer once it has occurred, or stopping a cancer from metastasizing.

It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

#### LIST OF REFERENCES

- 10 Altschul, S.F. *et al.* (1990). *J. Mol. Biol.* **215**: 195-197.  
American Cancer Society, Cancer Facts & Figures - 1992. (American Cancer Society, Atlanta, GA).  
Anand, R. (1992). *Techniques for the Analysis of Complex Genomes*, (Academic Press).  
Anderson, *et al.* (1980). *Proc. Natl. Acad. Sci. USA* **77**:5399-5403.  
Anderson, D.E. (1972). *J. Natl. Cancer Inst.* **48**:1029-1034.
- 15 Anderson, J.A., *et al.* (1992). *J. Otolaryngology* **21**:321.  
Antonarakis, S.E., *et al.* (1985). *New Eng. J. Med.* **313**:842-848.  
Ausubel, F.M., *et al.* (1992). *Current Protocols in Molecular Biology*, (J. Wiley and Sons, N.Y.)  
Beaucage & Carruthers (1981). *Tetra. Letts.* **22**:1859-1862.  
Berkner (1992). *Curr. Top. Microbiol. Immunol.* **158**:39-61.
- 20 Berkner, *et al.* (1988). *BioTechniques* **6**:616-629.  
Bickmore, W.A., *et al.* (1992). *Science* **257**:235-7.  
Bishop, D.T., *et al.* (1988). *Genet. Epidemiol.* **5**:151-169.  
Bishop, D.T. and Gardner, E.J. (1980). In: Banbury Report 4: Cancer Incidence in Defined Populations (J. Cairns, J.L. Lyon, M. Skolnick, eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 309-408.
- 25 Botstein, *et al.* (1980). *Am. J. Hum. Genet.* **32**:314-331.  
Bowcock, A.M., *et al.* (1993). *Am. J. Hum. Genet.* **52**:718.  
Bradyopadhyay and Temin (1984). *Mol. Cell. Biol.* **4**:749-754.  
Breakfield and Geller (1987). *Mol. Neurobiol.* **1**:337-371.  
Brinster, *et al.* (1981). *Cell* **27**:223-231.
- 30 Buchschacher and Panganiban (1992). *J. Virol.* **66**:2731-2739.  
Buckler, *et al.* (1991). *Proc. Natl. Acad. Sci. USA* **88**:4005-4009.  
Cannon-Albright, L., *et al.* (1994). *Cancer Research* **54**:2378-2385.  
Capecci, M.R. (1989). *Science* **244**:1288.  
Cariello (1988). *Human Genetics* **42**:726.
- 35 Claus, E., *et al.* (1991). *Am. J. Hum. Genet.* **48**:232-242.  
Conner, B.J., *et al.* (1983). *Proc. Natl. Acad. Sci. USA* **80**:278-282.  
Constantini and Lacy (1981). *Nature* **294**:92-94.  
Cotten, *et al.* (1990). *Proc. Natl. Acad. Sci. USA* **87**:4033-4037.  
Cotton, *et al.* (1988). *Proc. Natl. Acad. Sci. USA* **85**:4397.
- 40 Cropp, C.S., *et al.* (1994). *Cancer Res.* **54**:2548-2551.  
Culver, *et al.* (1992). *Science* **256**:1550-1552.  
Curiel, *et al.* (1991a). *Proc. Natl. Acad. Sci. USA* **88**:8850-8854.  
Curiel, *et al.* (1991b). *Hum. Gene Ther.* **3**:147-154.  
Deutscher, M. (1990). *Meth. Enzymology* **182** (Academic Press, San Diego, Cal.).
- 45 Donehower, L.A., *et al.* (1992). *Nature* **356**:215.  
Drummond, I. A., *et al.* (1994). *Mol. Cell Biol.* **14**:3800-9.  
Easton, D., *et al.* (1993). *Am. J. Hum. Genet.* **52**:678-701.  
Eccles, D.M., *et al.* (1990). *Oncogene* **5**:1599-1601.  
*Enhance and Eukaryotic Gene Expression*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1983).
- 50 Erickson, J. *et al.*, (1990). *Science* **249**:527-533.  
Fain, P.R. (1992). *Cytogen. Cell Genet.* **60**:178.  
Felgner, *et al.* (1987). *Proc. Natl. Acad. Sci. USA* **84**:7413-7417.  
Fiers, *et al.* (1978). *Nature* **273**:113.  
Fink, *et al.* (1992). *Hum. Gene Ther.* **3**:11-19.
- 55 Finkelstein, J., *et al.* (1990). *Genomics* **7**:167-172.  
Freese, *et al.* (1990). *Biochem. Pharmacol.* **40**:2189-2199.  
Friedman, T. (1991). In *Therapy for Genetic Diseases*, T. Friedman, ed., Oxford University Press, pp. 105-121.  
Futreal (1993). Ph.D. Thesis, University of North Carolina, Chapel Hill.

- Futreal, A., *et al.* (1992a). *Hum. Molec. Genet.* **1**:66.  
 Futreal, P.A., *et al.* (1992b). *Cancer Res.* **52**:2624-2627.  
 Glebov, O.K., *et al.* (1994). *Cancer Res.* **54**:3703-3709.  
 Glover, D. (1985). *DNA Cloning*, I and II (Oxford Press).  
 5 Go, R.C.P., *et al.* (1983). *J. Natl. Cancer Inst.* **71**:455-461.  
 Coding (1986). *Monoclonal Antibodies: Principles and Practice*, 2d ed. (Academic Press, N.Y.).  
 Godowski, *et al.* (1988). *Science* **241**:812-816.  
 Goldgar, D.E., *et al.* (1994). *J. Natl. Can. Inst.* **86**:3:200-209.  
 Gordon, *et al.* (1980). *Proc. Natl. Acad. Sci. USA* **77**:7380-7384.  
 10 Gorziglia and Kapikian (1992). *J. Virol.* **66**:4407-4412.  
 Graham and van der Eb (1973). *Virology* **52**:456-467.  
 Grompe, M., (1993). *Nature Genetics* **5**:111-117.  
 Grompe, M., *et al.*, (1989). *Proc. Natl. Acad. Sci. USA* **86**:5855-5892.  
 Guthrie, G. & Fink, G.R. (1991). *Guide to Yeast Genetics and Molecular Biology* (Academic Press).  
 15 Haber, D. A., *et al.* (1990). *Cell* **61**:1257-69.  
 Hall, J.M., *et al.* (1990). *Science* **250**:1684-1689.  
 Hall, J.M., *et al.* (1992). *Am. J. Hum. Genet.* **50**:1235-1241.  
 Harlow & Lane (1988). *Antibodies: A Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y).  
 Hasty, P., K., *et al.* (1991). *Nature* **350**:243.  
 20 Helseth, *et al.* (1990). *J. Virol.* **64**:2416-2420.  
 Hodgson, J. (1991). *Bio/Technology* **9**:19-21.  
 Huse, *et al.* (1989). *Science* **246**:1275-1281.  
 Innis *et al.* (1990). *PCR Protocols: A Guide to Methods and Applications* (Academic Press, San Diego, Cal.).  
 Jablonski, E., *et al.* (1986). *Nuc. Acids Res.* **14**:6115-6128.  
 25 Jacobs, I.J., *et al.* (1993). *Cancer Res.* **53**:1218-1221.  
 Jakoby, W.B. and Pastan, J.H. (eds.) (1979). *Cell Culture. Methods in Enzymology*, volume 58 (Academic Press, Inc.,  
 Harcourt Brace Jovanovich (New York)).  
 Jeffreys, *et al.* (1985). *Nature* **314**:67-73.  
 Johnson, *et al.* (1992). *J. Virol.* **66**:2952-2965.  
 30 Kamb, A. *et al.* (1994). *Science* **264**:436440.  
 Kandpal, *et al.* (1990). *Nucl. Acids Res.* **18**:1789-1795.  
 Kaneda. *et al.* (1989). *J. Biol. Chem.* **264**:12126-12129.  
 Kanehisa (1984). *Nucl. Acids Res.* **12**:203-213.  
 Kelsell, D.P. *et al.* (1993). *Human Mol Genet.* **2**:1823-1828.  
 35 Kinszler, K.W., *et al.* (1991) *Science* **251**:1366-1370.  
 Knudson, A.G. (1993). *Nature Genet.* **5**:103.  
 Kohler, G. and Milstein, C. (1975). *Nature* **256**:495-497.  
 Kozak, M. (1987). *Nucleic Acids Res.* **15**:8125-8148.  
 Kraemer, F.B. *et al.* (1993). *J. Lipid Res.* **34**:663-672.  
 40 Kubo, T., *et al.* (1988). *FEBS Letts.* **241**:119.  
 Landegren. *et al.* (1988). *Science* **242**:229.  
 Lim, *et al.* (1992). *Circulation* **83**:2007-2011.  
 Lindsay, S., *et al.* (1987). *Nature* **327**:336-368.  
 Litt, *et al.* (1989). *Am. J. Hum. Genet.* **44**:397-401.  
 45 Little, M.H., *et al.* (1992). *Proc. Natl. Acad. Sci. USA* **89**:4791.  
 Little, M.H., *et al.* (1993). *Hum. Mol. Genet.* **2**:259.  
 Lovett, *et al.* (1991). *Proc. Natl. Acad. Sci. USA* **88**:9628-9632.  
 Lynch, H.T., *et al.* (1990). *Gynecol. Oncol.* **36**:48-55.  
 Madzak, *et al.* (1992). *J. Gen. Virol.* **73**:1533-1536.  
 50 Malkin, D., *et al.* (1990). *Science* **250**:1233-1238.  
 Maniatis, T., *et al.* (1982). *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor,  
 N.Y.).  
 Mann and Baltimore (1985). *J. Virol.* **54**:401-407.  
 Margaritte, *et al.* (1992). *Am. J. Hum. Genet.* **50**:1231-1234.  
 55 Margolskee (1992). *Curr. Top. Microbiol. Immunol.* **158**:67-90.  
 Martin, R., *et al.* (1990). *BioTechniques* **9**:762-768.  
 Matteucci, M.D. and Caruthers, M.H. (1981). *J. Am. Chem. Soc.* **103**:3185.  
 Matthews & Kricka (1988). *Anal. Biochem.* **169**:1.

- Merrifield (1963). *J. Am. Chem. Soc.* **85**:2149-2156.
- Mettlin, C., et al. (1990). *American Journal of Epidemiology* **131**:973-983.
- Metzger, et al. (1988). *Nature* **334**:31-36.
- Miki et al. (1994). *Science* **266**:66.
- 5 Miller (1992). *Curr. Top. Microbiol. Immunol.* **158**:1-24.
- Miller, et al. (1985). *Mol. Cell. Biol.* **5**:431-437.
- Miller, et al. (1988). *J. Virol.* **62**:4337-4345.
- Mittlin (1989). *Clinical Chem.* **35**:1819.
- Modrich, P. (1991). *Ann. Rev. Genet.* **25**:229-253.
- 10 Mombaerts, P., et al. (1992). *Cell* **68**:869.
- Monaco, et al. (1986). *Nature* **323**:646.
- Moss (1992). *Curr. Top. Microbiol. Immunol.* **158**:25-38.
- Muzyczka (1992). *Curr. Top. Microbiol. Immunol.* **158**:97-123.
- Nabel (1992). *Hum. Gene Ther.* **3**:399-410.
- 15 Nabel, et al. (1990). *Science* **249**:1285-1288.
- Nakamura, et al. (1987). *Science* **235**:1616-1622.
- Narod, S.A., et al. (1991). *The Lancet* **338**:82-83.
- Newman, B., et al. (1988). *Proc. Natl. Acad. Sci. USA* **85**:3044-3048.
- Newton, C.R., Graham, A., Heptinstall, L.E., Powell, S.J., Summers, C., Kalsheker, N., Smith, J.C., and Markham, A.F.
- 20 (1989). *Nucl. Acids Res.* **17**:2503-2516.
- Nguyen, Q., et al. (1992). *BioTechniques* **13**:116-123.
- Novack, et al. (1986). *Proc. Natl. Acad. Sci. USA* **83**:586.
- Oh, J. (1985). *Analysis of Human Genetic Linkage*, Johns Hopkins University Press, Baltimore, Md, pp. 1-216.
- Ohi, et al. (1990). *Gene* **89**:279-282.
- 25 Oliphant, A., et al. (1991). *Nucleic Acid Res.* **19**:4794.
- Oliphant, A., et al. (1991). *Nucleic Acid Res.* **19**:4795.
- Orita, et al. (1989). *Proc. Natl. Acad. Sci. USA* **86**:2776-2770.
- Page, et al. (1990). *J. Virol.* **64**:5370-5276.
- Pellicer, et al. (1980). *Science* **209**:1414-1422.
- 30 Petropoulos, et al. (1992). *J. Virol.* **66**:3391-3397.
- Philpott, K.L., et al. (1992). *Science* **256**:1448.
- Pierce, et al. (1992). *Proc. Natl. Acad. Sci. USA* **89**:2056-2060.
- Quantin, et al. (1992). *Proc. Natl. Acad. Sci. USA* **89**:2581-2584.
- Rano & Kidd (1989). *Nucl. Acids Res.* **17**:8392.
- 35 Rigby, P.W.J., et al. (1977). *J. Mol. Biol.* **113**:237-251.
- Rosenfeld, et al. (1992). *Cell* **68**:143-155.
- Sambrook, J., et al. (1989). *Molecular Cloning: A Laboratory Manual*, 2nd Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
- Sato, T., et al. (1990). *Cancer Res.* **50**:7184-7189.
- 40 Scharf (1986). *Science* **233**:1076.
- Scopes, R. (1982). *Protein Purification: Principles and Practice*, (Springer-Verlag, N.Y.).
- Shaulian, E., et al. (1992). *Mol. Cell Biol.* **12**:5581-92.
- Sheffield, V.C., et al. (1989). *Proc. Natl. Acad. Sci. USA* **86**:232-236.
- Sheffield, V.C., et al. (1991). *Am. J. Hum. Genet.* **49**:699-706.
- 45 Shenk, et al. (1975). *Proc. Natl. Acad. Sci. USA* **72**:989.
- Shimada, et al. (1991). *J. Clin. Invest.* **88**:1043-1047.
- Shinkai, Y., et al. (1992). *Cell* **68**:855.
- Shizuya, H., et al. (1992). *Proc. Natl. Acad. Sci. USA* **89**:8794-8797.
- Simard, J., et al. (1993). *Human Mol. Genet.* **2**:1193-1199.
- 50 Skolnick, M.H. and Wallace, B.R. (1988). *Genomics* **2**:273-279.
- Skolnick, M.H., et al. (1990). *Science* **250**:1715-1720.
- Smith, S.A., et al. (1992). *Nature Genetics* **2**:128-131.
- Smith, T.F. and Waterman, M.S. (1981). *J. Mol. Biol.* **147**:195-197.
- Snouwaert, J.N., et al. (1992). *Science* **257**:1083.
- 55 Sorge, et al. (1984). *Mol. Cell. Biol.* **4**:1730-1737.
- Srivastava, S., et al. (1993). *Cancer Res.* **53**:4452-5.
- Sternberg (1990). *Proc. Natl. Acad. Sci. USA* **87**:103-107.
- Sternberg, et al. (1990). *The New Biologist* **2**:151-162.

- Stewart, *et al.* (1992). *Hum. Gene Ther.* 3:267-275.  
 Stratford-Perricaudet, *et al.* (1990). *Hum. Gene Ther.* 1:241-256.  
 Swift, M., *et al.* (1991). *N. Engl. J. Med.* 325:1831-1836.  
 Swift, M., *et al.* (1976). *Cancer Res.* 36:209-215.  
 5 Su, L. K., *et al.* (1993). *Cancer Res.* 53:2728-31.  
 Thomas, A. and Skolnick, M.H. (1994). *IMA Journal of Mathematics Applied in Medicine and Biology* (in press).  
 Tonolio, D., *et al.* (1990). Cold Spring Harbor Conference.  
 Valancius, V. & Smithies, O. (1991). *Mol. Cell Biol.* 11:1402.  
 van Dilla, *et al.* (1986). *Biotechnology* 4:537-552.  
 10 Wagner, *et al.* (1990). *Proc. Natl. Acad. Sci. USA* 87:3410-3414.  
 Wagner, *et al.* (1991). *Proc. Natl. Acad. Sci. USA* 88:4255-4259.  
 Wang and Huang (1989). *Biochemistry* 28:9508-9514.  
 Wartell, R.M., *et al.* (1990). *Nucl. Acids Res.* 18:2699-2705.  
 Weber, J.L. (1990). *Genomics* 7:524-530.  
 15 Weber and May (1989). *Am. J. Hum. Genet.* 44:388-396.  
 Weber, J.L., *et al.* (1990). *Nucleic Acid Res.* 18:4640.  
 Wells, J.A. (1991). *Methods in Enzymol.* 202:390-411.  
 Wetmur & Davidson (1968). *J. Mol. Biol.* 31:349-370.  
 White, M.B., *et al.*, (1992). *Genomics* 12:301-306.  
 20 White and Lalouel (1988). *Ann. Rev. Genet.* 22:259-279.  
 Wilkinson, *et al.* (1992). *Nucleic Acids Res.* 20:2233-2239.  
 Willams and Anderson (1984). *Genet. Epidemiol.* 1:7-20.  
 Wolff, *et al.* (1990). *Science* 247:1465-1468.  
 Wolff, *et al.* (1991). *BioTechniques* 11:474-485.  
 25 Wooster, R., *et al.* (1994). *Science* 265:2088.  
 Wu, *et al.* (1989a). *Genomics* 4:560-569.  
 Wu, *et al.* (1989b). *J. Biol. Chem.* 264:16985-16987.  
 Wu, *et al.* (1991). *J. Biol. Chem.* 266:14338-14342.  
 Zenke, *et al.* (1990). *Proc. Natl. Acad. Sci. USA* 87:3655-3659.  
 30 List of Patents and Patent Applications:  
 U.S. Patent No. 3,817,837  
 U.S. Patent No. 3,850,752  
 U.S. Patent No. 3,939,350  
 U.S. Patent No. 3,996,345  
 35 U.S. Patent No. 4,275,149  
 U.S. Patent No. 4,277,437  
 U.S. Patent No. 4,366,241  
 U.S. Patent No. 4,376,110  
 U.S. Patent No. 4,486,530  
 40 U.S. Patent No. 4,683,195  
 U.S. Patent No. 4,683,202  
 U.S. Patent No. 4,816,567  
 U.S. Patent No. 4,868,105  
 U.S. Patent No. 5,252,479  
 45 EPO Publication No. 225,807  
 European Patent Application Publication No. 0332435  
 Geysen, H., PCT published application WO 84/03564, published 13 September 1984  
 Hitzeman *et al.*, EP 73.675A  
 PCT published application WO 93/07282  
 50

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT:

10 (A) NAME: MYRIAD GENETICS INC.  
(B) STREET: 300 WAKARA WAY  
(C) CITY: SALT LAKE CITY  
(D) STATE: UTAH  
(E) COUNTRY: UNITED STATES OF AMERICA  
15 (F) POSTAL CODE (ZIP): 84108

(A) NAME: CENTRE DU RECHERCHE DU CHUL  
(B) STREET: 2705 LAURIER BOULEVARD  
20 (C) CITY: SAINTE-FOY  
(D) STATE: QUEBEC  
(E) COUNTRY: CANADA  
(F) POSTAL CODE (ZIP): G1V 4G2

25 (A) NAME: CANCER INSTITUTE  
(B) STREET: 1-31-1, KAMI-IKEBUKURO, TOSHIMO-KU  
(C) CITY: TOKYO  
(E) COUNTRY: JAPAN  
30 (F) POSTAL CODE (ZIP): 170

35 (ii) TITLE OF INVENTION: IN VIVO MUTATIONS AND POLYMORPHISMS IN  
THE 17q-LINKED BREAST AND OVARIAN CANCER  
SUSCEPTIBILITY GENE

(iii) NUMBER OF SEQUENCES: 85

40 (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
45 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5914 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 120..5711

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

25 AGCTCGCTGA GACTTCCTGG ACCCCGCACC AGGCTGTGGG GTTCTCAGA TAACTGGGCC      60
   CCTGCGCTCA GGAGGCCTTC ACCCTCTGCT CTGGGTAAAG TTCATTGGAA CAGAAAGAA      119
30 ATG GAT TTA TCT GCT CTT CGC GTT GAA GAA GTA CAA AAT GTC ATT AAT      167
   Met Asp Leu Ser Ala Leu Arg Val Glu Glu Val Gln Asn Val Ile Asn
     1           5           10           15

35 GCT ATG CAG AAA ATC TTA GAG TGT CCC ATC TGT CTG GAG TTG ATC AAG      215
   Ala Met Gln Lys Ile Leu Glu Cys Pro Ile Cys Leu Glu Leu Ile Lys
           20           25           30

40 GAA CCT GTC TCC ACA AAG TGT GAC CAC ATA TTT TGC AAA TTT TGC ATG      263
   Glu Pro Val Ser Thr Lys Cys Asp His Ile Phe Cys Lys Phe Cys Met
           35           40           45

```

5	CTG AAA CTT CTC AAC CAG AAG AAA GGG CCT TCA CAG TGT CCT TTA TGT Leu Lys Leu Leu Asn Gln Lys Lys Gly Pro Ser Gln Cys Pro Leu Cys 50 55 60	311
10	AAG AAT GAT ATA ACC AAA AGG AGC CTA CAA GAA AGT ACG AGA TTT AGT Lys Asn Asp Ile Thr Lys Arg Ser Leu Gln Glu Ser Thr Arg Phe Ser 65 70 75 80	359
15	CAA CTT GTT GAA GAG CTA TTG AAA ATC ATT TGT GCT TTT CAG CTT GAC Gln Leu Val Glu Glu Leu Leu Lys Ile Ile Cys Ala Phe Gln Leu Asp 85 90 95	407
20	ACA GGT TTG GAG TAT GCA AAC AGC TAT AAT TTT GCA AAA AAG GAA AAT Thr Gly Leu Glu Tyr Ala Asn Ser Tyr Asn Phe Ala Lys Lys Glu Asn 100 105 110	455
25	AAC TCT CCT GAA CAT CTA AAA GAT GAA GTT TCT ATC ATC CAA AGT ATG Asn Ser Pro Glu His Leu Lys Asp Glu Val Ser Ile Ile Gln Ser Met 115 120 125	503
30	GGC TAC AGA AAC CGT GCC AAA AGA CTT CTA CAG AGT GAA CCC GAA AAT Gly Tyr Arg Asn Arg Ala Lys Arg Leu Leu Gln Ser Glu Pro Glu Asn 130 135 140	551
35	CCT TCC TTG CAG GAA ACC AGT CTC AGT GTC CAA CTC TCT AAC CTT GGA Pro Ser Leu Gln Glu Thr Ser Leu Ser Val Gln Leu Ser Asn Leu Gly 145 150 155 160	599
40	ACT GTG AGA ACT CTG AGG ACA AAG CAG CGG ATA CAA CCT CAA AAG ACG Thr Val Arg Thr Leu Arg Thr Lys Gln Arg Ile Gln Pro Gln Lys Thr 165 170 175	647
45	TCT GTC TAC ATT GAA TTG GGA TCT GAT TCT TCT GAA GAT ACC GTT AAT Ser Val Tyr Ile Glu Leu Gly Ser Asp Ser Ser Glu Asp Thr Val Asn 180 185 190	695
50	AAG GCA ACT TAT TGC AGT GTG GGA GAT CAA GAA TTG TTA CAA ATC ACC Lys Ala Thr Tyr Cys Ser Val Gly Asp Gln Glu Leu Leu Gln Ile Thr 195 200 205	743
55	CCT CAA GGA ACC AGG GAT GAA ATC AGT TTG GAT TCT GCA AAA AAG GCT Pro Gln Gly Thr Arg Asp Glu Ile Ser Leu Asp Ser Ala Lys Lys Ala 210 215 220	791
60	GCT TGT GAA TTT TCT GAG ACG GAT GTA ACA AAT ACT GAA CAT CAT CAA Ala Cys Glu Phe Ser Glu Thr Asp Val Thr Asn Thr Glu His His Gln 225 230 235 240	839
65	CCC AGT AAT AAT GAT TTG AAC ACC ACT GAG AAG CGT GCA GCT GAG AGG Pro Ser Asn Asn Asp Leu Asn Thr Thr Glu Lys Arg Ala Ala Glu Arg 245 250 255	887
70	CAT CCA GAA AAG TAT CAG GGT AGT TCT GTT TCA AAC TTG CAT GTG GAG His Pro Glu Lys Tyr Gln Gly Ser Ser Val Ser Asn Leu His Val Glu 260 265 270	935

	CCA	TGT	GGC	ACA	AAT	ACT	CAT	GCC	AGC	TCA	TTA	CAG	CAT	GAG	AAC	AGC	983
	Pro	Cys	Gly	Thr	Asn	Thr	His	Ala	Ser	Ser	Leu	Gln	His	Glu	Asn	Ser	
			275					280						285			
5	AGT	TTA	TTA	CTC	ACT	AAA	GAC	AGA	ATG	AAT	GTA	GAA	AAG	GCT	GAA	TTC	1031
	Ser	Leu	Leu	Leu	Thr	Lys	Asp	Arg	Met	Asn	Val	Glu	Lys	Ala	Glu	Phe	
		290					295					300					
10	TGT	AAT	AAA	AGC	AAA	CAG	CCT	GGC	TTA	GCA	AGG	AGC	CAA	CAT	AAC	AGA	1079
	Cys	Asn	Lys	Ser	Lys	Gln	Pro	Gly	Leu	Ala	Arg	Ser	Gln	His	Asn	Arg	
		305				310					315					320	
15	TGG	GCT	GGA	AGT	AAG	GAA	ACA	TGT	AAT	GAT	AGG	CGG	ACT	CCC	AGC	ACA	1127
	Trp	Ala	Gly	Ser	Lys	Glu	Thr	Cys	Asn	Asp	Arg	Arg	Thr	Pro	Ser	Thr	
					325					330					335		
20	GAA	AAA	AAG	GTA	GAT	CTG	AAT	GCT	GAT	CCC	CTG	TGT	GAG	AGA	AAA	GAA	1175
	Glu	Lys	Lys	Val	Asp	Leu	Asn	Ala	Asp	Pro	Leu	Cys	Glu	Arg	Lys	Glu	
				340					345					350			
25	TGG	AAT	AAG	CAG	AAA	CTG	CCA	TGC	TCA	GAG	AAT	CCT	AGA	GAT	ACT	GAA	1223
	Trp	Asn	Lys	Gln	Lys	Leu	Pro	Cys	Ser	Glu	Asn	Pro	Arg	Asp	Thr	Glu	
			355					360					365				
30	GAT	GTT	CCT	TGG	ATA	ACA	CTA	AAT	AGC	AGC	ATT	CAG	AAA	GTT	AAT	GAG	1271
	Asp	Val	Pro	Trp	Ile	Thr	Leu	Asn	Ser	Ser	Ile	Gln	Lys	Val	Asn	Glu	
		370					375					380					
35	TGG	TTT	TCC	AGA	AGT	GAT	GAA	CTG	TTA	GGT	TCT	GAT	GAC	TCA	CAT	GAT	1319
	Trp	Phe	Ser	Arg	Ser	Asp	Glu	Leu	Leu	Gly	Ser	Asp	Asp	Ser	His	Asp	
		385				390					395					400	
40	GGG	GAG	TCT	GAA	TCA	AAT	GCC	AAA	GTA	GCT	GAT	GTA	TTG	GAC	GTT	CTA	1367
	Gly	Glu	Ser	Glu	Ser	Asn	Ala	Lys	Val	Ala	Asp	Val	Leu	Asp	Val	Leu	
					405					410					415		
45	AAT	GAG	GTA	GAT	GAA	TAT	TCT	GGT	TCT	TCA	GAG	AAA	ATA	GAC	TTA	CTG	1415
	Asn	Glu	Val	Asp	Glu	Tyr	Ser	Gly	Ser	Ser	Glu	Lys	Ile	Asp	Leu	Leu	
				420					425					430			
50	GCC	AGT	GAT	CCT	CAT	GAG	GCT	TTA	ATA	TGT	AAA	AGT	GAA	AGA	GTT	CAC	1463
	Ala	Ser	Asp	Pro	His	Glu	Ala	Leu	Ile	Cys	Lys	Ser	Glu	Arg	Val	His	
			435					440					445				
55	TCC	AAA	TCA	GTA	GAG	AGT	AAT	ATT	GAA	GAC	AAA	ATA	TTT	GGG	AAA	ACC	1511
	Ser	Lys	Ser	Val	Glu	Ser	Asn	Ile	Glu	Asp	Lys	Ile	Phe	Gly	Lys	Thr	
		450					455					460					
60	TAT	CGG	AAG	AAG	GCA	AGC	CTC	CCC	AAC	TTA	AGC	CAT	GTA	ACT	GAA	AAT	1559
	Tyr	Arg	Lys	Lys	Ala	Ser	Leu	Pro	Asn	Leu	Ser	His	Val	Thr	Glu	Asn	
		465				470					475				480		
65	CTA	ATT	ATA	GGA	GCA	TTT	GTT	ACT	GAG	CCA	CAG	ATA	ATA	CAA	GAG	CGT	1607
	Leu	Ile	Ile	Gly	Ala	Phe	Val	Thr	Glu	Pro	Gln	Ile	Ile	Gln	Glu	Arg	
					485					490					495		

## EP 0 705 903 A1

	CCC	CTC	ACA	AAT	AAA	TTA	AAG	CGT	AAA	AGG	AGA	CCT	ACA	TCA	GGC	CTT	1655
	Pro	Leu	Thr	Asn	Lys	Leu	Lys	Arg	Lys	Arg	Arg	Pro	Thr	Ser	Gly	Leu	
				500					505					510			
5	CAT	CCT	GAG	GAT	TTT	ATC	AAG	AAA	GCA	GAT	TTG	GCA	GTT	CAA	AAG	ACT	1703
	His	Pro	Glu	Asp	Phe	Ile	Lys	Lys	Ala	Asp	Leu	Ala	Val	Gln	Lys	Thr	
			515					520				525					
10	CCT	GAA	ATG	ATA	AAT	CAG	GGA	ACT	AAC	CAA	ACG	GAG	CAG	AAT	GGT	CAA	1751
	Pro	Glu	Met	Ile	Asn	Gln	Gly	Thr	Asn	Gln	Thr	Glu	Gln	Asn	Gly	Gln	
		530					535					540					
15	GTG	ATG	AAT	ATT	ACT	AAT	AGT	GGT	CAT	GAG	AAT	AAA	ACA	AAA	GGT	GAT	1799
	Val	Met	Asn	Ile	Thr	Asn	Ser	Gly	His	Glu	Asn	Lys	Thr	Lys	Gly	Asp	
	545					550				555					560		
20	TCT	ATT	CAG	AAT	GAG	AAA	AAT	CCT	AAC	CCA	ATA	GAA	TCA	CTC	GAA	AAA	1847
	Ser	Ile	Gln	Asn	Glu	Lys	Asn	Pro	Asn	Pro	Ile	Glu	Ser	Leu	Glu	Lys	
				565				570						575			
25	GAA	TCT	GCT	TTC	AAA	ACG	AAA	GCT	GAA	CCT	ATA	AGC	AGC	AGT	ATA	AGC	1895
	Glu	Ser	Ala	Phe	Lys	Thr	Lys	Ala	Glu	Pro	Ile	Ser	Ser	Ser	Ile	Ser	
				580				585						590			
30	AAT	ATG	GAA	CTC	GAA	TTA	AAT	ATC	CAC	AAT	TCA	AAA	GCA	CCT	AAA	AAG	1943
	Asn	Met	Glu	Leu	Glu	Leu	Asn	Ile	His	Asn	Ser	Lys	Ala	Pro	Lys	Lys	
			595				600					605					
35	AAT	AGG	CTG	AGG	AGG	AAG	TCT	TCT	ACC	AGG	CAT	ATT	CAT	GCG	CTT	GAA	1991
	Asn	Arg	Leu	Arg	Arg	Lys	Ser	Ser	Thr	Arg	His	Ile	His	Ala	Leu	Glu	
		610				615					620						
40	CTA	GTA	GTC	AGT	AGA	AAT	CTA	AGC	CCA	CCT	AAT	TGT	ACT	GAA	TTG	CAA	2039
	Leu	Val	Val	Ser	Arg	Asn	Leu	Ser	Pro	Pro	Asn	Cys	Thr	Glu	Leu	Gln	
	625					630				635					640		
45	ATT	GAT	AGT	TGT	TCT	AGC	AGT	GAA	GAG	ATA	AAG	AAA	AAA	AAG	TAC	AAC	2087
	Ile	Asp	Ser	Cys	Ser	Ser	Ser	Glu	Glu	Ile	Lys	Lys	Lys	Lys	Tyr	Asn	
				645				650						655			
50	CAA	ATG	CCA	GTC	AGG	CAC	AGC	AGA	AAC	CTA	CAA	CTC	ATG	GAA	GGT	AAA	2135
	Gln	Met	Pro	Val	Arg	His	Ser	Arg	Asn	Leu	Gln	Leu	Met	Glu	Gly	Lys	
			660					665						670			
55	GAA	CCT	GCA	ACT	GGA	GCC	AAG	AAG	AGT	AAC	AAG	CCA	AAT	GAA	CAG	ACA	2183
	Glu	Pro	Ala	Thr	Gly	Ala	Lys	Lys	Ser	Asn	Lys	Pro	Asn	Glu	Gln	Thr	
		675				680						685					
60	AGT	AAA	AGA	CAT	GAC	AGC	GAT	ACT	TTC	CCA	GAG	CTG	AAG	TTA	ACA	AAT	2231
	Ser	Lys	Arg	His	Asp	Ser	Asp	Thr	Phe	Pro	Glu	Leu	Lys	Leu	Thr	Asn	
		690				695					700						
65	GCA	CCT	GGT	TCT	TTT	ACT	AAG	TGT	TCA	AAT	ACC	AGT	GAA	CTT	AAA	GAA	2279
	Ala	Pro	Gly	Ser	Phe	Thr	Lys	Cys	Ser	Asn	Thr	Ser	Glu	Leu	Lys	Glu	
	705					710				715					720		

5	TTT GTC AAT CCT AGC CTT CCA AGA GAA GAA AAA GAA GAG AAA CTA GAA Phe Val Asn Pro Ser Leu Pro Arg Glu Glu Lys Glu Glu Lys Leu Glu 725 730 735	2327
10	ACA GTT AAA GTG TCT AAT AAT GCT GAA GAC CCC AAA GAT CTC ATG TTA Thr Val Lys Val Ser Asn Asn Ala Glu Asp Pro Lys Asp Leu Met Leu 740 745 750	2375
15	AGT GGA GAA AGG GTT TTG CAA ACT GAA AGA TCT GTA GAG AGT AGC AGT Ser Gly Glu Arg Val Leu Gln Thr Glu Arg Ser Val Glu Ser Ser Ser 755 760 765	2423
20	ATT TCA TTG GTA CCT GGT ACT GAT TAT GGC ACT CAG GAA AGT ATC TCG Ile Ser Leu Val Pro Gly Thr Asp Tyr Gly Thr Gln Glu Ser Ile Ser 770 775 780	2471
25	TTA CTG GAA GTT AGC ACT CTA GGG AAG GCA AAA ACA GAA CCA AAT AAA Leu Leu Glu Val Ser Thr Leu Gly Lys Ala Lys Thr Glu Pro Asn Lys 785 790 795 800	2519
30	TGT GTG AGT CAG TGT GCA GCA TTT GAA AAC CCC AAG GGA CTA ATT CAT Cys Val Ser Gln Cys Ala Ala Phe Glu Asn Pro Lys Gly Leu Ile His 805 810 815	2567
35	GGT TGT TCC AAA GAT AAT AGA AAT GAC ACA GAA GGC TTT AAG TAT CCA Gly Cys Ser Lys Asp Asn Arg Asn Asp Thr Glu Gly Phe Lys Tyr Pro 820 825 830	2615
40	TTG GGA CAT GAA GTT AAC CAC AGT CGG GAA ACA AGC ATA GAA ATG GAA Leu Gly His Glu Val Asn His Ser Arg Glu Thr Ser Ile Glu Met Glu 835 840 845	2663
45	GAA AGT GAA CTT GAT GCT CAG TAT TTG CAG AAT ACA TTC AAG GTT TCA Glu Ser Glu Leu Asp Ala Gln Tyr Leu Gln Asn Thr Phe Lys Val Ser 850 855 860	2711
50	AAG CGC CAG TCA TTT GCT CCG TTT TCA AAT CCA GGA AAT GCA GAA GAG Lys Arg Gln Ser Phe Ala Pro Phe Ser Asn Pro Gly Asn Ala Glu Glu 865 870 875 880	2759
55	GAA TGT GCA ACA TTC TCT GCC CAC TCT GGG TCC TTA AAG AAA CAA AGT Glu Cys Ala Thr Phe Ser Ala His Ser Gly Ser Leu Lys Lys Gln Ser 885 890 895	2807
60	CCA AAA GTC ACT TTT GAA TGT GAA CAA AAG GAA GAA AAT CAA GGA AAG Pro Lys Val Thr Phe Glu Cys Glu Gln Lys Glu Glu Asn Gln Gly Lys 900 905 910	2855
65	AAT GAG TCT AAT ATC AAG CCT GTA CAG ACA GTT AAT ATC ACT GCA GGC Asn Glu Ser Asn Ile Lys Pro Val Gln Thr Val Asn Ile Thr Ala Gly 915 920 925	2903
70	TTT CCT GTG GTT GGT CAG AAA GAT AAG CCA GTT GAT AAT GCC AAA TGT Phe Pro Val Val Gly Gln Lys Asp Lys Pro Val Asp Asn Ala Lys Cys 930 935 940	2951

5	AGT ATC AAA GGA GGC TCT AGG TTT TGT CTA TCA TCT CAG TTC AGA GGC Ser Ile Lys Gly Gly Ser Arg Phe Cys Leu Ser Ser Gln Phe Arg Gly 945 950 955 960	2999
10	AAC GAA ACT GGA CTC ATT ACT CCA AAT AAA CAT GGA CTT TTA CAA AAC Asn Glu Thr Gly Leu Ile Thr Pro Asn Lys His Gly Leu Leu Gln Asn 965 970 975	3047
15	CCA TAT CGT ATA CCA CCA CTT TTT CCC ATC AAG TCA TTT GTT AAA ACT Pro Tyr Arg Ile Pro Pro Leu Phe Pro Ile Lys Ser Phe Val Lys Thr 980 985 990	3095
20	AAA TGT AAG AAA AAT CTG CTA GAG GAA AAC TTT GAG GAA CAT TCA ATG Lys Cys Lys Lys Asn Leu Leu Glu Glu Asn Phe Glu Glu His Ser Met 995 1000 1005	3143
25	TCA CCT GAA AGA GAA ATG GGA AAT GAG AAC ATT CCA AGT ACA GTG AGC Ser Pro Glu Arg Glu Met Gly Asn Glu Asn Ile Pro Ser Thr Val Ser 1010 1015 1020	3191
30	ACA ATT AGC CGT AAT AAC ATT AGA GAA AAT GTT TTT AAA GAA GCC AGC Thr Ile Ser Arg Asn Asn Ile Arg Glu Asn Val Phe Lys Glu Ala Ser 1025 1030 1035 1040	3239
35	TCA AGC AAT ATT AAT GAA GTA GGT TCC AGT ACT AAT GAA GTG GGC TCC Ser Ser Asn Ile Asn Glu Val Gly Ser Ser Thr Asn Glu Val Gly Ser 1045 1050 1055	3287
40	AGT ATT AAT GAA ATA GGT TCC AGT GAT GAA AAC ATT CAA GCA GAA CTA Ser Ile Asn Glu Ile Gly Ser Ser Asp Glu Asn Ile Gln Ala Glu Leu 1060 1065 1070	3335
45	GGT AGA AAC AGA GGG CCA AAA TTG AAT GCT ATG CTT AGA TTA GGG GTT Gly Arg Asn Arg Gly Pro Lys Leu Asn Ala Met Leu Arg Leu Gly Val 1075 1080 1085	3383
50	TTG CAA CCT GAG GTC TAT AAA CAA AGT CTT CCT GGA AGT AAT TGT AAG Leu Gln Pro Glu Val Tyr Lys Gln Ser Leu Pro Gly Ser Asn Cys Lys 1090 1095 1100	3431
55	CAT CCT GAA ATA AAA AAG CAA GAA TAT GAA GAA GTA GTT CAG ACT GTT His Pro Glu Ile Lys Lys Gln Glu Tyr Glu Glu Val Val Gln Thr Val 1105 1110 1115 1120	3479
	AAT ACA GAT TTC TCT CCA TAT CTG ATT TCA GAT AAC TTA GAA CAG CCT Asn Thr Asp Phe Ser Pro Tyr Leu Ile Ser Asp Asn Leu Glu Gln Pro 1125 1130 1135	3527
	ATG GGA AGT AGT CAT GCA TCT CAG GTT TGT TCT GAG ACA CCT GAT GAC Met Gly Ser Ser His Ala Ser Gln Val Cys Ser Glu Thr Pro Asp Asp 1140 1145 1150	3575
	CTG TTA GAT GAT GGT GAA ATA AAG GAA GAT ACT AGT TTT GCT GAA AAT Leu Leu Asp Asp Gly Glu Ile Lys Glu Asp Thr Ser Phe Ala Glu Asn 1155 1160 1165	3623

EP 0 705 903 A1

	GAC ATT AAG GAA AGT TCT GCT GTT TTT AGC AAA AGC GTC CAG AAA GGA Asp Ile Lys Glu Ser Ser Ala Val Phe Ser Lys Ser Val Gln Lys Gly 1170 1175 1180	3671
5	GAG CTT AGC AGG AGT CCT AGC CCT TTC ACC CAT ACA CAT TTG GCT CAG Glu Leu Ser Arg Ser Pro Ser Pro Phe Thr His Thr His Leu Ala Gln 1185 1190 1195 1200	3719
10	GGT TAC CGA AGA GGG GCC AAG AAA TTA GAG TCC TCA GAA GAG AAC TTA Gly Tyr Arg Arg Gly Ala Lys Lys Leu Glu Ser Ser Glu Glu Asn Leu 1205 1210 1215	3767
15	TCT AGT GAG GAT GAA GAG CTT CCC TGC TTC CAA CAC TTG TTA TTT GGT Ser Ser Glu Asp Glu Glu Leu Pro Cys Phe Gln His Leu Leu Phe Gly 1220 1225 1230	3815
20	AAA GTA AAC AAT ATA CCT TCT CAG TCT ACT AGG CAT AGC ACC GTT GCT Lys Val Asn Asn Ile Pro Ser Gln Ser Thr Arg His Ser Thr Val Ala 1235 1240 1245	3863
25	ACC GAG TGT CTG TCT AAG AAC ACA GAG GAG AAT TTA TTA TCA TTG AAG Thr Glu Cys Leu Ser Lys Asn Thr Glu Glu Asn Leu Leu Ser Leu Lys 1250 1255 1260	3911
30	AAT AGC TTA AAT GAC TGC AGT AAC CAG GTA ATA TTG GCA AAG GCA TCT Asn Ser Leu Asn Asp Cys Ser Asn Gln Val Ile Leu Ala Lys Ala Ser 1265 1270 1275 1280	3959
35	CAG GAA CAT CAC CTT AGT GAG GAA ACA AAA TGT TCT GCT AGC TTG TTT Gln Glu His His Leu Ser Glu Glu Thr Lys Cys Ser Ala Ser Leu Phe 1285 1290 1295	4007
40	TCT TCA CAG TGC AGT GAA TTG GAA GAC TTG ACT GCA AAT ACA AAC ACC Ser Ser Gln Cys Ser Glu Leu Glu Asp Leu Thr Ala Asn Thr Asn Thr 1300 1305 1310	4055
45	CAG GAT CCT TTC TTG ATT GGT TCT TCC AAA CAA ATG AGG CAT CAG TCT Gln Asp Pro Phe Leu Ile Gly Ser Ser Lys Gln Met Arg His Gln Ser 1315 1320 1325	4103
50	GAA AGC CAG GGA GTT GGT CTG AGT GAC AAG GAA TTG GTT TCA GAT GAT Glu Ser Gln Gly Val Gly Leu Ser Asp Lys Glu Leu Val Ser Asp Asp 1330 1335 1340	4151
55	GAA GAA AGA GGA ACG GGC TTG GAA GAA AAT AAT CAA GAA GAG CAA AGC Glu Glu Arg Gly Thr Gly Leu Glu Glu Asn Asn Gln Glu Glu Gln Ser 1345 1350 1355 1360	4199
60	ATG GAT TCA AAC TTA GGT GAA GCA GCA TCT GGG TGT GAG AGT GAA ACA Met Asp Ser Asn Leu Gly Glu Ala Ala Ser Gly Cys Glu Ser Glu Thr 1365 1370 1375	4247
65	AGC GTC TCT GAA GAC TGC TCA GGG CTA TCC TCT CAG AGT GAC ATT TTA Ser Val Ser Glu Asp Cys Ser Gly Leu Ser Ser Gln Ser Asp Ile Leu 1380 1385 1390	4295

5	ACC ACT CAG CAG AGG GAT ACC ATG CAA CAT AAC CTG ATA AAG CTC CAG Thr Thr Gln Gln Arg Asp Thr Met Gln His Asn Leu Ile Lys Leu Gln 1395 1400 1405	4343
10	CAG GAA ATG GCT GAA CTA GAA GCT GTG TTA GAA CAG CAT GGG AGC CAG Gln Glu Met Ala Glu Leu Glu Ala Val Leu Glu Gln His Gly Ser Gln 1410 1415 1420	4391
15	CCT TCT AAC AGC TAC CCT TCC ATC ATA AGT GAC TCT TCT GCC CTT GAG Pro Ser Asn Ser Tyr Pro Ser Ile Ile Ser Asp Ser Ser Ala Leu Glu 1425 1430 1435 1440	4439
20	GAC CTG CGA AAT CCA GAA CAA AGC ACA TCA GAA AAA GCA GTA TTA ACT Asp Leu Arg Asn Pro Glu Gln Ser Thr Ser Glu Lys Ala Val Leu Thr 1445 1450 1455	4487
25	TCA CAG AAA AGT AGT GAA TAC CCT ATA AGC CAG AAT CCA GAA GGC CTT Ser Gln Lys Ser Ser Glu Tyr Pro Ile Ser Gln Asn Pro Glu Gly Leu 1460 1465 1470	4535
30	TCT GCT GAC AAG TTT GAG GTG TCT GCA GAT AGT TCT ACC AGT AAA AAT Ser Ala Asp Lys Phe Glu Val Ser Ala Asp Ser Ser Thr Ser Lys Asn 1475 1480 1485	4583
35	AAA GAA CCA GGA GTG GAA AGG TCA TCC CCT TCT AAA TGC CCA TCA TTA Lys Glu Pro Gly Val Glu Arg Ser Ser Pro Ser Lys Cys Pro Ser Leu 1490 1495 1500	4631
40	GAT GAT AGG TGG TAC ATG CAC AGT TGC TCT GGG AGT CTT CAG AAT AGA Asp Asp Arg Trp Tyr Met His Ser Cys Ser Gly Ser Leu Gln Asn Arg 1505 1510 1515 1520	4679
45	AAC TAC CCA TCT CAA GAG GAG CTC ATT AAG GTT GTT GAT GTG GAG GAG Asn Tyr Pro Ser Gln Glu Glu Leu Ile Lys Val Val Asp Val Glu Glu 1525 1530 1535	4727
50	CAA CAG CTG GAA GAG TCT GGG CCA CAC GAT TTG ACG GAA ACA TCT TAC Gln Gln Leu Glu Glu Ser Gly Pro His Asp Leu Thr Glu Thr Ser Tyr 1540 1545 1550	4775
55	TTG CCA AGG CAA GAT CTA GAG GGA ACC CCT TAC CTG GAA TCT GGA ATC Leu Pro Arg Gln Asp Leu Glu Gly Thr Pro Tyr Leu Glu Ser Gly Ile 1555 1560 1565	4823
60	AGC CTC TTC TCT GAT GAC CCT GAA TCT GAT CCT TCT GAA GAC AGA GCC Ser Leu Phe Ser Asp Asp Pro Glu Ser Asp Pro Ser Glu Asp Arg Ala 1570 1575 1580	4871
65	CCA GAG TCA GCT CGT GTT GGC AAC ATA CCA TCT TCA ACC TCT GCA TTG Pro Glu Ser Ala Arg Val Gly Asn Ile Pro Ser Ser Thr Ser Ala Leu 1585 1590 1595 1600	4919
70	AAA GTT CCC CAA TTG AAA GTT GCA GAA TCT GCC CAG AGT CCA GCT GCT Lys Val Pro Gln Leu Lys Val Ala Glu Ser Ala Gln Ser Pro Ala Ala 1605 1610 1615	4967

	GCT CAT ACT ACT GAT ACT GCT GGG TAT AAT GCA ATG GAA GAA AGT GTG Ala His Thr Thr Asp Thr Ala Gly Tyr Asn Ala Met Glu Glu Ser Val 1620 1625 1630	5015
5	AGC AGG GAG AAG CCA GAA TTG ACA GCT TCA ACA GAA AGG GTC AAC AAA Ser Arg Glu Lys Pro Glu Leu Thr Ala Ser Thr Glu Arg Val Asn Lys 1635 1640 1645	5063
10	AGA ATG TCC ATG GTG GTG TCT GGC CTG ACC CCA GAA GAA TTT ATG CTC Arg Met Ser Met Val Val Ser Gly Leu Thr Pro Glu Glu Phe Met Leu 1650 1655 1660	5111
15	GTG TAC AAG TTT GCC AGA AAA CAC CAC ATC ACT TTA ACT AAT CTA ATT Val Tyr Lys Phe Ala Arg Lys His His Ile Thr Leu Thr Asn Leu Ile 1665 1670 1675 1680	5159
20	ACT GAA GAG ACT ACT CAT GTT GTT ATG AAA ACA GAT GCT GAG TTT GTG Thr Glu Glu Thr Thr His Val Val Met Lys Thr Asp Ala Glu Phe Val 1685 1690 1695	5207
25	TGT GAA CGG ACA CTG AAA TAT TTT CTA GGA ATT GCG GGA GGA AAA TGG Cys Glu Arg Thr Leu Lys Tyr Phe Leu Gly Ile Ala Gly Gly Lys Trp 1700 1705 1710	5255
30	GTA GTT AGC TAT TTC TGG GTG ACC CAG TCT ATT AAA GAA AGA AAA ATG Val Val Ser Tyr Phe Trp Val Thr Gln Ser Ile Lys Glu Arg Lys Met 1715 1720 1725	5303
35	CTG AAT GAG CAT GAT TTT GAA GTC AGA GGA GAT GTG GTC AAT GGA AGA Leu Asn Glu His Asp Phe Glu Val Arg Gly Asp Val Val Asn Gly Arg 1730 1735 1740	5351
40	AAC CAC CAA GGT CCA AAG CGA GCA AGA GAA TCC CAG GAC AGA AAG ATC Asn His Gln Gly Pro Lys Arg Ala Arg Glu Ser Gln Asp Arg Lys Ile 1745 1750 1755 1760	5399
45	TTC AGG GGG CTA GAA ATC TGT TGC TAT GGG CCC TTC ACC AAC ATG CCC Phe Arg Gly Leu Glu Ile Cys Cys Tyr Gly Pro Phe Thr Asn Met Pro 1765 1770 1775	5447
50	ACA GAT CAA CTG GAA TGG ATG GTA CAG CTG TGT GGT GCT TCT GTG GTG Thr Asp Gln Leu Glu Trp Met Val Gln Leu Cys Gly Ala Ser Val Val 1780 1785 1790	5495
55	AAG GAG CTT TCA TCA TTC ACC CTT GGC ACA GGT GTC CAC CCA ATT GTG Lys Glu Leu Ser Ser Phe Thr Leu Gly Thr Gly Val His Pro Ile Val 1795 1800 1805	5543
60	GTT GTG CAG CCA GAT GCC TGG ACA GAG GAC AAT GGC TTC CAT GCA ATT Val Val Gln Pro Asp Ala Trp Thr Glu Asp Asn Gly Phe His Ala Ile 1810 1815 1820	5591
65	GGG CAG ATG TGT GAG GCA CCT GTG GTG ACC CGA GAG TGG GTG TTG GAC Gly Gln Met Cys Glu Ala Pro Val Val Thr Arg Glu Trp Val Leu Asp 1825 1830 1835 1840	5639

AGT GTA GCA CTC TAC CAG TGC CAG GAG CTG GAC ACC TAC CTG ATA CCC 5687  
Ser Val Ala Leu Tyr Gln Cys Gln Glu Leu Asp Thr Tyr Leu Ile Pro  
1845 1850 1855

5 CAG ATC CCC CAC AGC CAC TAC TGA CTGCAGCCAG CCACAGGTAC AGAGCCACAG 5741  
Gln Ile Pro His Ser His Tyr \*  
1860

GACCCAAGA ATGAGCTTAC AAAGTGGCCT TTCCAGGCC TGGGAGCTCC TCTCACTCTT 5801

CAGTCCTTCT ACTGTCCTGG CTACTAAATA TTTTATGTAC ATCAGCCTGA AAAGGACTTC 5861

TGGCTATGCA AGGGTCCCTT AAAGATTTTC TGCTTGAAGT CTCCCTTGGA AAT 5914

15

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 1864 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (11) MOLECULE TYPEF protein

## 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Leu Ser Ala Leu Arg Val Glu Glu Val Gln Asn Val Ile Asn  
1 5 10 15

30

Ala Met Gln Lys Ile Leu Glu Cys Pro Ile Cys Leu Glu Leu Ile Lys  
20 25 30

35

Glu Pro Val Ser Thr Lys Cys Asp His Ile Phe Cys Lys Phe Cys Met  
35 40 45

Leu Lys Leu Leu Asn Gln Lys Lys Gly Pro Ser Gln Cys Pro Leu Cys  
50 55 60

40

Lys Asn Asp Ile Thr Lys Arg Ser Leu Gln Glu Ser Thr Arg Phe Ser  
65 70 75 80

Gln Leu Val Glu Glu Leu Leu Lys Ile Ile Cys Ala Phe Gln Leu Asp  
85 90 95

45

Thr Gly Leu Glu Tyr Ala Asn Ser Tyr Asn Phe Ala Lys Lys Glu Asn  
100 105 110

5

Asn Ser Pro Glu His Leu Lys Asp Glu Val Ser Ile Ile Gln Ser Met  
115 120 125

Gly Tyr Arg Asn Arg Ala Lys Arg Leu Leu Gln Ser Glu Pro Glu Asn  
130 135 140

5

Pro	Ser	Leu	Gln	Glu	Thr	Ser	Leu	Ser	Val	Gln	Leu	Ser	Asn	Leu	Gly
145					150					155					160

## EP 0 705 903 A1

	Thr Val Arg Thr Leu Arg Thr Lys Gln Arg Ile Gln Pro Gln Lys Thr	165	170	175
5	Ser Val Tyr Ile Glu Leu Gly Ser Asp Ser Ser Glu Asp Thr Val Asn	180	185	190
	Lys Ala Thr Tyr Cys Ser Val Gly Asp Gln Glu Leu Leu Gln Ile Thr	195	200	205
10	Pro Gln Gly Thr Arg Asp Glu Ile Ser Leu Asp Ser Ala Lys Lys Ala	210	215	220
	Ala Cys Glu Phe Ser Glu Thr Asp Val Thr Asn Thr Glu His His Gln	225	230	235
15	Pro Ser Asn Asn Asp Leu Asn Thr Thr Glu Lys Arg Ala Ala Glu Arg	245	250	255
	His Pro Glu Lys Tyr Gln Gly Ser Ser Val Ser Asn Leu His Val Glu	260	265	270
20	Pro Cys Gly Thr Asn Thr His Ala Ser Ser Leu Gln His Glu Asn Ser	275	280	285
	Ser Leu Leu Leu Thr Lys Asp Arg Met Asn Val Glu Lys Ala Glu Phe	290	295	300
25	Cys Asn Lys Ser Lys Gln Pro Gly Leu Ala Arg Ser Gln His Asn Arg	305	310	315
30	Trp Ala Gly Ser Lys Glu Thr Cys Asn Asp Arg Arg Thr Pro Ser Thr	325	330	335
	Glu Lys Lys Val Asp Leu Asn Ala Asp Pro Leu Cys Glu Arg Lys Glu	340	345	350
35	Trp Asn Lys Gln Lys Leu Pro Cys Ser Glu Asn Pro Arg Asp Thr Glu	355	360	365
	Asp Val Pro Trp Ile Thr Leu Asn Ser Ser Ile Gln Lys Val Asn Glu	370	375	380
40	Trp Phe Ser Arg Ser Asp Glu Leu Leu Gly Ser Asp Asp Ser His Asp	385	390	395
45	Gly Glu Ser Glu Ser Asn Ala Lys Val Ala Asp Val Leu Asp Val Leu	405	410	415
	Asn Glu Val Asp Glu Tyr Ser Gly Ser Ser Glu Lys Ile Asp Leu Leu	420	425	430
50	Ala Ser Asp Pro His Glu Ala Leu Ile Cys Lys Ser Glu Arg Val His	435	440	445
	Ser Lys Ser Val Glu Ser Asn Ile Glu Asp Lys Ile Phe Gly Lys Thr	450	455	460

EP 0 705 903 A1

	Tyr	Arg	Lys	Lys	Ala	Ser	Leu	Pro	Asn	Leu	Ser	His	Val	Thr	Glu	Asn	465	470	475	480
5	Leu	Ile	Ile	Gly	Ala	Phe	Val	Thr	Glu	Pro	Gln	Ile	Ile	Gln	Glu	Arg	485	490	495	
10	Pro	Leu	Thr	Asn	Lys	Leu	Lys	Arg	Lys	Arg	Arg	Pro	Thr	Ser	Gly	Leu	500	505	510	
	His	Pro	Glu	Asp	Phe	Ile	Lys	Lys	Ala	Asp	Leu	Ala	Val	Gln	Lys	Thr	515	520	525	
15	Pro	Glu	Met	Ile	Asn	Gln	Gly	Thr	Asn	Gln	Thr	Glu	Gln	Asn	Gly	Gln	530	535	540	
	Val	Met	Asn	Ile	Thr	Asn	Ser	Gly	His	Glu	Asn	Lys	Thr	Lys	Gly	Asp	545	550	555	560
20	Ser	Ile	Gln	Asn	Glu	Lys	Asn	Pro	Asn	Pro	Ile	Glu	Ser	Leu	Glu	Lys	565	570	575	
25	Glu	Ser	Ala	Phe	Lys	Thr	Lys	Ala	Glu	Pro	Ile	Ser	Ser	Ser	Ile	Ser	580	585	590	
	Asn	Met	Glu	Leu	Glu	Leu	Asn	Ile	His	Asn	Ser	Lys	Ala	Pro	Lys	Lys	595	600	605	
30	Asn	Arg	Leu	Arg	Arg	Lys	Ser	Ser	Thr	Arg	His	Ile	His	Ala	Leu	Glu	610	615	620	
	Leu	Val	Val	Ser	Arg	Asn	Leu	Ser	Pro	Pro	Asn	Cys	Thr	Glu	Leu	Gln	625	630	635	640
35	Ile	Asp	Ser	Cys	Ser	Ser	Ser	Glu	Glu	Ile	Lys	Lys	Lys	Lys	Tyr	Asn	645	650	655	
	Gln	Met	Pro	Val	Arg	His	Ser	Arg	Asn	Leu	Gln	Leu	Met	Glu	Gly	Lys	660	665	670	
40	Glu	Pro	Ala	Thr	Gly	Ala	Lys	Lys	Ser	Asn	Lys	Pro	Asn	Glu	Gln	Thr	675	680	685	
45	Ser	Lys	Arg	His	Asp	Ser	Asp	Thr	Phe	Pro	Glu	Leu	Lys	Leu	Thr	Asn	690	695	700	
	Ala	Pro	Gly	Ser	Phe	Thr	Lys	Cys	Ser	Asn	Thr	Ser	Glu	Leu	Lys	Glu	705	710	715	720
50	Phe	Val	Asn	Pro	Ser	Leu	Pro	Arg	Glu	Glu	Lys	Glu	Glu	Lys	Leu	Glu	725	730	735	
	Thr	Val	Lys	Val	Ser	Asn	Asn	Ala	Glu	Asp	Pro	Lys	Asp	Leu	Met	Leu	740	745	750	
55	Ser	Gly	Glu	Arg	Val	Leu	Gln	Thr	Glu	Arg	Ser	Val	Glu	Ser	Ser	Ser	755	760	765	

EP 0 705 903 A1

	Ile	Ser	Leu	Val	Pro	Gly	Thr	Asp	Tyr	Gly	Thr	Gln	Glu	Ser	Ile	Ser	770	775	780
5	Leu	Leu	Glu	Val	Ser	Thr	Leu	Gly	Lys	Ala	Lys	Thr	Glu	Pro	Asn	Lys	785	790	795 800
	Cys	Val	Ser	Gln	Cys	Ala	Ala	Phe	Glu	Asn	Pro	Lys	Gly	Leu	Ile	His	805	810	815
10	Gly	Cys	Ser	Lys	Asp	Asn	Arg	Asn	Asp	Thr	Glu	Gly	Phe	Lys	Tyr	Pro	820	825	830
	Leu	Gly	His	Glu	Val	Asn	His	Ser	Arg	Glu	Thr	Ser	Ile	Glu	Met	Glu	835	840	845
15	Glu	Ser	Glu	Leu	Asp	Ala	Gln	Tyr	Leu	Gln	Asn	Thr	Phe	Lys	Val	Ser	850	855	860
	Lys	Arg	Gln	Ser	Phe	Ala	Pro	Phe	Ser	Asn	Pro	Gly	Asn	Ala	Glu	Glu	865	870	875 880
20	Glu	Cys	Ala	Thr	Phe	Ser	Ala	His	Ser	Gly	Ser	Leu	Lys	Lys	Gln	Ser	885	890	895
	Pro	Lys	Val	Thr	Phe	Glu	Cys	Glu	Gln	Lys	Glu	Glu	Asn	Gln	Gly	Lys	900	905	910
25	Asn	Glu	Ser	Asn	Ile	Lys	Pro	Val	Gln	Thr	Val	Asn	Ile	Thr	Ala	Gly	915	920	925
30	Phe	Pro	Val	Val	Gly	Gln	Lys	Asp	Lys	Pro	Val	Asp	Asn	Ala	Lys	Cys	930	935	940
	Ser	Ile	Lys	Gly	Gly	Ser	Arg	Phe	Cys	Leu	Ser	Ser	Gln	Phe	Arg	Gly	945	950	955 960
35	Asn	Glu	Thr	Gly	Leu	Ile	Thr	Pro	Asn	Lys	His	Gly	Leu	Leu	Gln	Asn	965	970	975
	Pro	Tyr	Arg	Ile	Pro	Pro	Leu	Phe	Pro	Ile	Lys	Ser	Phe	Val	Lys	Thr	980	985	990
40	Lys	Cys	Lys	Lys	Asn	Leu	Leu	Glu	Glu	Asn	Phe	Glu	Glu	His	Ser	Met	995	1000	1005
	Ser	Pro	Glu	Arg	Glu	Met	Gly	Asn	Glu	Asn	Ile	Pro	Ser	Thr	Val	Ser	1010	1015	1020
45	Thr	Ile	Ser	Arg	Asn	Asn	Ile	Arg	Glu	Asn	Val	Phe	Lys	Glu	Ala	Ser	1025	1030	1035 1040
50	Ser	Ser	Asn	Ile	Asn	Glu	Val	Gly	Ser	Ser	Thr	Asn	Glu	Val	Gly	Ser	1045	1050	1055
	Ser	Ile	Asn	Glu	Ile	Gly	Ser	Ser	Asp	Glu	Asn	Ile	Gln	Ala	Glu	Leu	1060	1065	1070
55																			

EP 0 705 903 A1

	Gly Arg Asn Arg Gly Pro Lys Leu Asn Ala Met Leu Arg Leu Gly Val	
	1075	1080 1085
5	Leu Gln Pro Glu Val Tyr Lys Gln Ser Leu Pro Gly Ser Asn Cys Lys	
	1090	1095 1100
	His Pro Glu Ile Lys Lys Gln Glu Tyr Glu Glu Val Val Gln Thr Val	
	1105	1110 1115 1120
10	Asn Thr Asp Phe Ser Pro Tyr Leu Ile Ser Asp Asn Leu Glu Gln Pro	
	1125	1130 1135
	Met Gly Ser Ser His Ala Ser Gln Val Cys Ser Glu Thr Pro Asp Asp	
15	1140	1145 1150
	Leu Leu Asp Asp Gly Glu Ile Lys Glu Asp Thr Ser Phe Ala Glu Asn	
	1155	1160 1165
20	Asp Ile Lys Glu Ser Ser Ala Val Phe Ser Lys Ser Val Gln Lys Gly	
	1170	1175 1180
	Glu Leu Ser Arg Ser Pro Ser Pro Phe Thr His Thr His Leu Ala Gln	
	1185	1190 1195 1200
25	Gly Tyr Arg Arg Gly Ala Lys Lys Leu Glu Ser Ser Glu Glu Asn Leu	
	1205	1210 1215
	Ser Ser Glu Asp Glu Glu Leu Pro Cys Phe Gln His Leu Leu Phe Gly	
30	1220	1225 1230
	Lys Val Asn Asn Ile Pro Ser Gln Ser Thr Arg His Ser Thr Val Ala	
	1235	1240 1245
	Thr Glu Cys Leu Ser Lys Asn Thr Glu Glu Asn Leu Leu Ser Leu Lys	
35	1250	1255 1260
	Asn Ser Leu Asn Asp Cys Ser Asn Gln Val Ile Leu Ala Lys Ala Ser	
	1265	1270 1275 1280
40	Gln Glu His His Leu Ser Glu Glu Thr Lys Cys Ser Ala Ser Leu Phe	
	1285	1290 1295
	Ser Ser Gln Cys Ser Glu Leu Glu Asp Leu Thr Ala Asn Thr Asn Thr	
45	1300	1305 1310
	Gln Asp Pro Phe Leu Ile Gly Ser Ser Lys Gln Met Arg His Gln Ser	
	1315	1320 1325
	Glu Ser Gln Gly Val Gly Leu Ser Asp Lys Glu Leu Val Ser Asp Asp	
50	1330	1335 1340
	Glu Glu Arg Gly Thr Gly Leu Glu Glu Asn Asn Gln Glu Glu Gln Ser	
	1345	1350 1355 1360
55	Met Asp Ser Asn Leu Gly Glu Ala Ala Ser Gly Cys Glu Ser Glu Thr	
	1365	1370 1375

EP 0 705 903 A1

	Ser Val Ser Glu Asp Cys Ser Gly Leu Ser Ser Gln Ser Asp Ile Leu	
	1380	1385 1390
5	Thr Thr Gln Gln Arg Asp Thr Met Gln His Asn Leu Ile Lys Leu Gln	
	1395	1400 1405
	Gln Glu Met Ala Glu Leu Glu Ala Val Leu Glu Gln His Gly Ser Gln	
	1410	1415 1420
10	Pro Ser Asn Ser Tyr Pro Ser Ile Ile Ser Asp Ser Ser Ala Leu Glu	
	1425	1430 1435 1440
	Asp Leu Arg Asn Pro Glu Gln Ser Thr Ser Glu Lys Ala Val Leu Thr	
15		1445 1450 1455
	Ser Gln Lys Ser Ser Glu Tyr Pro Ile Ser Gln Asn Pro Glu Gly Leu	
	1460	1465 1470
20	Ser Ala Asp Lys Phe Glu Val Ser Ala Asp Ser Ser Thr Ser Lys Asn	
	1475	1480 1485
	Lys Glu Pro Gly Val Glu Arg Ser Ser Pro Ser Lys Cys Pro Ser Leu	
	1490	1495 1500
25	Asp Asp Arg Trp Tyr Met His Ser Cys Ser Gly Ser Leu Gln Asn Arg	
	1505	1510 1515 1520
	Asn Tyr Pro Ser Gln Glu Glu Leu Ile Lys Val Val Asp Val Glu Glu	
30		1525 1530 1535
	Gln Gln Leu Glu Glu Ser Gly Pro His Asp Leu Thr Glu Thr Ser Tyr	
	1540	1545 1550
35	Leu Pro Arg Gln Asp Leu Glu Gly Thr Pro Tyr Leu Glu Ser Gly Ile	
	1555	1560 1565
	Ser Leu Phe Ser Asp Asp Pro Glu Ser Asp Pro Ser Glu Asp Arg Ala	
	1570	1575 1580
40	Pro Glu Ser Ala Arg Val Gly Asn Ile Pro Ser Ser Thr Ser Ala Leu	
	1585	1590 1595 1600
	Lys Val Pro Gln Leu Lys Val Ala Glu Ser Ala Gln Ser Pro Ala Ala	
	1605	1610 1615
45	Ala His Thr Thr Asp Thr Ala Gly Tyr Asn Ala Met Glu Glu Ser Val	
	1620	1625 1630
	Ser Arg Glu Lys Pro Glu Leu Thr Ala Ser Thr Glu Arg Val Asn Lys	
50		1635 1640 1645
	Arg Met Ser Met Val Val Ser Gly Leu Thr Pro Glu Glu Phe Met Leu	
	1650	1655 1660
55	Val Tyr Lys Phe Ala Arg Lys His His Ile Thr Leu Thr Asn Leu Ile	
	1665	1670 1675 1680

EP 0 705 903 A1

Thr Glu Glu Thr Thr His Val Val Met Lys Thr Asp Ala Glu Phe Val  
1685 1690 1695

Cys Glu Arg Thr Leu Lys Tyr Phe Leu Gly Ile Ala Gly Gly Lys Trp  
1700 1705 1710

Val Val Ser Tyr Phe Trp Val Thr Gln Ser Ile Lys Glu Arg Lys Met  
1715 1720 1725

Leu Asn Glu His Asp Phe Glu Val Arg Gly Asp Val Val Asn Gly Arg  
1730 1735 1740

Asn His Gln Gly Pro Lys Arg Ala Arg Glu Ser Gln Asp Arg Lys Ile  
1745 1750 1755 1760

Phe Arg Gly Leu Glu Ile Cys Cys Tyr Gly Pro Phe Thr Asn Met Pro  
1765 1770 1775

Thr Asp Gln Leu Glu Trp Met Val Gln Leu Cys Gly Ala Ser Val Val  
1780 1785 1790

Lys Glu Leu Ser Ser Phe Thr Leu Gly Thr Gly Val His Pro Ile Val  
1795 1800 1805

Val Val Gln Pro Asp Ala Trp Thr Glu Asp Asn Gly Phe His Ala Ile  
1810 1815 1820

Gly Gln Met Cys Glu Ala Pro Val Val Thr Arg Glu Trp Val Leu Asp  
1825 1830 1835 1840

Ser Val Ala Leu Tyr Gln Cys Gln Glu Leu Asp Thr Tyr Leu Ile Pro  
1845 1850 1855

Gln Ile Pro His Ser His Tyr \*  
1860

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: s754 A

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTAGCCTGGG CAACAAACGA

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: s754 B

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCAGGAAGCA GGAATGGAAC

20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: s975 A

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TAGGAGATGG ATTATTGGTG

20

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: s975 B

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGCAACTTT GCAATGAGTG

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 22 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: tdj1474 A

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CAGAGTGAGA CCTTGTCTCA AA

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: tdj1474 B

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTCTGCAAAC ACCTTAAACT CAG

23

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: tdj1239 A

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AACCTGGAAG GCAGAGGTTG

20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:  
(B) CLONE: tdj1239 B

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

10

TCTGTACCTG CTAAGCAGTG G

21

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 111 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

25

- (A) ORGANISM: Homo sapiens

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..111

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

G GKC TTA CTC TGT TGT CCC AGC TGG AGT ACA GWG TGC GAT CAT GAG  
Xaa Leu Leu Cys Cys Pro Ser Trp Ser Thr Xaa Cys Asp His Glu  
1865 1870 1875

46

35

GCT TAC TGT TGC TTG ACT CCT AGG CTC AAG CGA TCC TAT CAC CTC AGT  
Ala Tyr Cys Cys Leu Thr Pro Arg Leu Lys Arg Ser Tyr His Leu Ser  
1880 1885 1890 1895

94

40

CTC CAA GTA GCT GGA CT  
Leu Gln Val Ala Gly  
1900

111

45

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 36 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

55

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Xaa Leu Leu Cys Cys Pro Ser Trp Ser Thr Xaa Cys Asp His Glu Ala  
 1 5 10 15  
 Tyr Cys Cys Leu Thr Pro Arg Leu Lys Arg Ser Tyr His Leu Ser Leu  
 20 25 30  
 Gln Val Ala Gly  
 35

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1534 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAGGCTAGAG GGCAGGCACT TTATGGCAAA CTCAGGTAGA ATTCTTCCTC TTCCGTCTCT 60  
 TTCCTTTTAC GTCATCGGGG AGACTGGGTG GCAATCGCAG CCCGAGAGAC GCATGGCTCT 120  
 TTCTGCCCTC CATCCTCTGA TGTACCTTGA TTTCGTATTC TGAGAGGCTG CTGCTTAGCG 180  
 GTAGCCCCTT GGTTCCTCGTG GCAACGGAAA AGCGCGGGAA TTACAGATAA ATTAAAACTG 240  
 CGACTGCGCG GCGTGAGCTC GCTGAGACTT CCTGGACCCC GCACCAGGCT GTGGGGTTTC 300  
 TCAGATAACT GGGCCCCTGC GCTCAGGAGG CCTTCACCTT CTGCTCTGGG TAAAGGTAGT 360  
 AGAGTCCCGG GAAAGGGACA GGGGGCCCAA GTGATGCTCT GGGGTACTGG CGTGGGAGAG 420  
 TGGATTTCCG AAGCTGACAG ATGGGTATTC TTTGACGGGG GGTAGGGGCG GAACCTGAGA 480  
 GGCCTAAGGC GTTGTGAACC CTGGGGAGGG GGGCAGTTTG TAGGTCGCGA GGAAGCGCT 540  
 GAGGATCAGG AAGGGGGCAC TGAGTGTCG TGGGGGAATC CTCGTGATAG GAACTGGAAT 600  
 ATGCCTTGAG GGGGACACTA TGTCTTTAAA AACGTCGGCT GGTCATGAGG TCAGGAGTTC 660  
 CAGACCAGCC TGACCAACGT GGTGAAACTC CGTCTCTACT AAAAATACNA AAATTAGCCG 720

EP 0 705 903 A1

	GGCGTGGTGC CGCTCCAGCT ACTCAGGAGG CTGAGGCAGG AGAATCGCTA GAACCCGGGA	780
5	GGCGGAGGTT GCAGTGAGCC GAGATCGCGC CATTGCACTC CAGCCTGGGC GACAGAGCGA	840
	GACTGTCTCA AAACAAAACA AAACAAAACA AAACAAAAA CACCGGCTGG TATGTATGAG	900
	AGGATGGGAC CTTGTGGAAG AAGAGGTGCC AGGAATATGT CTGGGAAGGG GAGGAGACAG	960
10	GATTTTGTGG GAGGGAGAAC TTAAGAACTG GATCCATTG CGCCATTGAG AAAGCGCAAG	1020
	AGGGAAGTAG AGGAGCGTCA GTAGTAACAG ATGCTGCCGG CAGGGATGTG CTTGAGGAGG	1080
15	ATCCAGAGAT GAGAGCAGGT CACTGGGAAA GGTTAGGGGC GGGGAGGCCT TGATTGGTGT	1140
	TGGTTTGGTC GTTGTGATT TTGGTTTTAT GCAAGAAAA GAAAACAACC AGAAACATTG	1200
	GAGAAAGCTA AGGCTACCAC CACCTACCCG GTCAGTCACT CCTCTGTAGC TTTCTCTTTC	1260
20	TTGGAGAAAG GAAAAGACCC AAGGGGTTGG CAGCGATATG TGAAAAAATT CAGAATTTAT	1320
	GTTGTCTAAT TACAAAAAGC AACTTCTAGA ATCTTTAAAA ATAAAGGACG TTGTCATTAG	1380
	TTCTTCTGGT TTGTATTATT CTAAACCTT CCAAATCTTC AAATTTACTT TATTTTAAAA	1440
25	TGATAAAATG AAGTTGTCAT TTTATAAACC TTTTAAAAAG ATATATATAT ATGTTTTTCT	1500
	AATGTGTAA AGTTCATTGG AACAGAAAGA AATG	1534

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1924 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

50	GAGGCTAGAG GGCAGGCACT TTATGGCAAA CTCAGGTAGA ATTCTTCCTC TTCCGTCTCT	60
	TTCTTTTAC GTCATCGGGG AGACTGGGTG GCAATCGCAG CCCGAGAGAC GCATGGCTCT	120
	TTCTGCCCTC CATCCTCTGA TGTACCTTGA TTTCGTATTC TGAGAGGCTG CTGCTTAGCG	180
55	GTAGCCCCTT GGTTTCCGTG GCAACGGAAA AGCGCGGGAA TTACAGATAA ATTAAACTG	240

## EP 0 705 903 A1

	CGACTGCGCG	GCGTGAGCTC	GCTGAGACTT	CCTGGACCCC	GCACCAGGCT	GTGGGGTTTC	300
5	TCAGATAACT	GGGCCCCCTGC	GCTCAGGAGG	CCTTCACCCT	CTGCTCTGGG	TAAAGGTAGT	360
	AGAGTCCCGG	GAAAGGGACA	GGGGGCCCAA	GTGATGCTCT	GGGGTACTGG	CGTGGGAGAG	420
	TGGATTTCCG	AAGCTGACAG	ATGGGTATTTC	TTTGACGGGG	GGTAGGGGCG	GAACCTGAGA	480
10	GGCGTAAGGC	GTTGTGAACC	CTGGGGAGGG	GGGCAGTTTG	TAGGTCGCGA	GGGAAGCGCT	540
	GAGGATCAGG	AAGGGGGCAC	TGAGTGTCCG	TGGGGGAATC	CTCGTGATAG	GAACTGGAAT	600
15	ATGCCTTGAG	GGGGACACTA	TGTCTTTAAA	AACGTCGGCT	GGTCATGAGG	TCAGGAGTTC	660
	CAGACCAGCC	TGACCAACGT	GGTGAAACTC	CGTCTCTACT	AAAAATACNA	AAATTAGCCG	720
	GGCGTGGTGC	CGCTCCAGCT	ACTCAGGAGG	CTGAGGCAGG	AGAATCGCTA	GAACCCGGGA	780
20	GGCGGAGGTT	GCAGTGAGCC	GAGATCGCGC	CATTGCACTC	CAGCCTGGGC	GACAGAGCGA	840
	GACTGTCTCA	AAACAAAACA	AAACAAAACA	AAACAAAAAA	CACCGGCTGG	TATGTATGAG	900
	AGGATGGGAC	CTTGTGGAAG	AAGAGGTGCC	AGGAATATGT	CTGGGAAGGG	GAGGAGACAG	960
25	GATTTTGTGG	GAGGGAGAAC	TTAAGAACTG	GATCCATTTC	CGCCATTGAG	AAAGCGCAAG	1020
	AGGGAAGTAG	AGGAGCGTCA	GTAAGTAACAG	ATGCTGCCCG	CAGGGATGTG	CTTGAGGAGG	1080
30	ATCCAGAGAT	GAGAGCAGGT	CACTGGGAAA	GGTTAGGGGC	GGGGAGGCCT	TGATTGGTGT	1140
	TGGTTTGGTC	GTTGTTGATT	TTGGTTTTAT	GCAAGAAAAA	GAAAACAACC	AGAAACATTG	1200
	GAGAAAGCTA	AGGCTACCAC	CACCTACCCG	GTCAGTCACT	CCTCTGTAGC	TTTCTCTTTC	1260
35	TTGGAGAAAG	GAAAAGACCC	AAGGGGTTGG	CAGCGATATG	TGAAAAAATT	CAGAATTTAT	1320
	GTTGTCTAAT	TACAAAAAGC	AACTTCTAGA	ATCTTTAAAA	ATAAAGGACG	TTGTCAATTAG	1380
40	TTCTTCTGGT	TTGTATTATT	CTAAAACCTT	CCAAATCTTC	AAATTTACTT	TATTTTAAAA	1440
	TGATAAAATG	AAGTTGTCAT	TTTATAAACC	TTTTAAAAAG	ATATATATAT	ATGTTTTTCT	1500
	AATGTGTTAA	AGTTCATTGG	AACAGAAAGA	AATGGATTTA	TCTGCTCTTC	GCGTTGAAGA	1560
45	AGTACAAAAT	GTCATTAATG	CTATGCAGAA	AATCTTAGAG	TGTCCCATCT	GGTAAGTCAG	1620
	CACAAGAGTG	TATTAATTTG	GGATTCCCTAT	GATTATCTCC	TATGCAAATG	AACAGAATTG	1680
50	ACCTTACATA	CTAGGGAAGA	AAAGACATGT	CTAGTAAGAT	TAGGCTATTG	TAATTGCTGA	1740
	TTTTCTTAAC	TGAAGAACTT	TAAAAATATA	GAAAATGATT	CCTTGTTCTC	CATCCACTCT	1800
	GCCTCTCCCA	CTCCTCTCCT	TTTCAACACA	ATCCTGTGGT	CCGGGAAGA	CAGGGCTCTG	1860
55	TCTTGATTGG	TTCTGCACTG	GGCAGGATCT	GTTAGATACT	GCATTTGCTT	TCTCCAGCTC	1920

TAAA

1924

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 631 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

25	AAATGCTGAT GATAGTATAG AGTATTGAAG GGATCAATAT AATTCTGTTT TGATATCTGA	60
	AAGCTCACTG AAGGTAAGGA TCGTATTCTC TGCTGTATTC TCAGTTCCTG ACACAGCAGA	120
	CATTTAATAA ATATTGAACG AACTTGAGGC CTTATGTTGA CTCAGTCATA ACAGCTCAAA	180
30	GTTGAACTTA TTCACTAAGA ATAGCTTTAT TTTTAAATAA ATTATTGAGC CTCATTTTATT	240
	TTCTTTTTTCT CCCCCCCTA CCCTGCTAGT CTGGAGTTGA TCAAGGAACC TGTCTCCACA	300
35	AAGTGTGACC ACATATTTTG CAAGTAAGTT TGAATGTGTT ATGTGGCTCC ATTATTAGCT	360
	TTTGTTTTTIG TCCTTCATAA CCCAGGAAAC ACCTAACTTT ATAGAAGCTT TACTTTCTTC	420
	AATTAAGTGA GAACGAAAAT CCAACTCCAT TTCATTCTTT CTCAGAGAGT ATATAGTTAT	480
40	CAAAAGTTGG TTGTAATCAT AGTTCCTGGT AAAGTTTTGA CATATATTAT CTTTTTTTTT	540
	TTTTGAGACA AGTCTCGCTC TGTCGCCCAG GCTGGAGTGC AGTGGCATGA GGCTTGCTCA	600
45	CTGCACCTCC GCCCCCGAGT TCAGCGACTC T	631

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 481 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGAGATCTAG	ACCACATGGT	CAAAGAGATA	GAATGTGAGC	AATAAATGAA	CCTTAAATTT	60
TTCAACAGCT	ACTTTTTTTT	TTTTTTTTTG	AGACAGGGKC	TTACTCTGTT	GTCCCAGCTG	120
GAGTACAGWG	TGCGATCATG	AGGCTTACTG	TTGCTTGACT	CCTAGGCTCA	AGCGATCCTA	180
TCACCTCAGT	CTCCAAGTAG	CTGGACTGTA	AGTGCACACC	ACCATATCCA	GCTAAATTTT	240
GTGTTTTCTG	TAGAGACGGG	GTTTCGCCAT	GTTTCCCAGG	CTGGTCTTGA	ACTTTGGGCT	300
TAACCCGTCT	GCCCACCTAG	GCATCCCCAA	GTGCTAGGAT	TACAGGTGTG	AGTCATCATG	360
CCTGGCCAGT	ATTTTAGTTA	GCTCTGTCTT	TTCAAGTCAT	ATACAAGTTC	ATTTTCTTTT	420
AAGTTTAGTT	AACAACCTTA	TATCATGTAT	TCTTTTCTAG	CATAAAGAAA	GATTCGAGGC	480
C						481

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 522 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGTGATCATA	ACAGTAAGCC	ATATGCATGT	AAGTTCAGTT	TTCATAGATC	ATTGCTTATG	60
TAGTTTtaggt	TTTTGCTTAT	GCAGCATCCA	AAAACAATTA	GGAAACTATT	GCTTGTAATT	120
CACCTGCCAT	TACTTTTTTAA	ATGGCTCTTA	AGGGCAGTTG	TGAGATTATC	TTTTCATGGC	180

EP 0 705 903 A1

TATTTGCCTT TTGAGTATTC TTTCTACAAA AGGAAGTAAA TTAAATTGTT CTTTCTTTCT 240  
 TTATAATTTA TAGATTTTGC ATGCTGAAAC TTCTCAACCA GAAGAAAGGG CCTTCACAGT 300  
 5 GTCCTTTATG TAAGAATGAT ATAACCAAAA GGTATATAAT TTGGTAATGA TGCTAGGTTG 360  
 GAAGCAACCA CAGTAGGAAA AAGTAGAAAT TATTTAATAA CATAGCGTTC CTATAAAACC 420  
 10 ATTCATCAGA AAAATTTATA AAAGAGTTTT TAGCACACAG TAAATTATTT CCAAAGTTAT 480  
 TTTCTGAAA GTTTTATGGG CATCTGCCTT ATACAGGTAT TG 522

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 465 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHEICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGTAGGCTTA AATGAATGAC AAAAAGTTAC TAAATCACTG CCATCACACG GTTTATACAG 60  
 35 ATGTCAATGA TGTATTGATT ATAGAGGTTT TCTACTGTTG CTGCATCTTA TTTTATTTG 120  
 TTTACATGTC TTTTCTTATT TTAGTGCTCT TAAAAGGTTG ATAATCACTT GCTGAGTGTG 180  
 40 TTTCTCAAAC AATTTAATTT CAGGAGCCTA CAAGAAAGTA CGAGATTTAG TCAACTTGTT 240  
 GAAGAGCTAT TGAAAATCAT TTGTGCTTTT CAGCTTGACA CAGGTTTGGA GTGTAAGTGT 300  
 TGAATATCCC AAGAATGACA CTCAGTGCT GTCCATGAAA ACTCAGGAAG TTTGCACAAT 360  
 45 TACTTTCTAT GACGTGGTGA TAAGACCTTT TAGTCTAGGT TAATTTTAGT TCTGTATCTG 420  
 TAATCTATTT TAAAAAATTA CTCCCACTGG TCTCACACCT TATTT 465

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 513 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAAAAATCAC	AGGTAACCTT	AATGCATTGT	CTTAACACAA	CAAAGAGCAT	ACATAGGGTT	60
TCTCTTGGTT	TCTTTGATTA	TAATTCATAC	ATTTTCTCT	AACTGCAAAC	ATAATGTTTT	120
CCCTTGTATT	TTACAGATGC	AAACAGCTAT	AATTTTGCAA	AAAAGGAAAA	TAACTCTCCT	180
GAACATCTAA	AAGATGAAGT	TTCTATCATC	CAAAGTATGG	GCTACAGAAA	CCGTGCCAAA	240
AGACTTCTAC	AGAGTGAACC	CGAAAATCCT	TCCTTGGTAA	AACCATTGT	TTTCTTCTTC	300
TTCTTCTTCT	TCTTTTCTTT	TTTTTTTCTT	TTTTTTTGTG	AGATGGAGTC	TTGCTCTGTG	360
GCCCAGGCTA	GAAGCAGTCC	TCCTGCCTTA	GCCNCCTTAG	TAGCTGGGAT	TACAGGCACG	420
CGCACCATGC	CAGGCTAATT	TTTGTATTTT	TAGTAGAGAC	GGGGTTTCAT	CATGTTGGCC	480
AGGCTGGTCT	CGAACTCCTA	ACCTCAGGTG	ATC			513

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6769 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATGATGGAGA	TCTTAAAAAG	TAATCATTCT	GGGGCTGGGC	GTAGTAGCTT	GCACCTGTAA	60
TCCCAGCACT	TCGGGAGGCT	GAGGCAGGCA	GATAATTTGA	GGTCAGGAGT	TTGAGACCAG	120

EP 0 705 903 A1

	CCTGGCCAAC ATGGTGAAAC CCATCTCTAC TAAAAATACA AAAATTAGCT GGGTGTGGTG	180
5	GCACGTACCT GTAATCCCAG CTACTCGGGA GGCGGAGGCA CAAGAATTGC TTGAACCTAG	240
	GACGCGGAGG TTGCAGCGAG CCAAGATCGC GCCACTGCAC TCCAGCCTGG GCCGTAGAGT	300
10	GAGACTCTGT CTCAAAAAAG AAAAAAAGT AATTGTTCTA GCTGGGCGCA GTGGCTCTTG	360
	CCTGTAATCC CAGCACTTTG GGAGGCCAAG GCGGGTGGAT CTCGAGTCCT AGAGTTCAAG	420
	ACCAGCCTAG GCAATGTGGT GAAACCCCAT CGCTACAAAA AATACAAAAA TTAGCCAGGC	480
15	ATGGTGGCGT GCGCATGTAG TCCCAGCTCC TTGGGAGGCT GAGGTGGGAG GATCACTTGA	540
	ACCCAGGAGA CAGAGGTTGC AGTGAACCGA GATCACGCCA CCACGCTCCA GCCTGGGCAA	600
20	CAGAACAAGA CTCTGTCTAA AAAAATACAA ATAAAATAAA AGTAGTTCTC ACAGTACCAG	660
	CATTCATTTT TCAAAAGATA TAGAGCTAAA AAGGAAGGAA AAAAAAAGTA ATGTTGGGCT	720
	TTTAAATACT CGTTCCTATA CTAAATGTTC TTAGGAGTGC TGGGGTTTTA TTGTCATCAT	780
25	TTATCCTTTT TAAAAATGTT ATTGGCCAGG CACGGTGGCT CATGGCTGTA ATCCCAGCAC	840
	TTTGGGAGGC CGAGGCAGGC AGATCACCTG AGGTCAGGAG TGTGAGACCA GCCTGGCCAA	900
30	CATGGCGAAA CCTGTCTCTA CTAAAAATAC AAAAATTAAC TAGGCGTGGT GGTGTACGCC	960
	TGTAGTCCCA GCTACTCGGG AGGCTGAGGC AGGAGAATCA ACTGAACCAG GGAGGTGGAG	1020
	GTTGCAGTGT GCCGAGATCA CGCCACTGCA CTCTAGCCTG GCAACAGAGC AAGATTCTGT	1080
35	CTCAAAAAAA AAAACATAT ATACACATAT ATCCCAAAGT GCTGGGATTA CATATATATA	1140
	TATATATATA TATTATATAT ATATATATAT ATATATGTGA TATATATGTG ATATATATAT	1200
	AACATATATA TATGTAATAT ATATGTGATA TATATATAAT ATATATATGT AATATATATG	1260
40	TGATATATAT ATATACACAC ACACACACAT ATATATGTAT GTGTGTGTAC ACACACACAC	1320
	ACAAATTAGC CAGGCATAGT TGCACACGCT TGGTAGACCC AGCTACTCAG GAGGCTGAGG	1380
45	GAGGAGAATC TCTTGAACCT AGGAGGCGGA GGTTCAGTG AGCTGAGATT GCGCCACTGC	1440
	ACTCCAGCCT GGGTGACAGA GCAGGACTCT GTACACCCCC CAAAACAAAA AAAAAAGTTA	1500
50	TCAGATGTGA TTGGAATGTA TATCAAGTAT CAGCTTCAAA ATATGCTATA TTAATACTTC	1560
	AAAAATTACA CAAATAATAC ATAATCAGGT TTGAAAAATT TAAGACAACM SAARAAAAAA	1620
	WYCMAATCAC AMATATCCCA CACATTTTAT TATTMCTMCT MCWATTATTT TGWAGAGMCT	1680
55	GGGTCTCACY CYKTTGCTWA TGCTGGTCTT TGAACYCCYK GCCYCAARCA RTCCTSCTCC	1740
	ABCCTCCCAA RGTGCTGGGG ATWATAGGCA TGARCTAACC GCACCCAGCC CCAGACATTT	1800

## EP 0 705 903 A1

	TAGTGTGTAA ATTCCTGGGC ATTTTTTCAA GGCATCATAC ATGTTAGCTG ACTGATGATG	1860
	GTCAATTTAT TTTGTCCATG GTGTCAAGTT TCTCTTCAGG AGGAAAAGCA CAGAAGTGGC	1920
5	CAACAATTGC TTGACTGTTC TTTACCATAC TGTTTTAGCAG GAAACCAGTC TCAGTGTCCA	1980
	ACTCTCTAAC CTTGGAAGTG TGAGAAGTCT GAGGACAAAG CAGCGGATAC AACCTCAAAA	2040
10	GACGTCTGTC TACATTGAAT TGGGTAAGGG TCTCAGGTTT TTAAAGTATT TAATAATAAT	2100
	TGCTGGATTC CTTATCTTAT AGTTTTGCCA AAAATCTTGG TCATAATTTG TATTTGTGGT	2160
	AGGCAGCTTT GGGAAAGTGAA TTTTATGAGC CCTATGGTGA GTTATAAAAA ATGTAAAAGA	2220
15	CGCAGTTCCC ACCTTGAAGA ATCTTACTTT AAAAAGGGAG CAAAAGAGGC CAGGCATGGT	2280
	GGCTCACACC TGTAATCCCA GCACTTTGGG AGGCCAAAGT GGGTGGATCA CCTGAGGTCG	2340
20	GGAGTTCGAG ACCAGCCTAG CCAACATGGA GAAACTCTGT CTGTACCAAA AAATAAAAAA	2400
	TTAGCCAGGT GTGGTGGCAC ATAAGTGTAA TCCCAGCTAC TCGGGAGGCT GAGGCAGGAG	2460
	AATCACTTGA ACCCGGGAGG TGGAGGTTGC GGTGAACCGA GATCGCACCA TTGCACTCCA	2520
25	GCCTGGGCAA AAATAGCGAA ACTCCATCTA AAAAAAAAAA AGAGAGCAAA AGAAAGAMTM	2580
	TCTGGTTTTA AMTMTGTGTA AATATGTTTT TGGAAAGATG GAGAGTAGCA ATAAGAAAAA	2640
30	ACATGATGGA TTGCTACAGT ATTTAGTTCC AAGATAAATT GTACTAGATG AGGAAGCCTT	2700
	TTAAGAAGAG CTGAATTGCC AGGCGCAGTG GCTCACGCCT GTAATCCCAG CACTTTGGGA	2760
	GGCCGAGGTG GGCGGATCAC CTGAGGTCGG GAGTTCAAGA CCAGCCTGAC CAACATGGAG	2820
35	AAACCCCATC TCTACTAAAA AAAAAAAAAA AAAAATTAGC CGGGGTGGTG GCTTATGCCT	2880
	GTAATCCCAG CTAATCAGGA GGCTGAGGCA GGAGAATCGC TTGAACCCAG GAAGCAGAGG	2940
40	TTGCAGTGAG CCAAGATCGC ACCATTGCAC TCCAGCCTAG GCAACAAGAG TGAACTCCA	3000
	TCTCAAAAAA AAAAAAAAAA AGCTGAATCT TGGCTGGGCA GGATGGCTCG TGCCTGTAAT	3060
	CCTAACGCTT TGGAAGACCG AGGCAGAAGG ATTGGTTGAG TCCACGAGTT TAAGACCAGC	3120
45	CTGGCCAACA TAGGGGAACC CTGTCTCTAT TTTTAAATA ATAATACATT TTTGGCCGGT	3180
	GCGGTGGCTC ATGCCTGTAA TCCCAATACT TTGGGAGGCT GAGGCAGGTA GATCACCTGA	3240
50	GGTCAGAGTT CGAGACCAGC CTGGATAACC TGGTGAAACC CCTCTTTACT AAAAATACAA	3300
	AAAAAAAAAA AAATTAGCTG GGTGTGGTAG CACATGCTTG TAATCCCAGC TACTTGGGAG	3360
	GCTGAGGCAG GAGAATCGCT TGAACCAGGG AGGCGGAGGT TACAATGAGC CAACACTACA	3420
55	CCACTGCACT CCAGCCTGGG CAATAGAGTG AGACTGCATC TCAAAAAAT AATAATTTTT	3480

EP 0 705 903 A1

	AAAAATAATA	AATTTTTTTA	AGCTTATAAA	AAGAAAAGTT	GAGGCCAGCA	TAGTAGCTCA	3540
5	CATCTGTAAT	CTCAGCAGTG	GCAGAGGATT	GCTTGAAGCC	AGGAGTTTGA	GACCAGCCTG	3600
	GGCAACATAG	CAAGACCTCA	TCTCTACAAA	AAAATTTCTT	TTTTAAATTA	GCTGGGTGTG	3660
	GTGGTGTGCA	TCTGTAGTCC	CAGCTACTCA	GGAGGCAGAG	GTGAGTGGAT	ACATTGAACC	3720
10	CAGGAGTTTG	AGGCTGTAGT	GAGCTATGAT	CATGCCACTG	CACTCCAACC	TGGGTGACAG	3780
	AGCAAGACCT	CAAAAAAAAA	AAAAAAAAAGA	GCTGCTGAGC	TCAGAATTCA	AACTGGGCTC	3840
15	TCAAATTGGA	TTTTCTTTTA	GAATATATTT	ATAATTAATA	AGGATAGCCA	TCTTTTGAGC	3900
	TCCCAGGCAC	CACCATCTAT	TTATCATAAC	ACTTACTGTT	TTCCCCCTT	ATGATCATAA	3960
	ATTCCTAGAC	AACAGGCATT	GTAAAAATAG	TTATAGTAGT	TGATATTTAG	GAGCACTTAA	4020
20	CTATATTCCA	GGCACTATTG	TGCTTTTCTT	GTATAACTCA	TTAGATGCTT	GTCAGACCTC	4080
	TGAGATTGTT	CCTATTATAC	TTATTTTACA	GATGAGAAAA	TTAAGGCACA	GAGAAGTTAT	4140
25	GAAATTTTTT	CAAGGTATTA	AACCTAGTAA	GTGGCTGAGC	CATGATTCAA	ACCTAGGAAG	4200
	TTAGATGTCA	GAGCCTGTGC	TTTTTTTTTG	TTTTTGTTTT	TGTTTTTCAGT	AGAAACGGGG	4260
	GTCTCACTTT	GTTGGCCAGG	CTGGTCTTGA	ACTCCTAACC	TCAAATAATC	CACCCATCTC	4320
30	GGCCTCCTCA	AGTGCTGGGA	TTACAGGTGA	GAGCCACTGT	GCCTGGCGAA	GCCCATGCCT	4380
	TTAACCACTT	CTCTGTATTA	CATACTAGCT	TAAC TAGCAT	TGTACCTGCC	ACAGTAGATG	4440
35	CTCAGTAAAT	ATTTCTAGTT	GAATATCTGT	TTTTCAACAA	GTACATTTTT	TTAACCCCTT	4500
	TAATTAAGAA	AACTTTTATT	GATTTATTTT	TTGGGGGGAA	ATTTTTTAGG	ATCTGATTCT	4560
	TCTGAAGATA	CCGTTAATAA	GGCAACTTAT	TGCAGGTGAG	TCAAAGAGAA	CCTTTGTCTA	4620
40	TGAAGCTGGT	ATTTTCCTAT	TTAGTTAATA	TTAAGGATTG	ATGTTTCTCT	CTTTTAAAA	4680
	ATATTTTAAC	TTTTATTTTA	GGTTCAGGGA	TGTATGTGCA	GTTTGTATA	TAGGTAAACA	4740
45	CACGACTTGG	GATTTGGTGT	ATAGATTTTT	TTCATCATCC	GGGTACTAAG	CATACCCAC	4800
	AGTTTTTTGT	TTGCTTTCTT	TCTGAATTTT	TCCCTCTTCC	CACCTTCCTC	CCTCAAGTAG	4860
	GCTGGTGTTT	CTCCAGACTA	GAATCATGGT	ATTGGAAGAA	ACCTTAGAGA	TCATCTAGTT	4920
50	TAGTTCTCTC	ATTTTATAGT	GGAGGAAATA	CCCTTTTTGT	TGTTGGATT	TAGTTATTAG	4980
	CACTGTCCAA	AGGAATTTAG	GATAACAGTA	GAACCTGCA	CATGCTTGCT	TCTAGCAGAT	5040
55	TGTTCTCTAA	GTTCTCATA	TACAGTAATA	TTGACACAGC	AGTAATTGTG	ACTGATGAAA	5100
	ATGTTCAAGG	ACTTCATTTT	CAACTCTTTC	TTTCCTCTGT	TCCTTATTTT	CACATATCTC	5160

## EP 0 705 903 A1

TCAAGCTTTG TCTGTATGTT ATATAATAAA CTACAAGCAA CCCCAACTAT GTTACCTACC 5220  
 TTCCTTAGGA ATTATTGCTT GACCCAGGTT TTTTTTTTTT TTTTTTTTGA GACGGGGTCT 5280  
 5 TGCCCTGTTG CCAGGATGGA GTGTAGTGGC GCCATCTCGG CTCACTGCAA TCTCCAACCTC 5340  
 CCTGGTTCAA GCGATTCTCC TGTCTCAATC TCACGAGTAG CTGGGACTAC AGGTATACAC 5400  
 10 CACCACGCCC GGTTAATTGA CCATTCCATT TCTTTCTTTC TCTCTTTTTT TTTTTTTTTT 5460  
 TTGAGACAGA GTCTTGCTCT GTTGCCCAGG CTGGAGTACA GAGGTGTGAT CTCACCTCTC 5520  
 CGCAACGTCT GCCTCCCAGG TTGAAGCCAT ACTCCTGCCT CAGCCTCTCT AGTAGCTGGG 5580  
 15 ACTACAGGCG CGCGCCACCA CACCCGGCTA ATTTTTGTAT TTTTAGTAGA GATGGGGTTT 5640  
 CACCATGTTG GCCAGGCTGG TCTTGAACCTC ATGACCTCAA GTGGTCCACC CGCCTCAGCC 5700  
 20 TCCCAAAGTG CTGGAATTAC AGGCTTGAGC CACCGTGCCC AGCAACCATT TCATTTCAAC 5760  
 TAGAAGTTTC TAAAGGAGAG AGCAGCTTTC ACTAACTAAA TAAGATTGGT CAGCTTTCTG 5820  
 TAATCGAAAG AGCTAAAATG TTTGATCTTG GTCATTTGAC AGTTCTGCAT ACATGTAACCT 5880  
 25 AGTGTTTCTT ATTAGGACTC TGTCTTTTCC CTATAGTGTG GGAGATCAAG AATTGTTACA 5940  
 AATCACCCCT CAAGGAACCA GGGATGAAAT CAGTTTGGAT TCTGCAAAAA AGGGTAATGG 6000  
 30 CAAAGTTTGC CAACTTAACA GGCCTGAAA AGAGAGTGGG TAGATACAGT ACTGTAATTA 6060  
 GATTATTCTG AAGACCATTT GGGACCTTTA CAACCCACAA AATCTCTTGG CAGAGTTAGA 6120  
 GTATCATTCT CTGTCAAATG TCGTGGTATG GTCTGATAGA TTTAAATGGT ACTAGACTAA 6180  
 35 TGTACCTATA ATAAGACCTT CTTGTAACCTG ATTGTTGCCC TTTCGCTTTT TTTTTTGTTT 6240  
 GTTTGTTTGT TTTTTTTTGA GATGGGGTCT CACTCTGTTG CCCAGGCTGG AGTGCAGTGA 6300  
 40 TGCAATCTTG GCTCACTGCA ACCTCCACCT CCAAAGGCTC AAGCTATCCT CCCACTTCAG 6360  
 CCTCCTGAGT AGCTGGGACT ACAGGCGCAT GCCACCACAC CCGGTTAATT TTTTGTGGTT 6420  
 TTATAGAGAT GGGGTTTCAC CATGTTACCG AGGCTGGTCT CAAACTCCTG GACTCAAGCA 6480  
 45 GTCTGCCCAC TTCAGCCTCC CAAAGTGCTG CAGTTACAGG CTTGAGCCAC TGTGCCTGGC 6540  
 CTGCCCTTTA CTTTAAATTG GTGTATTTGT GTTTCATCTT TTACCTACTG GTTTTTAAAT 6600  
 50 ATAGGGAGTG GTAAGTCTGT AGATAGAACA GAGTATTAAG TAGACTTAAT GGCCAGTAAT 6660  
 CTTTAGAGTA CATCAGAACC AGTTTTCTGA TGGCCAATCT GCTTTTAATT CACTCTTAGA 6720  
 CGTTAGAGAA ATAGGTGTGG TTTCTGCATA GGGAAAATTC TGAAATTAA 6769  
 55

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4249 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GATCCTAAGT	GGAAATAATC	TAGGTAAATA	GGAATTAAAT	GAAAGAGTAT	GAGCTACATC	60
TTCAGTATAC	TTGGTAGTTT	ATGAGGTTAG	TTTCTCTAAT	ATAGCCAGTT	GGTTGATTTT	120
CACCTCCAAG	GTGTATGAAG	TATGTATTTT	TTTAATGACA	ATTCAGTTTT	TGAGTACCTT	180
GTTATTTTTG	TATATTTTCA	GCTGCTTG TG	AATTTTCTGA	GACGGATGTA	ACAAATACTG	240
AACATCATCA	ACCCAGTAAT	AATGATTTGA	ACACCACTGA	GAAGCGTGCA	GCTGAGAGGC	300
ATCCAGAAAA	GTATCAGGGT	AGTTCTGTTT	CAAAC TTGCA	TGTGGAGCCA	TGTGGCACAA	360
ATACTCATGC	CAGCTCATT A	CAGCATGAGA	ACAGCAGTTT	ATTACTCACT	AAAGACAGAA	420
TGAATGTAGA	AAAGGCTGAA	TTCTGTAATA	AAAGCAAACA	GCCTGGCTTA	GCAAGGAGCC	480
AACATAACAG	ATGGGCTGGA	AGTAAGGAAA	CATGTAATGA	TAGGCGGACT	CCCAGCACAG	540
AAAAAAAGGT	AGATCTGAAT	GCTGATCCCC	TGTGTGAGAG	AAAAGAATGG	AATAAGCAGA	600
AACTGCCATG	CTCAGAGAAT	CCTAGAGATA	CTGAAGATGT	TCCTTGGATA	ACACTAAATA	660
GCAGCATTCA	GAAAGTTAAT	GAGTGGTTTT	CCAGAAGTGA	TGAACTGTTA	GGTTCTGATG	720
ACTCACATGA	TGGGGAGTCT	GAATCAAATG	CCAAAGTAGC	TGATGTATTG	GACGTTCTAA	780
ATGAGGTAGA	TGAATATTCT	GGTTCTTCAG	AGAAAATAGA	CTTACTGGCC	AGTGATCCTC	840
ATGAGGCTTT	AATATGTAAA	AGTGAAAGAG	TTCACTCCAA	ATCAGTAGAG	AGTAATATTG	900
AAGGCCAAAT	ATTTGGGAAA	ACCTATCGGA	AGAAGGCAAG	CCTCCCCAAC	TTAAGCCATG	960
TAAGTGAAAA	TCTAATTATA	GGAGCATT TG	TTACTGAGCC	ACAGATAATA	CAAGAGCGTC	1020
CCCTCACAAA	TAAATTAAAAG	CGTAAAAGGA	GACCTACATC	AGGCCTTCAT	CCTGAGGATT	1080

	TTATCAAGAA AGCAGATTTG GCAGTTCAAA AGACTCCTGA AATGATAAAT CAGGGAAC TA	1140
5	ACCAAACGGA GCAGAATGGT CAAGTGATGA ATATTACTAA TAGTGGTCAT GAGAATAAAA	1200
	CAAAAGGTGA TTCTATTCAG AATGAGAAAA ATCCTAACCC AATAGAATCA CTCGAAAAAG	1260
	AATCTGCTTT CAAAACGAAA GCTGAACCTA TAAGCAGCAG TATAAGCAAT ATGGAACTCG	1320
10	AATTAAATAT CCACAATTCA AAAGCACCTA AAAAGAATAG GCTGAGGAGG AAGTCTTCTA	1380
	CCAGGCATAT TCATGCGCTT GAACTAGTAG TCAGTAGAAA TCTAAGCCCA CCTAATTGTA	1440
15	CTGAATTGCA AATTGATAGT TGTTC TAGCA GTGAAGAGAT AAAGAAAAAA AAGTACAACC	1500
	AAATGCCAGT CAGGCACAGC AGAAACCTAC AACTCATGGA AGGTAAAGAA CCTGCAACTG	1560
	GAGCCAAGAA GAGTAACAAG CCAAATGAAC AGACAAGTAA AAGACATGAC AGCGATACTT	1620
20	TCCCAGAGCT GAAGTTAACA AATGCACCTG GTTCTTTTAC TAAGTGTTCA AATACCAGTG	1680
	AACTTAAAGA ATTTGTCAAT CCTAGCCTTC CAAGAGAAGA AAAAGAAGAG AACTAGAAAC	1740
25	AGTTAAAGTG TCTAATAATG CTGAAGACCC CAAAGATCTC ATGTTAAGTG GAGAAAGGGT	1800
	TTTGCAAACT GAAAGATCTG TAGAGAGTAG CAGTATTTCA TTGGTACCTG GTACTGATTA	1860
	TGGCACTCAG GAAAGTATCT CGTTACTGGA AGTTAGCACT CTAGGGAAGG CAAAAACAGA	1920
30	ACCAAATAAA TGTGTGAGTC AGTGTGCAGC ATTTGAAAAAC CCCAAGGGAC TAATTCATGG	1980
	TTGTTCCAAA GATAATAGAA ATGACACAGA AGGCTTTAAG TATCCATTGG GACATGAAGT	2040
35	TAACCACAGT CGGGAAACAA GCATAGAAAT GGAAGAAAGT GAACTTGATG CTCAGTATTT	2100
	GCAGAATACA TTCAAGGTTT CAAAGCGCCA GTCATTTGCT CCGTTTTCAA ATCCAGGAAA	2160
	TGCAGAAGAG GAATGTGCAA CATTCTCTGC CCACTCTGGG TCCTTAAAGA AACAAAGTCC	2220
40	AAAAGTCACT TTTGAATGTG AACAAAAGGA AGAAAATCAA GGAAAGAATG AGTCTAATAT	2280
	CAAGCCTGTA CAGACAGTTA ATATCACTGC AGGCTTTCCT GTGGTTGGTC AGAAAGATAA	2340
45	GCCAGTTGAT AATGCCAAAT GTAGTATCAA AGGAGGCTCT AGGTTTTGTC TATCATCTCA	2400
	G TTCAGAGGC AACGAAACTG GACTCATTAC TCCAAATAAA CATGGACTTT TACAAAACCC	2460
	ATATCGTATA CCACCACTTT TTCCCATCAA GTCATTTGTT AAAACTAAAT GTAAGAAAAA	2520
50	TCTGCTAGAG GAAAACTTTG AGGAACATTC AATGTCACCT GAAAGAGAAA TGGGAAATGA	2580
	GAACATTCCA AGTACAGTGA GCACAATTAG CCGTAATAAC ATTAGAGAAA ATGTTTTTAA	2640
	AGAAGCCAGC TCAAGCAATA TTAATGAAGT AGGTTCCAGT ACTAATGAAG TGGGCTCCAG	2700
55	TATTAATGAA ATAGGTTCCA GTGATGAAAA CATTCAAGCA GAACTAGGTA GAAACAGAGG	2760

	GCCAAAATTG AATGCTATGC TTAGATTAGG GGTTTTGCAA CCTGAGGTCT ATAAACAAAG	2820
5	TCTTCCTGGA AGTAATTGTA AGCATCCTGA AATAAAAAAG CAAGAATATG AAGAAGTAGT	2880
	TCAGACTGTT AATACAGATT TCTCTCCATA TCTGATTTCA GATAACTTAG AACAGCCTAT	2940
	GGGAAGTAGT CATGCATCTC AGGTTTGTTT TGAGACACCT GATGACCTGT TAGATGATGG	3000
10	TGAAATAAAG GAAGATACTA GTTTTGCTGA AAATGACATT AAGGAAAGTT CTGCTGTTTT	3060
	TAGCAAAAGC GTCCAGAAAG GAGAGCTTAG CAGGAGTCCT AGCCCTTTCA CCCATACACA	3120
15	TTTGGCTCAG GGTTACCGAA GAGGGGCCAA GAAATTAGAG TCCTCAGAAG AGAACTTATC	3180
	TAGTGAGGAT GAAGAGCTTC CCTGCTTCCA ACACTTGTTA TTTGGTAAAG TAAACAATAT	3240
	ACCTTCTCAG TCTACTAGGC ATAGCACCGT TGCTACCGAG TGTCTGTCTA AGAACACAGA	3300
20	GGAGAATTTA TTATCATTGA AGAATAGCTT AAATGACTGC AGTAACCAGG TAATATTGGC	3360
	AAAGGCATCT CAGGAACATC ACCTTAGTGA GGAAACAAAA TGTTCTGCTA GCTTGTTTTTC	3420
25	TTCACAGTGC AGTGAATTGG AAGACTTGAC TGCAAATACA AACACCCAGG ATCCTTTCTT	3480
	GATTGGTTCT TCCAAACAAA TGAGGCATCA GTCTGAAAGC CAGGGAGTTG GTCTGAGTGA	3540
	CAAGGAATTG GTTTCAGATG ATGAAGAAAG AGGAACGGGC TTGGAAGAAA ATAATCAAGA	3600
30	AGAGCAAAGC ATGGATTCAA ACTTAGGTAT TGGAACCAGG TTTTGTGTT TGCCCCAGTC	3660
	TATTTATAGA AGTGAGCTAA ATGTTTATGC TTTTGGGGAG CACATTTTAC AAATTTCCAA	3720
35	GTATAGTTAA AGGAACTGCT TCTTAAACTT GAAACATGTT CCTCCTAAGG TGCTTTTCAT	3780
	AGAAAAAGT CCTTCACACA GCTAGGACGT CATCTTTGAC TGAATGAGCT TTAACATCCT	3840
	AATTACTGGT GGACTTACTT CTGGTTTCAT TTTATAAAGC AAATCCCGGT GTCCCAAAGC	3900
40	AAGGAATTTA ATCATTTTGT GTGACATGAA AGTAAATCCA GTCCTGCCAA TGAGAAGAAA	3960
	AAGACACAGC AAGTTGCAGC GTTTATAGTC TGCTTTTACA TCTGAACCTC TGTTTTTGT	4020
45	ATTTAAGGTG AAGCAGCATC TGGGTGTGAG AGTGAAACAA GCGTCTCTGA AGACTGCTCA	4080
	GGGCTATCCT CTCAGAGTGA CATTTTAACC ACTCAGGTAA AAAGCGTGTG TGTGTGTGCA	4140
50	CATGCGTGTG TGTGGTGTCC TTTGCATTCA GTAGTATGTA TCCCACATTC TTAGGTTTGC	4200
55	TGACATCATC TCTTTGAATT AATGGCACAA TTGTTTGTGG TTCATTGTC	4249

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 710 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

NGNGAATGTA ATCCTAATAT TTCNCNCNA CTAAAAGAA TACCACTCCA ANGGCATCNC	60
AATACATCAA TCAATTGGGG AATTGGGATT TTCCCTCNCT AACATCANTG GAATAATTTT	120
ATGGCATTAA TTGCATGAAT GTGGTTAGAT TAAAAGGTGT TCATGCTAGA ACTTGTAGTT	180
CCATACTAGG TGATTTCAT TCCTGTGCTA AAATTAATTT GTATGATATA TTNTCATTTA	240
ATGGAAAGCT TCTCAAAGTA TTTCAATTTT TTGGTACCAT TTATCGTTTT TGAAGCAGAG	300
GGATACCATG CAACATAACC TGATAAAGCT CCAGCAGGAA ATGGCTGAAC TAGAAGCTGT	360
GTTAGAACAG CATGGGAGCC AGCCTTCTAA CAGCTACCCT TCCATCATAA GTGACTCTTC	420
TGCCCTTGAG GACCTGCGAA ATCCAGAACA AAGCACATCA GAAAAAGGTG TGTATTGTTG	480
GCCAAACACT GATATCTTAA GCAAAATTCT TTCCTTCCCC TTTATCTCCT TCTGAAGAGT	540
AAGGACCTAG CTCCAACATT TTATGATCCT TGCTCAGCAC ATGGGTAATT ATGGAGCCTT	600
GGTTCTTGTC CCTGCTCACA ACTAATATAC CAGTCAGAGG GACCCAAGGC AGTCATTCAT	660
GTTGTCATCT GAGATACCTA CAACAAGTAG ATGCTATGGG GAGCCCATGG	710

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 473 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCATTGGTGC TAGCATCTGT CTGTTGCATT GCTTGTGTTT ATAAAATTCT GCCTGATATA	60
CTTGTTAAAA ACCAATTTGT GTATCATAGA TTGATGCTTT TGAAAAAAT CAGTATTCTA	120
ACCTGAATTA TCACTATCAG AACAAAGCAG TAAAGTAGAT TTGTTTTCTC ATTCCATTTA	180
AAGCAGTATT AACTTCACAG AAAAGTAGTG AATACCCTAT AAGCCAGAAT CCAGAAGGCC	240
TTTCTGCTGA CAAGTTTGAG GTGTCTGCAG ATAGTTCTAC CAGTAAAAAT AAAGAACCAG	300
GAGTGGAAAG GTAAGAAACA TCAATGTAAA GATGCTGTGG TATCTGACAT CTTTATTTAT	360
ATTGAACTCT GATTGTTAAT TTTTTCACC ATACTTCTC CAGTTTTTTT GCATACAGGC	420
ATTTATACAC TTTTATTGCT CTAGGATACT TCTTTTGTTC AATCCTATAT AGG	473

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 421 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GGATAAGNTC AAGAGATATT TTGATAGGTG ATGCAGTGAT NAATTGNGAA AATTTNCTGC	60
CTGCTTTTAA TCTTCCCCCG TTCTTTCTTC CTNCCTCCCT CCCTTCCTNC CTCCCGTCCCT	120
TNCCTTTCCT TTCCCTCCCT TCCNCCTTCT TTCCNTCTNT CTTTCCTTTC TTTCCTGTCT	180
ACCTTTCTTT CCTTCCTCCC TTCCTTTTCT TTTCTTTCTT TCCTTTCCTT TTCTTTCCTT	240
TCTTTCCTTT CCTTTCCTTC TTGACAGAGT CTTGCTCTGT CACTCAGGCT GGAGTGCAGT	300

GGCGTGATCT CGNCTCACTG CAACCTCTGT CTCCCAGGTT CAAGCAATTT TCCTGCCTCA . 360  
 5 GCCTCCCGAG TAGCTGAGAT TACAGGCGCC AGCCACCACA CCCAGCTACT GACCTGCTTT 420  
 T 421

## (2) INFORMATION FOR SEQ ID NO:25:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 997 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAACAGCTGG GAGATATGGT GCCTCAGACC AACCCCATGT TATATGTCAA CCCTGACATA 60  
 TTGGCAGGCA ACATGAATCC AGACTTCTAG GCTGTCATGC GGGCTCTTTT TTGCCAGTCA . 120  
 TTTCTGATCT CTCTGACATG AGCTGTTTCA TTTATGCTTT GGCTGCCCAG CAAGTATGAT 180  
 35 TTGTCCTTTC ACAATTGGTG GCGATGGTTT TCTCCTTCCA TTTATCTTTC TAGGTCATCC 240  
 CCTTCTAAAT GCCCATCATT AGATGATAGG TGGTACATGC ACAGTTGCTC TGGGAGTCTT 300  
 40 CAGAATAGAA ACTACCCATC TCAAGAGGAG CTCATTAAGG TTGTTGATGT GGAGGAGCAA 360  
 CAGCTGGAAG AGTCTGGGCC ACACGATTTG ACGGAAACAT CTTACTTGCC AAGGCAAGAT 420  
 CTAGGTAATA TTTCATCTGC TGTATTGGAA CAAACACTYT GATTTTACTC TGAATCCTAC 480  
 45 ATAAAGATAT TCTGGTTAAC CAACTTTTAG ATGTACTAGT CTATCATGGA CACTTTTGTT 540  
 ATACTTAATT AAGCCCACTT TAGAAAAATA GCTCAAGTGT TAATCAAGGT TTAAGGAGAA 600  
 50 ATTATTGAAA CTGTTAATCC ATCTATATTT TAATTAATGG TTAACTAAT GATTTTGAGG 660  
 ATGWGGGAGT CKTGGTGTAC TCTAMATGTA TTATTTTCAAG CCAGGCATAG TGGCTCACGC 720  
 CTGGTAATCC CAGTAYYCMR GAGCCCGAGG CAGGTGGAGC CAGCTGAGGT CAGGAGTTCA 780  
 55 AGACCTGTCT TGGCCAACAT GGGNGAAACC CTGTCTTCTT CTTAAAAAAN ACAAAAAAAA 840

TTAACTGGGT TGTGCTTAGG TGNATGCCCC GNATCCTAGT TTTTCTTGNG GGTGAGGGA 900  
 5 GGAGATCACN TTGGACCCCG GAGGGGNGGG TGGGGGNGAG CAGGNCAAAA CACNGACCCA 960  
 GCTGGGGTGG AAGGGAAGCC CACTCNAAAA AANNTTN 997

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 639 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TTTTTAGGAA ACAAGCTACT TTGGATTTC ACCAACACCT GTATTCATGT ACCCATTTTT 60  
 30 CTCTTAACCT AACTTTATTG GTCITTTTAA TTCTTAACAG AGACCAGAAC TTTGTAATTC 120  
 AACATTCATC GTTGTGTAAA TTAAACTTCT CCCATTCCTT TCAGAGGGAA CCCCTTACCT 180  
 35 GGAATCTGGA ATCAGCCTCT TCTCTGATGA CCCTGAATCT GATCCTTCTG AAGACAGAGC 240  
 CCCAGAGTCA GCTCGTGTTG GCAACATACC ATCTTCAACC TCTGCATTGA AAGTTCCCCA 300  
 ATTGAAAGTT GCAGAATCTG CCCAGAGTCC AGCTGCTGCT CATACTACTG ATACTGCTGG 360  
 40 GTATAATGCA ATGGAAGAAA GTGTGAGCAG GGAGAAGCCA GAATTGACAG CTTCAACAGA 420  
 AAGGGTCAAC AAAAGAATGT CCATGGTGGT GTCTGGCCTG ACCCCAGAAG AATTTGTGAG 480  
 45 TGTATCCATA TGTATCTCCC TAATGACTAA GACTTAACAA CATTCTGGAA AGAGTTTAT 540  
 GTAGGTATTG TCAATTAATA ACCTAGAGGA AGAAATCTAG AAAACAATCA CAGTTCTGTG 600  
 TAATTTAATT TCGATTACTA ATTTCTGAAA ATTTAGAAY 639

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 922 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

10 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

15 NCCCNCCCC CNAATCTGAA ATGGGGGTAA CCCCCCCCCA ACCGANACNT GGGTNGCNTA • 60  
 GAGANTTTAA TGGCCCN TTC TGAGGNACAN AAGCTTAAGC CAGGNGACGT GGANCNATGN 120  
 20 GTTGTTTNTT GTTTGGTTAC CTCCAGCCTG GGTGACAGAG CAAGACTCTG TCTAAAAAAA 180  
 AAAAAAAAAA AAATCGACTT TAAATAGTTC CAGGACACGT GTAGAACGTG CAGGATTGCT 240  
 AUSTAGGTAA ACATATGCCA TGGTGGGATA ACTAGTATTC TGAGCTGTGT GCTAGAGGTA 300  
 25 ACTCATGATA ATGGAATATT TGATTTAATT TCAGATGCTC GTGTACAAGT TTGCCAGAAA 360  
 ACACCACATC ACTTTAACTA ATCTAATTAC TGAAGAGACT ACTCATGTTG TTATGAAAAC 420  
 30 AGGTATACCA AGAACCTTTA CAGAATACCT TGCATCTGCT GCATAAAACC ACATGAGGCG 480  
 AGGCACGGTG GCGCATGCCT GTAATCGCAG CACTTTGGGA GGCCGAGGCG GGCAGATCAC 540  
 GAGATTAGGA GATCGAGACC ATCCTGGCCA GCATGGTGAA ACCCGTCTC TACTANNAAA 600  
 35 TGGNAAAATT ANCTGGGTGT GGTGCGGTGC NCCTGTAGTC CCAGCTACTC GTGAGGCTGA 660  
 GGCAGGAGAA TCACTTGAAC CGGGGAAATG GAGGTTTCAG TGAGCAGAGA TCATNCCCCT 720  
 40 NCATTCCAGC CTGGCGACAG AGCAAGGCTC CGTCNCCNAA AAAATAAAAA AAAACGTGAA 780  
 CAAATAAGAA TATTTGTTGA GCATAGCATG GATGATAGTC TTCTAATAGT CAATCAATTA 840  
 CTTTATGAAA GACAAATAAT AGTTTTGCTG CTTCTTACC TCCTTTTGTT TTGGGTAAAG 900  
 45 ATTTGGAGTG TGGGCCAGGC AC 922

(2) INFORMATION FOR SEQ ID NO:28:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 867 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GATCTATAGC TAGCCTTGGC GTCTAGAAGA TGGGTGTTGA GAAGAGGGAG TGGAAAGATA	60
TTTCCTCTGG TCTTAACTTC ATATCAGCCT CCCCTAGACT TCCAAATATC CATACCTGCT	120
GGTTATAATT AGTGGTGTTT TCAGCCTCTG ATTCTGTCAC CAGGGGTTTT AGAATCATAA	180
ATCCAGATTG ATCTTGGGAG TGTA AAAAAC TGAGGCTCTT TAGCTTCTTA GGACAGCACT	240
TCCTGATTTT GTTTTCAACT TCTAATCCTT TGAGTGTTTT TCATTCTGCA GATGCTGAGT	300
TTGTGTGTGA ACGGACACTG AAATATTTTC TAGGAATTGC GGGAGGAAAA TGGGTAGTTA	360
GCTATTTCTG TAAGTATAAT ACTATTTCTC CCTCCTCCC TTAAACACCT CAGAATTGCA	420
TTTTTACACC TAACATTTAA CACCTAAGGT TTTTGCTGAT GCTGAGTCTG AGTTACCAAA	480
AGGTCTTTAA ATTGTAATAC TAAACTACTT TTATCTTTAA TATCACTTTG TTCAAGATAA	540
GCTGGTGATG CTGGGAAAAT GGGTCTCTTT TATAACTAAT AGGACCTAAT CTGCTCCTAG	600
CAATGTTAGC ATATGAGCTA GGGATTTATT TAATAGTCGG CAGGAATCCA TGTGCARCAG	660
NCAAACCTAT AATGTTTAAA TTAAACATCA ACTCTGTCTC CAGAAGGAAA CTGCTGCTAC	720
AAGCCTTATT AAAGGGCTGT GGCTTTAGAG GGAAGGACCT CTCCTCTGTC ATTCTTCCTG	780
TGCTCTTTTG TGAATCGCTG ACCTCTCTAT CTCCTGAAA AGAGCACGTT CTTCTGCTGT	840
ATGTAACCTG TCTTTTCTAT GATCTCT	867

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 561 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

NAAAAACGGG GNNGGGANTG GGCCTTAAAN CCAAAGGGCN AACTCCCCAA CCATTNAAAA 60  
 10 ANTGACNNGG GATTATTAAA ANCGGCGGGA AACATTTCAC NGCCCAACTA ATATTGTAA 120  
 ATTAAACCA CCACCNCTGC NCCAAGGAGG GAAACTGCTG CTACAAGCCT TATTAAAGGG 180  
 15 CTGTGGCTTT AGAGGGAAGG ACCTCTCCTC TGTCATTCTT CCTGTGCTCT TTTGTGAATC 240  
 GCTGACCTCT CTATGTCCGT GAAAAGAGCA CGTTCTTCGT CTGTATGTAA CCTGTCTTTT 300  
 CTATGATCTC TTTAGGGGTG ACCCAGTCTA TTAAAGAAAG AAAAATGCTG AATGAGGTAA 360  
 20 GTACTTGATG TTACAAACTA ACCAGAGATA TTCATTCACT CATATAGTTA AAAATGTATT 420  
 TGCTTCCTTC CATCAATGCA CCACTTTCCT TAACAATGCA CAAATTTTCC ATGATAATGA 480  
 25 GGATCATCAA GAATTATGCA GGCCTGCACT GTGGCTCATA CCTATAATCC CAGCGCTTTG 540  
 GGAGGCTGAG GCGCTTGGAT C 561

(2) INFORMATION FOR SEQ ID NO:30:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 567 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

40

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AATTTTTTGT ATTTTATAGTA GAGATGAGGT TCACCATGTT GGTCTAGATC TGGTGTGCGAA 60  
 50 CGTCCTGACC TCAAGTGATC TGCCAGCCTC AGTCTCCCAA AGTGCTAGGA TTACAGGGGT 120  
 GAGCCACTGC GCCTGGCCTG AATGCCTAAA ATATGACGTG TCTGCTCCAC TTCCATTGAA 180  
 55 GGAAGCTTCT CTTTCTCTTA TCCTGATGGG TTGTGTTTGG TTTCTTTCAG CATGATTTTG 240

AAGTCAGAGG AGATGTGGTC AATGGAAGAA ACCACCAAGG TCCAAAGCGA GCAAGAGAAT 300  
 5 CCCAGGACAG AAAGGTAAAG CTCCCTCCCT CAAGTTGACA AAAATCTCAC CCCACCACTC 360  
 TGTATTCCAC TCCCCTTTGC AGAGATGGGC CGCTTCATTT TGTAAGACTT ATTACATACA 420  
 TACACAGTGC TAGATACTTT CACACAGGTT CTTTTTTCAC TCTTCCATCC CAACCACATA 480  
 10 AATAAGTATT GTCTCTACTT TATGAATGAT AAAACTAAGA GATTTAGAGA GGCTGTGTAA 540  
 TTTGGATTCC CGTCTCGGGT TCAGATC 567

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 633 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

35 TTGGCCTGAT TGGTGACAAA AGTGAGATGC TCAGTCCTTG AATGACAAAG AATGCCTGTA 60  
 GAGTTGCAGG TCCAACTACA TATGCACTTC AAGAAGATCT TCTGAAATCT AGTAGTGTTT 120  
 40 TGGACATTGG ACTGCTTGTC CCTGGGAAGT AGCAGCAGAA ATGATCGGTG GTGAACAGAA 180  
 GAAAAAGAAA AGCTCTTCCT TTTTGAAAGT CTGTTTTTTG AATAAAAGCC AATATTCTTT 240  
 TATAACTAGA TTTTCCTTCT CTCCATTCCC CTGTCCCTCT CTCTTCCTCT CTTCTTCCAG 300  
 45 ATCTTCAGGG GGCTAGAAAT CTGTTGCTAT GGGCCCTTCA CCAACATGCC CACAGGTAAG 360  
 AGCCTGGGAG AACCCAGAG TTCCAGCACC AGCCTTTGTC TTACATAGTG GAGTATTATA 420  
 50 AGCAAGGTCC CACGATGGGG GTTCCTCAGA TTGCTGAAAT GTTCTAGAGG CTATTCTATT 480  
 TCTCTACCAC TCTCCAAACA AAACAGCACC TAAATGTTAT CCTATGGCAA AAAAAACTA 540  
 TACCTTGTCC CCCTTCTCAA GAGCATGAAG GTGGTTAATA GTTAGGATTC AGTATGTTAT 600  
 55 TGTTTCAGAT GGC GTTGAGC TGCTGTAGT GCC 633

## (2) INFORMATION FOR SEQ ID NO:32:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 470 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TTTGAGAGAC	TATCAAACCT	TATACCAAGT	GGCCTTATGG	AGACTGATAA	CCAGAGTACA	60
TGGCATATCA	GTGGCAAATT	GACTTAAAAT	CCATACCCCT	ACTATTTTAA	GACCATTGTC	120
CTTTGGAGCA	GAGAGACAGA	CTCTCCCAT	GAGAGGTCTT	GCTATAAGCC	TTCATCCGGA	180
GAGTGTAGGG	TAGAGGGCCT	GGGTAAAGTA	TGCAGATTAC	TGCAGTGATT	TTACATGTAA	240
ATGTCCATTT	TAGATCAACT	GGAATGGATG	GTACAGCTGT	GTGGTGCTTC	TGTGGTGAAG	300
GAGCTTTCAT	CATTCACCCT	TGGCACAGTA	AGTATTGGGT	GCCCTGTCAG	TGTGGGAGGA	360
CACAATATTC	TCTCCTGTGA	GCAAGACTGG	CACCTGTCAG	TCCCTATGGA	TGCCCCTACT	420
GTAGCCTCAG	AAGTCTTCTC	TGCCCACATA	CCTGTGCCAA	AAGACTCCAT		470

## (2) INFORMATION FOR SEQ ID NO:33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 517 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

5 GGTGGTACGT GTCTGTAGTT CCAGCTACTT GGGAGGCTGA GATGGAAGGA TTGCTTGAGC 60  
 CCAGGAGGCA GAGGTGGNAN NTTACGCTGA GATCACACCA CTGCACTCCA GCCTGGGTGA 120  
 CAGAGCAAGA CCCTGTCTCA AAAACAAACA AAAAAATGA TGAAGTGACA GTTCCAGTAG 180  
 10 TCCTACTTTG ACACTTTGAA TGCTCTTTCC TTCCTGGGGA TCCAGGGTGT CCACCCAATT 240  
 GTGGTTGTGC AGCCAGATGC CTGGACAGAG GACAATGGCT TCCATGGTAA GGTGCCTCGC 300  
 ATGTACCTGT GCTATTAGTG GGGTCCTTGT GCATGGGTTT GGTATTATCAC TCATTACCTG 360  
 15 GTGCTTGAGT AGCACAGTTC TTGGCACATT TTAAATATT TGTTGAATGA ATGGCTAAAA 420  
 TGTCTTTTGT ATGTTTTTAT TGTTATTTGT TTTATATTGT AAAAGTAATA CATGAACTGT 480  
 20 TTCCATGGGG TGGGAGTAAG ATATGAATGT TCATCAC 517

## (2) INFORMATION FOR SEQ ID NO:34:

## (i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 434 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

40 CAGTAATCCT NAGAACTCAT ACGACCGGGC CCCTGGAGTC GNTGNTTNGA GCCTAGTCCN 60  
 45 GGAGAATGAA TTGACACTAA TCTCTGCTTG TGTTCTCTGT CTCCAGCAAT TGGGCAGATG 120  
 TGTGAGGCAC CTGTGGTGAC CCGAGAGTGG GTGTTGGACA GTGTAGCACT CTACCAGTGC 180  
 CAGGAGCTGG ACACCTACCT GATACCCCAG ATCCCCCACA GCCACTACTG ACTGCAGCCA 240  
 50 GCCACAGGTA CAGAGCCACA GGACCCCAAG AATGAGCTTA CAAAGTGGCC TTTCCAGGCC 300  
 CTGGGAGCTC CTCTCACTCT TCAGTCCTTC TACTGTCCTG GCTACTAAAT ATTTTATGTA 360  
 CATCAGCCTG AAAAGGACTT CTGGCTATGC AAGGGTCCCT TAAAGATTTT CTGCTTGAAG 420  
 55 TCTCCCTTGG AAAT 434

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GATAAATTAA AACTGCGACT GCGCGGCGTG

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GTAGTAGAGT CCCGGGAAAG GGACAGGGGG

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATATATATAT GTTTTCTAA TGTGTTAAAG

30

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GTAAGTCAGC ACAAGAGTGT ATTAATTGG

30

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TTTCTTTTTC TCCCCCCCCT ACCCTGCTAG

30

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GTAAGTTTGA ATGTGTTATG TGGCTCCATT

30

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AGCTACTTTT TTTTTTTTTT TTTGAGACAG

30

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTAAGTGCAC ACCACCATAT CCAGCTAAAT

30

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

AATTGTTCTT TCTTTCTTTA TAATTTATAG

30

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GTATATAATT TGGTAATGAT GCTAGGTTGG

30

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GAGTGTGTTT CTCAAACAAT TTAATTTTCAG

30

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GTAAGTGTG AATATCCCAA GAATGACACT

30

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

AAACATAATG TTTTCCCTTG TATTTTACAG

30

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GTAAAACCAT TTGTTTCTT CTTCTTCTTC

30

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

TGCTTGACTG TTCTTTACCA TACTGTTTAG

30

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

GTAAGGGTCT CAGGTTTTTT AAGTATTTAA

30

## (2) INFORMATION FOR SEQ ID NO:51:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

TGATTTATTT TTTGGGGGGA AATTTTITAG

30

## (2) INFORMATION FOR SEQ ID NO:52:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GTGAGTCAAA GAGAACCTTT GTCTATGAAG

30

## (2) INFORMATION FOR SEQ ID NO:53:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

TCTTATTAGG ACTCTGTCTT TTCCCTATAG

30

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GTAATGGCAA AGTTTGCCAA CTTAACAGGC

30

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GAGTACCTTG TTATTTTGT ATATTTTCAG

30

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GTATTGGAAC CAGGTTTTTG TGTTTGCCCC

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

ACATCTGAAC CTCTGTTTTT GTTATTTAAG

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

AGGTAAAAAG CGTGTGTGTG TGTGCACATG

## (2) INFORMATION FOR SEQ ID NO:59:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

CATTCTCTTG GTACCATTGA TCGTTTTTGA

## (2) INFORMATION FOR SEQ ID NO:60:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GTGTGTATTG TTGGCCAAAC ACTGATATCT

## (2) INFORMATION FOR SEQ ID NO:61:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

AGTAGATTTG TTTTCTCATT CCATTAAAG

30

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GTAAGAAACA TCAATGTAAA GATGCTGTGG

30

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

ATGGTTTTCT CCTTCCATTT ATCTTTCTAG

30

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GTAATATTTTC ATCTGCTGTA TTGGAACAAA

30

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

TGTAAATTAA ACTTCTCCCA TTCCTTTCAG

30

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GTGAGTGTAT CCATATGTAT CTCCTAATG

30

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

ATGATAATGG AATATTTGAT TTAATTTTCAG

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GTATACCAAG AACCTTTACA GAATACCTTG

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

CTAATCCTTT GAGTGTTTT CATTCTGCAG

30

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GTAAGTATAA TACTATTTCT CCCCTCCTCC

30

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

TGTAACCTGT CTTTCTATG ATCTCTTTAG

30

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

GTAAGTACTT GATGTTACAA ACTAACCAGA

30

15 (2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25 (iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

35 TCCTGATGGG TTGTGTTTGG TTTCTTTCAG

30

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

50 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

55 GTAAAGCTCC CTCCCTCAAG TTGACAAAAA

30

## (2) INFORMATION FOR SEQ ID NO:75:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CTGTCCCTCT CTCTTCCTCT CTTCTTCCAG

## (2) INFORMATION FOR SEQ ID NO:76:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GTAAGAGCCT GGGAGAACCC CAGAGTTCCA

## (2) INFORMATION FOR SEQ ID NO:77:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

AGTGATTTTA CATGTAAATG TCCATTTTAG

30

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

GTAAGTATTG GGTGCCCTGT CAGTGTGGGA

30

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

TTGAATGCTC TTTCCTTCCT GGGGATCCAG

30

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GTAAGGTGCC TCGCATGTAC CTGTGCTATT

30

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

CTAATCTCTG CTTGTGTTCT CTGTCTCCAG

30

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Cys Pro Ile Cys Leu Glu Leu Ile Lys Glu Pro Val Ser Thr Lys Cys  
1 5 10 15

Asp His Ile Phe Cys Lys Phe Cys Met Leu Lys Leu Leu Asn Gln Lys  
20 25 30

Lys Gly Pro Ser Gln Cys Pro Leu Cys Lys  
35 40

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 45 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Cys Pro Ile Cys Leu Glu Leu Lys Glu Pro Val Ser Ala Asp Cys  
1 5 10 15

Asn His Ser Phe Cys Arg Ala Cys Ile Thr Leu Asn Tyr Glu Ser Asn  
20 25 30

Arg Asn Thr Asp Gly Lys Gly Asn Cys Pro Val Cys Arg  
35 40 45

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 41 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Cys Pro Ile Cys Leu Asp Met Leu Lys Asn Thr Met Thr Thr Lys Glu  
1 5 10 15

Cys Leu His Arg Phe Cys Ser Asp Cys Ile Val Thr Ala Leu Arg Ser  
20 25 30

Gly Asn Lys Glu Cys Pro Thr Cys Arg  
 35 40

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Cys Pro Val Cys Leu Gln Tyr Phe Ala Glu Pro Met Met Leu Asp Cys  
 1 5 10 15

Gly His Asn Ile Cys Cys Ala Cys Leu Ala Arg Cys Trp Gly Thr Ala  
 20 25 30


Cys Thr Asn Val Ser Cys Pro Gln Cys Arg  
 35 40

Claims

1. An isolated nucleic acid coding for a mutant or polymorphic BRCA1 polypeptide, said nucleic acid containing in comparison to the BRCA1 polypeptide encoding sequence set forth in SEQ.ID No:1 one or more mutations or polymorphisms selected from the mutations set forth in Tables 12, 12A and 14 and the polymorphisms set forth in Tables 18 and 19.
2. An isolated nucleic acid as claimed in claim 1 which is a DNA coding for a mutant BRCA1 polypeptide, said DNA containing in comparison to the BRCA1 polypeptide encoding sequence set forth in SEQ.ID No: 1 one or more mutations set forth in Tables 12, 12A and 14.
3. An isolated nucleic acid as claimed in claim 1 which is a DNA coding for a polymorphic BRCA1 polypeptide, said DNA containing in comparison to the BRCA1 polypeptide encoding sequence set forth in SEQ.ID No:1 one or more polymorphisms set forth in Tables 18 and 19.
4. A nucleic acid probe wherein the nucleotide sequence is a portion of a nucleic acid as claimed in any one of claims 1 to 3 including a mutation or polymorphism compared to the nucleotide sequence set forth in SEQ.ID No: 1 selected from the mutations set forth in Tables 12, 12A and 14 and the polymorphisms set forth in Tables 18 and 19.
5. A replicative cloning vector which comprises an isolated DNA according to any one of claims 1 to 4 and a replicon operative in a host cell for said vector.
6. An expression vector which comprises an isolated DNA according to any one of claims 1 to 4 wherein the coding sequence for said mutant or polymorphic BRCA1 polypeptide is operably-linked to a promoter sequence capable of directing expression of said coding sequence in host cells for said vector.

7. Host cells transformed with a vector as claimed in claim 5 or claim 6.
8. A method of producing a mutant or polymorphic BRCA1 polypeptide compared to the BRCA1 polypeptide having the amino acid sequence set forth in SEQ.ID No:2 which comprises (i) culturing host cells as claimed in claim 7 containing an expression vector encoding said polypeptide under conditions suitable for production of said polypeptide and (ii) recovering said polypeptide.
9. A method as claimed in claim 8 which further comprises labelling the recovered polypeptide.
10. A preparation of a polypeptide substantially free of other proteins, said polypeptide being a mutant or polymorphic BRCA1 polypeptide compared to the BRCA1 polypeptide having the amino acid sequence set forth in SEQ.ID No:2 which is obtainable by expression of a nucleotide coding sequence derived from the nucleotide sequence set forth in SEQ.ID No:1 by incorporation of one or more mutations or polymorphisms selected from the mutations set forth in Tables 12, 12A and 14 and the polymorphisms set forth in Tables 18 and 19.
11. A preparation of a polypeptide as claimed in claim 10 which is a mutant BRCA1 polypeptide obtainable by expression of a nucleotide coding sequence derived from the nucleotide sequence set forth in SEQ.ID No:1 by incorporation of a mutation set forth in Tables 12, 12A and 14.
12. A preparation of a polypeptide substantially free of other proteins, said polypeptide being an antigenic fragment of a polypeptide as defined in claim 10 or claim 11 having a mutation or polymorphism compared to the BRCA1 polypeptide having the amino acid sequence set forth in SEQ.ID No:2.
13. A preparation as claimed in any one of claims 10 to 12 wherein said polypeptide is labelled.
14. A polypeptide as defined in any one of claims 10 to 12 which is in the form of a fusion protein.
15. Use of a polypeptide as defined in any one of claims 10 to 12 and 14 as an immunogen for antibody production.
16. A use as claimed in claim 15 wherein one or more antibodies produced are subsequently labelled or bound to a solid support.
17. A method for diagnosing a predisposition for breast and ovarian cancer in a human subject which comprises determining whether there is a germline alteration in the sequence of the BRCA 1 gene in a tissue sample of said subject compared to the nucleotide sequence set forth in SEQ.ID No:1 or a wild-type allelic variant thereof, said alteration indicating a predisposition to said cancer being selected from the mutations as set forth in Tables 12, 12A and 14.
18. A method for diagnosing a breast or ovarian lesion of a human subject for neoplasia associated with the BRCA1 gene locus, which comprises determining whether there is a mutation in the sequence of the BRCA1 gene in a sample from said lesion compared to the nucleotide sequence set forth in SEQ.ID No:1 or a wild-type allelic variant thereof, said mutation being selected from the mutations as set forth in Tables 12, 12A and 14.
19. A method as claimed in claim 17 or claim 18 which comprises analyzing mRNA or protein of said sample to determine whether an expression product is present indicative of expression of a mutant BRCA1 allele as defined in claim 1.
20. A method as claimed in claim 19 wherein the mRNA encoded by the BRCA1 gene in said sample is investigated.
21. A method as claimed in claim 20 wherein mRNA from said sample is contacted with a BRCA1 gene probe under conditions suitable for hybridization of said probe to an RNA corresponding to said BRCA1 gene and hybridization of said probe is determined.
22. A method as claimed in claim 17 or claim 18 wherein a BRCA1 gene probe is contacted with genomic DNA isolated from said sample under conditions suitable for hybridization of said probe to said gene and hybridization of said probe is determined.
23. A method as claimed in claim 21 or claim 22 wherein said probe is an allele-specific probe for a mutant BRCA1 allele as defined in claim 1.

24. A method as claimed in claim 17 or claim 18 which comprises determining whether there is a mutation in the BRCA1 gene in said sample by observing shifts in electrophoretic mobility of single-stranded DNA from said sample on non-denaturing polyacrylamide gels.
- 5 25. A method as claimed in claim 17 or claim 18 wherein all or part of the BRCA1 gene in said sample is amplified and the sequence of said amplified sequence is determined.
- 10 26. A method as claimed in claim 17 or claim 18 wherein oligonucleotide primers are employed which are specific for a mutant BRCA1 allele as defined in claim 1 to determine whether said allele is present in said sample by nucleic acid amplification.
27. A method as claimed in claim 17 or claim 18 wherein all or part of the BRCA1 gene in said sample is cloned to produce a cloned sequence and the sequence of said cloned sequence is determined.
- 15 28. A method as claimed in any one of claims 17 to 20 which comprises determining whether there is a mismatch between molecules (1) BRCA1 gene genomic DNA or BRCA1 mRNA isolated from said sample, and (2) a nucleic acid probe complementary to human wild-type BRCA1 gene DNA, when molecules (1) and (2) are hybridized to each other to form a duplex.
- 20 29. A method as claimed in any one of claims 17 to 20 wherein amplification of BRCA1 gene sequences in said sample is carried out and hybridization of the amplified sequences to one or more nucleic acid probes which comprise a wild-type BRCA1 gene sequence or a mutant BRCA1 gene sequence as defined in claim 1 is determined.
- 25 30. A method as claimed in claim 17 or claim 18 which comprises determining *in situ* hybridization of the BRCA1 gene in said sample with one or more nucleic acid probes which comprise a wild-type BRCA1 gene sequence or a mutant BRCA1 gene sequence as defined in claim 1.



Map of the early onset breast and ovarian cancer region (BRCA1)

FIGURE 1




FIGURE 2

# Schematic Map of STS', Pls, and Bac's in the Region




FIGURE 3




FIGURE 4

SEQ ID  
NO:

BRCA1

RPT1

RIN1

RFP1

C3HC4 motif

CPICLELIKEPVSTK-CDHIFCKFCMLKLLNQKK---GPSQCPLCK  
 CPICLELLKEPVSAAD-CNHSFCRACITLNYE9NRNTDGGKGNCPVCR  
 CPIGLDMLKNTMTTKECLHRCSDCIVTALRS-----GNKECPTCR  
 CPVCLQYFAEPPMLD-CGHNICCACLARCWGTAC---TNVSCPQCR  
 C--C-----C-H--C--C-----C--C

FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9A




FIGURE 9B






FIGURE 9C

1 gaggctagagggcaggcactttatggcaaaactcaggtagaattcttctctctccgctctct  
 61 ttcctttttacgtcatcgaggagactgggtggcaatcgagcccgagagacgcatggctct  
 121 ttctgcccctccatcctctgatgtaccttgatttcgtattctgagaggctgctgcttagcg  
 181 gtagcccccttggtttccgtggcaacggaaaagcgcggaattacagataaaattaaaactg  
 241 cgactgcgcggcggtgAGCTCGCTGAGACTTCCTGGACCCCGCACCAGGCTGTGGGGTTTC  
 301 TCAGATAACTGGGCCCCCTGCGCTCAGGAGGCCTTCACCTCTGCTCTGGGTAAAGgtagt  
 361 agagtccccgggaaagggaacagggggcccaagtgatgctctggggtaactggcggtgggagag  
 421 tggatttccgaagctgacagatgggtattctttgacggggggtagggggcggaacctgaga  
 481 ggcgtaaggcggtgtgaaccctggggagggggcagtttgtaggctcgcgaggggaagcgct  
 541 gaggtacaggaagggggcactgagtgtccgtgggggaatcctcgtgataggaaactggaat  
 601 atgccttgagggggacactatgtctttaaaccgtcggtggtcatgaggtcaggagttc  
 661 cagaccagcctgaccaacgtggtgaaactccgtctctactaaaaatacnaaaattagccg  
 721 ggcggtggtgcccgtccagctactcaggaggctgaggcaggagaatcgctagaaccgggga  
 781 ggcgagggttgacgtgagccgagatcgcgccattgcaactccagcctgggagacagagcga  
 841 gactgtctcaaaacaaaacaaaacaaaacaaaacaaaacacccggctggtatgtatgag  
 901 aggatgggaccttggtggaagaagaggtgccaggaatatgtctgggaaggggaggagacag  
 961 gattttgtgggaggggagaacttaagaactggatccatttgcgccattgagaaagcgcaag  
 1021 agggaagtagaggagcgtcagtagtaacagatgctgccggcagggatgtgcttgaggagg  
 1081 atccagagatgagagcaggtcactgggaaaggttagggggcgggaggccttgattggtgt  
 1141 tgggttggtcgttggtgattttggttttatgcaagaaaaagaaaacaaccagaaacattg  
 1201 gagaaagctaaggctaccaccacctaccgggtcagtcactcctctgtagctttctctttc  
 1261 ttggagaaaggaaaagacccaaggggttggcagcgatatgtgaaaaaattcagaatttat  
 1321 gttgtctaattacaaaaagcaacttctagaatctttaaataaaaggagcgttgctattag  
 1381 tctctctggtttgtattattctaaaaccttccaaatcttcaaatttactttattttaaaa  
 1441 tgataaaatgaagttgtcattttataaacctttttaaagatatatatatatgtttttct  
 1501 aatgtgttaaagTTCATTGGAACAGAAAGAAATGGATTATCTGCTCTTCGCGTTGAAGA  
 1561 AGTACAAAATGTCATTAATGCTATGCAGAAAATCTTAGAGTGTCCCATCTGytaagtcag  
 1621 cacaagagtgtattaatttgggattcctatgattatctcctatgcaaatgaacagaattg  
 1681 accttacatactaggggaagaaaagacatgtctagtaagattaggctattgtaattgctga  
 1741 ttttcttaactgaagaactttaaaaatatagaaaatgattccttggttctccatccactct  
 1801 gcctctcccactcctctccttttcaacacaatcctgtggtccgggaaagacagggtctg  
 1861 tcttgattggttctgcaactgggcaggatctgttagatactgcatttgctttctccagctc  
 1921 taaavvvvvvvvvvvvaatgctgatgatagatagagtattgaagggatcaatataat  
 1981 tctgttttgatatctgaaagctcactgaaggtaaggatcgtattctctgctgtattctca  
 2041 gttcctgacacagcagacattttaataaatattgaacgaacttgaggccttatgttgactc  
 2101 agtcataacagctcaaagttgaacttattcactaagaatagctttattttttaataaatt  
 2161 attgagcctcattttattttctttttctccccccctaccctgctagTCTGGAGTTGATCA  
 2221 AGGAACCTGTCTCCACAAAGTGTGACCACATATTTTGCAAgtaagtttgaatggttatg  
 2281 tggctccattattagcttttggttttgctcttcataaccaggaaacacctaactttata  
 2341 gaagctttactttcttcaattaagtgagaacgaaaatccaactccatttctctttctc  
 2401 agagagtataatagttatcaaaagttggttgtaatcatagttcctggtaaagtttgacat  
 2461 atattatcttttttttttttgagacaagtcctcgtctgctcgcccaggctggagtgaggt  
 2521 ggcagtagggtgctcactgcacctccgcccccgagttcagcgactctvvvvvvvvvvvv  
 2581 vtgagatctagaccacatgggtcaaagagatagaatgtgagcaataaatgaaccttaaat  
 2641 tttcaacagctacttttttttttttttttttgagacagGGKCTTACTCTGTTGTCCAGCT  
 2701 GGAGTACAGWGTGCGATCATGAGGCTTACTGTTGCTTGACTCCTAGGCTCAAGCGATCCT  
 2761 ATCACCTCAGTCTCCAAGTAGCTGGACTgtaagtgacaccaccatatccagctaaattt  
 2821 tgtgttttctgtagagacggggtttcgccatgtttcccaggctggtcttgaactttgggc  
 2881 ttaaccgctctgcccacctaggcatcccaaagtgttaggattacaggtgtgagtcacat  
 2941 gcctggccagttatttagttagctctgtcttttcaagtcataatacaagttcattttcttt  
 3001 taagtttagttaacaaccttatatcatgtattctttcttagcataaagaaagattcgagg

Figure 10A



6121 gtgattggaatgtatatcaagtatcagcttcaaaaatgctatattaataacttcaaaaat  
 6181 tacacaaataatacataatcagggtttgaaaaatttaagacaacmsaaraaaaaawycmaa  
 6241 tcacamatatcccacacattttattattmctmctmcwattattttgwagagmctgggtct  
 6300 cacycykttgctwatgctgggtctttgaacyccykgccycaarcartcctsetccabccctc  
 6361 ccaargtgctggggatwataggcatgarctaaccgcacccagccccagacatttttagtgt  
 6421 gtaaatccctgggcattttttcaaggcatcatacatgttagctgactgatgatgggtcaat  
 6481 ttatttttgtccatgggtgtcaagttttctcttcaggaggaaaagcacagaactggccaaagaa  
 6541 ttgcttgactgttctttaccatactgttttagCAGGAAACCAAGTCTCAGTGTCCAACCTCTC  
 6601 TAACCTTGGAACCTGTGAGAACTCTGAGGACAAAGCAGCGGATACAACCTCAAAAGACGTC  
 6661 TGTCTACATTGAATTGGGtaaggggtctcagggttttttaagtatttaataataattgctgg  
 6721 attccttatcttatagttttgccccaaatcttggtcataatttgtagttttgtggtaggcag  
 6781 ctttgggaagtgaattttatgagccctatgggtgagttataaagaatgtaaaagacgcagt  
 6841 tcccaccttgaagaatcttacttttaaaaaggaggcaaaagaggccaggcatggtgggtca  
 6901 cacctgtaatcccagcactttggggaggccaaagtgggtggatcacctgaggtcgggaggtt  
 6961 cgagaccagcctagccaacatggagaaaactctgtctgtaccaaaaataaaaaattagcc  
 7021 aggtgtgggtggcācataactgtaatcccagctactcgggagggtgaggcaggagaaatcac  
 7081 ttgaacccgggaggtggaggttgcggtgaaccgagatcgaccattgcaactccagcctgg  
 7141 gcaaaaaatagcgaaactccatctaaaaaagagagcaaaagaaagamtmtctggt  
 7201 ttttaamtmtgtgtaaatatgtttttggaaagatggagagtagcaataagaaaaaacatga  
 7261 tggatttgctacagtatttagttccaagataaattgtactagatgaggaagccttttaaga  
 7321 agagctgaattgccaggcgagtggtcctcagcctgtaatcccagcactttggggaggccga  
 7381 ggtggggcggatcacctgaggtcgggagttcaagaccagcctgaccaacatggagaaaccc  
 7441 catctctactaaaaaaaaaaaaaaaaaattagccgggggtgggtggcttatgcctgtaatc  
 7501 ccagctactcaggagggtgaggcaggagaatcgcttgaacccaggaagcagaggttgca  
 7561 tgagccaagatcgaccattgcaactccagcctaggcaacaagagtgaactccatctcaa  
 7621 aaaaaaaaaaaaaagagctgaatcttggtcgggcaggatgggtcgtgctgtaatcctaac  
 7681 gctttggaagaccgaggcagaaggattggttgagtcacagagtttaagaccagcctggcc  
 7741 aacatagggggaaccctgtctctatttttaaaataataatacatattttggccgggtg  
 7801 gctcatgcctgtaatccaataactttggggagggtgaggcaggtagatcacctgaggtcag  
 7861 agttcgagaccagcctggataacctgggtgaaacccctctttactaaaaatacaaaaaaa  
 7921 aaaaaaattagctgggtgtggttagcacatgcttgtaatcccagctactttggggagggtgag  
 7981 gcaggagaatcgcttgaaccaggggaggcggaggttacaatgagccaacactacaccactg  
 8041 cactccagcctgggcaatagagttagactgcctctcaaaaaataataatttttaaaaat  
 8101 aataaatttttttaagcttataaaaaagaaagttagggccagcatagtagctcacatctg  
 8161 taatctcagcagtgccagaggattgcttgaagccaggagtttgagaccagcctgggcaac  
 8221 atagcaagacctcatctctacaaaaaattttcttttttaaatagctgggtgtggtggtg  
 8281 tgcactctgtagtcccagctactcaggaggcagaggtgagtggtatgacattgaacccaggag  
 8341 tttgaggctgtagttagctatgatcatgccactgcactccaacctgggtgacagagcaag  
 8401 acctcaaaaaaaaaaaaaaaaaaagagctgctgagctcagaattcaaaactgggtctctcaaat  
 8461 tggattttcttttagaatatatttataattaaaaaggatagccatcttttgagctcccag  
 8521 gcaccaccatctatttatcataacacttactgttttcccccttatgatcataaattcct  
 8581 agacaacaggcatttgtaaaaaatagttatagtagttgatatttaggagcacttaactatat  
 8641 tccaggcactattgtgcttttctgtataactcattagatgcttgtagacctgtgagat  
 8701 tggtcctattatacttattttacagatgagaaaatttaaggcacagagaagttatgaaatt  
 8761 tttccaagggtattaaacctagtaagtgggtgagccatgattcaaacctaggaagttagat  
 8821 gtcagagcctgtgcttttttttggtttttggtttttgcagtagaaacgggggtctca  
 8881 ctttggttggccaggctgggtcttgaactcctaacctcaataatccacccatctcggcctc  
 8941 ctcaagtgtgggattacagggtgagagccactgtgctggcgaagcccatgcctttaacc  
 9001 acttctctgtattacatactagcttaactagcattgtacctgccacagtagatgctcagt  
 9061 aaatatttctagttgaatatctgtttttcaacaagtacattttttgaaccttttaatta  
 9121 agaaaacttttattgatttttttttgggggggaaatttttttagGATCTGATTCTTCTGAA

Figure 10C

9241 GATACCGTTAATAAGGCAACTTATTGCGAGgtgagtc aaagagaac cctttgtctatgaagc  
9301 tgggtatttttctatttagttaatataggattgatgtttctctctcttttataaaatattt  
9361 taactttttatttttaggttcagggatgtatgtgcagtttgttatataggtaaacacacgac  
9421 ttgggatttgggtgtatagatttttttcatcatccgggtactaagcataccccacagtttt  
9481 ttgtttgctttctttctgaatttctccctcttcccaccttctccctcaagtaggctgggt  
9541 gtttctccagactagaatcatgggtattggaagaaaccttagagatcatctagtttagttc  
9601 tctcatttttatagtggaggaaataccctttttgtttgttggatttagttattagcactgt  
9661 ccaaaggaatttaggataacagtagaactctgcacatgcttgttcttagcagattgttct  
9721 ctaagttcctcatatacagtaatattgacacagcagtaattgtgactgatgaaaatgtt  
9781 aaggacttcattttcaactctttcttctctgttctcttattttccacatatctctcaagc  
9841 tttgtctgtatgttatataataaatacaagcaaccccaactatgttacctaccttccct  
9901 aggaattattgcttgaccagggttttttttttttttttttggagacggggtcttgcct  
9961 gttgccaggatggaggtgtagtggcgccatctcggtcactgccaatcccaactcctctgggt  
10021 tcaagcgattctcctgtctcaatctcacgagtagctgggactacaggtatacaccaccac  
10081 gcccggttaattgaccattccatttctttctttctctcttttttttttttttttttttga  
10141 gagagtcttgtctgttggccaggctggagtacagaggtgtgatctcaactctccgcaac  
10201 gtctgcctcccagggtgaagccatactcctgcctcagcctctctagtagctgggactaca  
10261 ggcgcgcgccaccacacccggctaatttttgtatttttagtagagatgggggttccacat  
10321 gttggccaggctgggtcttgaactcatgacctcaagtgggtccaccgcctcagcctccaa  
10381 agtgtctggaattacaggcttgagccaccgtgccagcaaccatttcatttcaactagaag  
10441 tttctaaaggagagagcagctttcactaactaaataagattgggtcagctttctgtaatcg  
10501 aaagagctaaaatgtttgatctttgggtcatttgacagttctgcatacatgtaactagtgtt  
10561 tcttattaggactctgtcttttccctatagTGTGGGAGATCAAGAATTGTTACAAATCAC  
10621 CCTCAAGGAACACAGGATGAAATCAGTTTGGATTCTGCAAAAAGGGtaattggcaaagt  
10681 ttgccaacttaacaggcactgaaaagagatgggtagatcacagtactgtaattagattat  
10741 tctgaagaccatttgggacctttacaaccacaaaatctcttggcagagttagagattca  
10801 ttctctgtcaaatgtcgtgggtatgggtctgatagatttaaatgggtactagactaatgtacc  
10861 tataataagaccttcttgttaactgattgttgcccttttcgcttttttttttgtttgtttgt  
10921 ttgttttttttttgagatgggggtctcactctgttgccaggctggagtgcagtgatgcaat  
10981 cttgggtcactgcaacctccacctccaaaggctcaagctatcctcccacttcagcctcct  
11041 gagtagctgggactacaggcgcatgccaccacacccggtaattttttgtgggttttatag  
11101 agatgggggtttccacatgttaccgaggctgggtctcaaaactcctggactcaagcagctctgc  
11161 ccacttcagcctcccaaagtgtcaggttacaggcttgagccactgtgcctggcctgccc  
11221 tttacttttaattgggtgtatttgtgtttcatcttttacctactgggtttttaatataggg  
11281 agtggttaagtctgtagatagaacagagtaattaagtagacttaattggccagtaattctttag  
11341 agtaacatcagaacaggttttctgtatgggccaactctgcttttaattcactcttagacgttag  
11401 agaaatagggtgtggtttctgtcatagggaaaattctgaaattaaavvvvvvvvvvgatc  
11461 ctaagtggaaataatctaggtaaataggaattaaatgaaagagtatgagctacatcttca  
11521 gtatacttggtagtttatgagggttagtttctctaataatagccagtttggttgatttccacc  
11581 tccaagggtgtatgaagtatgtatttttttaatgacaattcagtttttgagtaccttggtta  
11641 tttttgtatattttcagCTGCTTGTGAATTTTCTGAGACGGATGTAACAAATACTGAACA  
11701 TCATCAACCCAGTAATAATGATTTGAACACCACTGAGAAGCGTGCAGCTGAGAGGCATCC  
11761 AGAAAAGTATCAGGGTAGTTCTGTTTTCAAACCTGCATGTGGAGCCATGTGGCACAATAAC  
11821 TCATGCCAGCTCATTACAGCATGAGAACAGCAGTTTATTACTCACTAAAGACAGAATGAA  
11881 TGTAGAAAAGGCTGAATTCTGTAATAAAAGCAAACAGCCTGGCTTAGCAAGGAGCCAACA  
11941 TAACAGATGGGCTGGAAGTAAGGAAACATGTAATGATAGGCGGACTCCCAGCACAGAAAA  
12001 AAAGGTAGATCTGAATGCTGATCCCCTGTGTGAGAGAAAAGAATGGAATAAGCAAGAACT  
12061 GCCATGCTCAGAGAAATCCTAGAGACTCTGAAGATGTTCTCTTGATAACACTAAATAGCAG  
12121 CATTGAGAAAAGTTAATGAGTGGTTTTCCGAAAGTATGAACTGTTAGGTTCTGATGACTC  
12181 ACATGATGGGGAGTCTGAATCAAATGCCAAAGTAGCTGATGTATTGGACGTTCTAAATGA  
GGTAGATGAATATTCTGGTTCTTCAGAGAAAATAGACTTACTGGCCAGTGTATCCTCATGA

Figure 10D

12241 GGCTTTAATATGTAAAAGTGAAAGAGTTCACTCCAAATCAGTAGAGAGTAATATTGAAGG  
 12301 CCAAATATTTGGGAAAACCTATCGGAAGAAGGCAAGCCTCCCCAACTTAAGCCATGTAAC  
 12361 TGAAAATCTAATTATAGGAGCATTGTGTTACTGAGCCACAGATAATACAAGAGCGTCCCCT  
 12421 CACAAATAAATTAAAGCGTAAAAGGAGACCTACATCAGGCCTTCATCCTGAGGATTTTAT  
 12481 CAAGAAAGCAGATTTGGCAGTTCAAAAGACTCCTGAAATGATAAATCAGGGAACTAACC  
 12541 AACGGAGCAGAATGGTCAAGTGATGAATATTACTAATAGTGGTCATGAGAATAAAACAAA  
 12601 AGGTGATTCTATTGAGAAATGAGAAAAATCCTAACCCAAATAGAATCACTCGAAAAAGAATC  
 12661 TGCTTTCAAACGAAAGCTGAACCTATAAGCAGCAGTATAAGCAATATGGAACTCGAATT  
 12721 AAATATCCACAATTCAAAGCACCTAAAAAGAATAGGCTGAGGAGGAAGTCTTCTACCAG  
 12781 GCATATTCATGCGCTTGAAGTAGTAGTCAGTAGAAATCTAAGCCACCTAATTGTACTGA  
 12841 ATTGCAAAATTGATAGTTGTTCTAGCAGTGAAGAGATAAAGAAAAAAGTACAAACCAAT  
 12901 GCCAGTCAGGCACAGCAGAAACCTACAACCTCATGGAAGGTAAAGAACCTGCAACTGGAGC  
 12961 CAAGAAGAGTAACAAGCCAAATGAACAGACAAGTAAAGACATGACAGCGATACTTTCCC  
 13021 AGAGCTGAAGTTAACAATGCACCTGGTTCTTTTACTAAGTGTTCAAATACCAGTGAAC  
 13081 TAAAGAATTTGTCAATCCTAGCCTTCCAAGAGAAGAAAAAGAAGAGAACTAGAAACAGT  
 13141 TAAAGTGTCTAAATAGCTGAAGACCCCAAAGATCTCATGTTAAGTGGAGAAAGGGTTT  
 13201 GCAAACTGAAAGATCTGTAGAGAGTAGCAGTATTTTCATGGTACCTGGTACTGATTGG  
 13261 CACTCAGGAAAGTATCTCGTTACTGGAAGTTAGCACTCTAGGGAAGGCAAAAACAGAAC  
 13321 AAATAAATGTGTGAGTCAGTGTGCAGCATTGAAAACCCCAAGGGACTAATTCATGGTTG  
 13381 TTCCAAAGATAATAGAAATGACACAGAAGGCTTTAAGTATCCATTGGGACATGAAGTTAA  
 13441 CCACAGTCGGGAAACAAGCATAGAAATGGAAGAAAGTGAACCTTGATGCTCAGTATTTGCA  
 13501 GAATACATTCAAGGTTTCAAAGCGCCAGTCATTTGCTCCTGTTTCAAATCCAGGAAATGC  
 13561 AGAAGAGGAATGTGCAACATTCTCTGCCACTCTGGGTCTTAAAGAAACAAAGTCCAAA  
 13621 AGTCACTTTTGAATGTGAACAAAGGAAGAAAATCAAGGAAAGAAATGAGTCTAATATCAA  
 13681 GCCTGTACAGACAGTTAATATCACTGCAGGCTTTCCTGTGGTTGGTCAGAAAGATAAGCC  
 13741 AGTTGATAATGCCAAATGTAGTATCAAAGGAGGCTCTAGGTTTGTCTATCATCTCAGTT  
 13801 CAGAGGCAACGAAACTGGACTCATTACTCCAAATAAACATGGACTTTTACAAAACCCATA  
 13861 TCGTATACCACCCTTTTTCCCATCAAGTCATTTGTTAAAACTAAATGTAAGAAAAATCT  
 13921 GCTAGAGGAAAACCTTTGAGGAACATTCAATGTACCTGAAAGAGAAATGGGAAATGAGAA  
 13981 CATTCCAAGTACAGTGAGCACAATAGCCGTAATAACATTAGAGAAAATGTTTTTAAAGA  
 14041 AGCCAGCTCAAGCAATATTAATGAAGTAGGTTCCAGTACTAATGAAGTGGGCTCCAGTAT  
 14101 TAATGAAATAGGTTCCAGTGATGAAAACATTCAAGCAGAAGTGGTAGAAACAGAGGGCC  
 14161 AAAATTGAATGCTATGCTTAGATTAGGGGTTTTGCAACCTGAGGTCTATAAACAAAGTCT  
 14221 TCCTGGAAGTAATTGTAAGCATCCTGAAATAAAAAAGCAAGAATATGAAGAAGTAGTTCA  
 14281 GACTGTTAATACAGATTTCTCTCCATATCTGATTTTCAAGATAACTTAGAACAGCCTATGGG  
 14341 AAGTAGTCATGCATCTCAGGTTTGTCTGAGACACCTGATGACCTGTTAGATGATGGTGA  
 14401 AATAAAGGAAGATACTAGTTTTGCTGAAAATGACATTAAGGAAAGTCTGCTGTTTTTAG  
 14461 CAAAAGCGTCCAGAAAGGAGAGCTTAGCAGGAGTCTAGCCCTTTCACCCATACACATTT  
 14521 GGCTCAGGGTTACCGAAGAGGGGCCAAGAAATTAGAGTCTCAGAAAGAGAACTTATCTAG  
 14581 TGAGGATGAAGAGCTTCCCTGCTTCCAACACTTGTTATTTGGTAAAGTAAACAATATACC  
 14641 TTCTCAGTCTACTAGGCATAGCACCGTTGCTACCGAGTGTCTGTCTAAGAACACAGAGGA  
 14701 GAATTTATTATCATTGAAGAATAGCTTAAATGACTGCAGTAACCAGGTAATATTGGCAAA  
 14761 GGCATCTCAGGAACATCACCTTAGTGAGGAAACAAAATGTTCTGCTAGCTTGTTTTCTTC  
 14821 ACAGTGCAGTGAATTGGAAGACTTGACTGCAAATACAAACACCCAGGATCCTTTCTTGAT  
 14881 TGGTTCTTCCAAACAAATGAGGCATCAGTCTGAAAGCCAGGGAGTTGGTCTGAGTGACAA  
 14941 GGAATTGGTTTCAGATGATGAAGAAAGAGGAACGGGCTTGGAAGAAAATAATCAAGAAGA  
 15001 GCAAAGCATGGATTCAAACCTTAGGtattggaaccagggttttgtgttgcctccagtcctat  
 15061 ttatagaagtgaagctaaatggtttatgcttttggggagcacattttacaaatttccaagta  
 15121 tagttaaaggaactgcttcttaaacttgaaacatggttcctcctaaggtgcttttcataga  
 15181 aaaaagtccttcacacagctaggacgtcatctttgactgaatgagctttaacatcctaata  
 15241 tactggtggacttaactctggtttcatctttataaagcaaatccgggtgtcccaaagcaag

Figure 10E



18361 gtacccatttttctcttaaccttaatttattgggtctttttaattcttaacagagaccaga  
 18421 actttgttaattcaacattcatcggttggtgtaaattaaacttctccattcctttcagAGGG  
 18481 AACCCCTTACCTGGAATCTGGAATCAGCCTCTTCTCTGATGACCCTGAATCTGATCCTTC  
 18541 TGAAGACAGAGCCCCAGAGTCAGCTCGTGTGGCAACATACCATCTTCAACCTCTGCATT  
 18601 GAAAGTTCCCAATTGAAAGTTGCAGAATCTGCCAGAGTCCAGCTGCTGCTCATACTAC  
 18661 TGATACTGCTGGGTATAATGCAATGGAAGAAAGTGTGAGCAGGGAGAAGCCAGAATTGAC  
 18721 AGCTTCAACAGAAAGGGTCAACAAAAGAATGTCCATGGTGGTGTCTGGCCTGACCCAGA  
 18781 AGAATTTgtgagtgtatccatagtatctccctaatgactaagacttaacaacattctgg  
 18841 aaagagttttatgtaggtattgtcaattaataacctagaggaagaaatctagaaaacaat  
 18901 cacagttctgtgtaatttaatttcgattactaatttctgaaaatttagaayvvvvvvvv  
 18961 vvvnnccnnccccnnaatctgaaatgggggttaaccccccccaaccganacntgggtng  
 19021 cntagaganttttaatggcccnttctgaggnacanaagcttaagccagngacgtggancn  
 19081 atgngttgtttnttgttttggttacctccagcctgggtgacagagcaagactctgtctaaa  
 19141 aaaaaaaaaaaaaaaaaaatcgactttaaatagttccaggacacgtgtagaacgtgcaggat  
 19201 tgctacgttaggtaaacatatgccatgggtgggataactagttctgtgactgtgtgctaga  
 19261 ggtaactcatgataatgggaatatttgatttaatttcagATGCTCGTGTACAAGTTTGCCA  
 19321 GAAAACACCACATCACTTTAACTAATCTAATTACTGAAGAGACTACTCATGTTGTTATGA  
 19381 AAACAGgtataccaagaacctttacagaataaccttgcatctgctgcataaaaccacatga  
 19441 ggcgaggcacggtggcgcatgcctgttaatcgagcactttgggagggccgagggcgagga  
 19501 tcacgagatttaggagatcgagaccatcctggccagcatgggtgaaaccccgctctctactan  
 19561 naaatggnaaaaattanctgggtgtgggtcgcggtgncctgtagtcccagctactcgtgagg  
 19621 ctgaggcaggagaatcacttgaaccgggggaaatggaggtttcagttagcagagatcatnc  
 19681 cccnctattccagcctggcgacagagcaagggtccgtcncnnaaaaaataaaaaaaaaacg  
 19741 tgaacaaataagaatatttgttgagcatagcatggatgatagtcttctaatagtcaatca  
 19801 attactttatgaaagacaaataatagttttgctgcttccctacctccttttgttttgggt  
 19861 taagatttggagtggtggccaggcacvvvvvvvvvvvvvgatctatagctagccttggcg  
 19921 tctagaagatgggtgttgagaagagggagtggaagatatctcctctgggtcttaacttca  
 19981 tatcagcctcccctagacttccaaatatccatacctgctgggtataaattagtggtgtttt  
 20041 cagcctctgattctgtcaccaggggttttagaatcataaatccagattgatcttgggagt  
 20101 gtaaaaaactgaggctcttttagcttcttaggacagcagttcctgattttgttttcaactt  
 20161 ctaatcctttgagtggtttttcattctgcagATGCTGAGTTTGTGTGTGAACGGACACTGA  
 20221 AATATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTCTgttaagtataata  
 20281 ctatttctccctcctcccttttaacacctcagaattgcatttttacacctaacatttaac  
 20341 acctaaaggttttctgtgactgtgactgtgattaccaaaagggtctttaaattgtaatact  
 20401 aaactactttttatcttttaatatcatcttgggtcaagataagctgggtgatgctgggaaaatg  
 20461 ggtctctttttataactaataggacctaatctgctcctagcaatgtagcatatgagctag  
 20521 ggattttatttaatagtcggcaggaatccatgtgcarcagncaaacttataatgtttaaat  
 20581 taaacatcaactctgtctccagaaggaaactgctgctacaagccttattaaagggctgtg  
 20641 gcttttagaggaaggacctctcctctgtcattcttctctgtgctcttttgtgaatcgctga  
 20701 cctctctatctcctgtaaaagagcacgttcttctgtgctgtatgtaacctgtcttttctatg  
 20761 atctctvvvvvvvvvvvvvnaaaaacggggngggantgggccttaaanccaaagggcna  
 20821 actcccccaaccattnaaaaantgacnggggattattaaaanccggcggaacatttcacn  
 20881 gcccactaatattgttaaattaaaaccaccacnctgcnccaaggaggggaaactgctgc  
 20941 tacaagccttatttaaagggctgtggcttttagaggaaggacctctcctctgtcattcttc  
 21001 ctgtgctcttttgtgaatcgctgacctctctatgtccgtgaaaagagcacgttcttcgtc  
 21061 tgtatgtaacctgtcttttctatgatctcttttagGGGTGACCCAGTCTATTAAAGAAAGA  
 21121 AAAATGCTGAATGAGgtaagtacttgatgttacaaactaaccagagatattcattcagtc  
 21181 atatagttaaaaatgtatttgccttccctccatcaatgcaccacttcccttaacaatgcac  
 21241 aaatttccatgataatgaggatcatcaagaattatgcaggcctgcacttggtggtcctacac  
 21301 ctataatcccagcgcttggggaggctgaggcgcttggtatcvvvvvvvvvvvvvaattttt  
 21361 tgtatttttagtagagatgagggtccaccatgttggtctagatctgggtgcgaacgtcctg

Figure 10G

153



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 95 30 5605

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	NAT GENET;8(4):399-404 , 1 August 1994 FRIEDMAN LS ET AL 'Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.' * the whole document *	1-30	C12N15/12 C07K14/82 C12Q1/68 G01N33/574 C12N5/10
Y	CANCER RESEARCH , vol. 52 , 1992 pages 6999-6968, PENG LIANG ET AL. 'Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells' * the whole document *	1-30	
Y	CANCER SURVEYS, vol. 18, 1993 pages 7-15, M.R.STAMPFER ET AL. 'Culture systems for study of human mammary epithelial cell proliferation, differentiation and transformation' * the whole document *	1-30	TECHNICAL FIELDS SEARCHED (Int.Cl.6)  C07K C12N
Y	WO-A-92 00311 (UNIV PRINCETON) 9 January 1992 * claims 1-30 *	1-30	
Y	WO-A-94 00764 (US GOVERNMENT) 6 January 1994 * page 10, line 19 - page 14, line 10; claims 1-3 *	30	
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 18 January 1996	Examiner Gurdjian, D
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons Δ : member of the same patent family, corresponding document</p>			

EPO FORM 1501 (01.01.92) (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 95 30 5605

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A, D	SCIENCE, vol. 250, 1990 pages 1684-1689, HALL J.M. ET AL. 'Li8nkage of early-onset familial breast cancer to chromosome 17q21' * the whole document *	1-4	<div>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</div>
A	AM.J.HUM.GENET., vol. 52, 1993 pages 718-722, BOWCOCK A.M. ET AL. 'thra1 and d17s183 flank an interval of <4 cM for the breast-ovarian cancer gene BRCA1 on chromosome 17q21' * the whole document *	1-4	
A	HUM MOL GENET;3(11):1919-26 1994, NEUHAUSEN SL ET AL 'A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1.' * the whole document *	1-4	
A	J NATL CANCER INST;86(3):200-9 1994, GOLDGAR DE ET AL 'A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.' * the whole document *	1-4	
		-/--	
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 18 January 1996	Examiner Gurdjian, D
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPF FORM 1503 01/91 (PWC/01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 95 30 5605

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)	
A	DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US acc. number 94064027, HALL J M ET AL 'CLOSING IN ON A BREAST CANCER GENE ON CHROMOSOME 17Q' * abstract *	1-4		
D	& AM J HUM GENET, 50 (6). 1992. 1235-1242., ---			
A	DATABASE CANCERLIT NATIONAL CANCER INSTITUTE, BETHESDA, MD, US acc. number 92174193, SATO T ET AL 'THE HUMAN PROHIBITIN GENE LOCATED ON CHROMOSOME 17Q21 IS MUTATED IN SPORADIC BREAST CANCER' * abstract *	1-4		
P,X	& CANCER RES;52(6):1643-6 1992, --- SCIENCE;266(5182):66-71 1994, MIKI Y ET AL 'A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.' * the whole document *	1-4		TECHNICAL FIELDS SEARCHED (Int.Cl.6)
P,X	SCIENCE, vol. 266, 7 October 1994 pages 120-122, FUTREAL P.A. ET AL. 'Brcal mutations in primary breast and ovarian carcinomas' * the whole document *	1-4		
P,X	NAT GENET;8(4):387-91 1994, CASTILLA LH ET AL 'Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.' * the whole document *	1-4		
The present search report has been drawn up for all claims				
Place of search BERLIN		Date of completion of the search 18 January 1996	Examiner Gurdjian, D	
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>				

EPO FORM 1503 01/92 (P/C/01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 95 30 5605

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	WO-A-95 19369 (UNIV VANDERBILT) 20 July 1995 * the whole document *	1-30	
T	SCIENCE;265(5181):2088-90 1994, WOOSTER R ET AL 'Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.' * the whole document *	1-4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 18 January 1996	Examiner Gurdjian, D
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 150 (01.92) (P6/C01)

